var title_f37_7_38000="Micrograph showing calcification";
var content_f37_7_38000=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F72408&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F72408&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Micrograph showing arterial calcification in a patient with calciphylaxis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 436px; height: 188px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Low and high power view of characteristic arterial calcifications in the absence of vasculitic change from a patient with calciphylaxis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_7_38000=[""].join("\n");
var outline_f37_7_38000=null;
var title_f37_7_38001="Angioedema lip PI";
var content_f37_7_38001=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F86559&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F86559&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Angioedema of the lips",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 323px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Angioedema causes puffiness of the tissues under the skin, often in the face. This photo shows angioedema of the lips.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_7_38001=[""].join("\n");
var outline_f37_7_38001=null;
var title_f37_7_38002="Doppler US artery";
var content_f37_7_38002=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F79020&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F79020&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Normal Doppler arterial waveform",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 350px; height: 444px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Longitudinal ultrasound image of the right neck with color and spectral Doppler demonstrates the normal sharp upstroke of the common carotid artery waveform. The variety of colors shown within the carotid artery (deep to the internal jugular vein) is called \"aliasing,\" a phenomenon seen when the color scale is set too low for the vessel interrogated. In this case, a venous preset was chosen and a lower velocity scale was selected by the machine.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Lauren W Averill, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_7_38002=[""].join("\n");
var outline_f37_7_38002=null;
var title_f37_7_38003="Pentobarbital: Patient drug information";
var content_f37_7_38003=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Pentobarbital: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/31/4601?source=see_link\">",
"     see \"Pentobarbital: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?17/24/17801?source=see_link\">",
"     see \"Pentobarbital: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F208174\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Nembutal&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F208175\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Nembutal&reg; Sodium",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10024207\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10024209\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691482",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or control seizures.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to put you to sleep for surgery.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691762",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat brain swelling.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10024208\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to pentobarbital or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10024213\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697693",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may be habit-forming with long-term use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696966",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow laws about driving with a seizure problem.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696708",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Birth control pills and other hormone-based birth control may not work to stop pregnancy. Use 2 kinds of birth control while taking this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10024214\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10024216\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10024211\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695976",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a muscle or vein.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given into a vein for a period of time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10024218\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10963 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-CCFD8525CC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_7_38003=[""].join("\n");
var outline_f37_7_38003=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208174\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208175\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024207\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024209\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024208\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024213\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024214\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024216\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024211\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024218\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?4/31/4601?source=related_link\">",
"      Pentobarbital: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?17/24/17801?source=related_link\">",
"      Pentobarbital: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_7_38004="CABG PI";
var content_f37_7_38004=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F73589&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F73589&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 553px\">",
"   <div class=\"ttl\">",
"    Coronary artery bypass graft surgery",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 533px; height: 599px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    During coronary artery bypass surgery, the surgeon removes a piece of blood vessel from the leg, chest, arm, or belly. Then the surgeon uses that piece of blood vessel (called a \"graft\") to reroute blood around the blocked artery. The surgery is called \"bypass surgery\" because it bypasses the blockage. Some people have more than one blocked artery bypassed. In this picture, the graft came from a vein in the leg called the \"saphenous vein.\" But grafts can come from other places, too.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_7_38004=[""].join("\n");
var outline_f37_7_38004=null;
var title_f37_7_38005="Functional end to end colocolic stapled anastomosis";
var content_f37_7_38005=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F72031&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F72031&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 551px\">",
"   <div class=\"ttl\">",
"    Functional end to end colocolic stapled anastomosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 531px; height: 683px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The functional end-to-end anastomosis is technically a side-to-side approach of constructing an anastomosis between the proximal and a mobile distal colon. It is not used for colorectal anastomoses.",
"    <br>",
"     <br>",
"      Figure A depicts dividing the proximal colon with a linear stapler. The distal colon is also divided with a linear stapler.",
"      <br>",
"       Figure B depicts cutting the antimesenteric stapled corners from both the proximal and distal colon.",
"       <br>",
"        Figure C depicts inserting the linear stapler into both lumens.",
"        <br>",
"         Figure D depicts the stapled anastomosis between the proximal and distal colon, with&nbsp;the joined&nbsp;lumens open.",
"         <br>",
"          Figure E depicts Allis clamps securing the lumen in preparation for closure.",
"          <br>",
"           Figure F&nbsp;depicts a linear stapler placed distal to the Allis clamps and closing the lumen.",
"           <br>",
"            Figure G depicts the stapled functional end-to-end anastomosis.",
"            <div class=\"footnotes\">",
"            </div>",
"            <div class=\"reference\">",
"            </div>",
"           </br>",
"          </br>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_7_38005=[""].join("\n");
var outline_f37_7_38005=null;
var title_f37_7_38006="Dissecting cellulitis scars";
var content_f37_7_38006=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F81039&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F81039&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Dissecting cellulitis of the scalp",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 377px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Extensive scarring in a patient with dissecting cellulitis of the scalp.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_7_38006=[""].join("\n");
var outline_f37_7_38006=null;
var title_f37_7_38007="Lamivudine: Drug information";
var content_f37_7_38007=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Lamivudine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?19/53/20309?source=see_link\">",
"    see \"Lamivudine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/0/36871?source=see_link\">",
"    see \"Lamivudine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709005\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F186636\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Epivir-HBV&reg;;",
"     </li>",
"     <li>",
"      Epivir&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F186637\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      3TC&reg;;",
"     </li>",
"     <li>",
"      Apo-Lamivudine&reg;;",
"     </li>",
"     <li>",
"      Apo-Lamivudine&reg; HBV;",
"     </li>",
"     <li>",
"      Heptovir&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F186676\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antiretroviral Agent, Reverse Transcriptase Inhibitor (Nucleoside)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F186641\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     The formulation and dosage of Epivir-HBV&reg; are not appropriate for patients infected with both HBV and HIV; tenofovir and lamivudine are a preferred NRTI backbone in a fully suppressive antiretroviral regimen and for the treatment of HBV coinfection (DHHS, 2013).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      HIV:",
"     </b>",
"     Oral (use with at least two other antiretroviral agents): 150 mg twice daily",
"     <b>",
"      or",
"     </b>",
"     300 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     &lt;50 kg (DHHS [pediatric], 2010): 4 mg/kg twice daily  (maximum: 150 mg twice daily)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Postexposure prophylaxis for HIV exposure (unlabeled use [CDC, 2005]):",
"     </b>",
"     Oral: 150 mg/dose twice daily or 300 mg/dose once daily (in combination with zidovudine, tenofovir, stavudine, or didanosine, with or without a protease inhibitor depending on risk)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Treatment of hepatitis B (Epivir-HBV&reg;):",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     Use in HBV treatment is discouraged due to rapid resistance development; consider use only if other anti-HBV antiviral regimens with more favorable resistance patterns cannot be used. Oral: 100 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Treatment duration (AASLD practice guidelines):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Hepatitis Be antigen (HBeAg) positive chronic hepatitis: Treat &ge;1 year until HBeAg seroconversion and undetectable serum HBV DNA; continue therapy for &ge;6 months after HBeAg seroconversion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     HBeAg negative chronic hepatitis: Treat &gt;1 year until hepatitis B surface antigen (HBsAg) clearance",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Patients not achieving &lt;2 log decrease in serum HBV DNA after at least 6 months of therapy should either receive additional treatment or be switched to an alternative therapy (Lok, 2009).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Treatment of hepatitis B/HIV coinfection (in patients with both infections requiring treatment): Note:",
"     </b>",
"     The formulation and dosage of Epivir-HBV&reg; are not appropriate for patients infected with both HBV and HIV. Tenofovir and lamivudine are a preferred NRTI backbone in a fully suppressive antiretroviral regimen for the treatment of HIV/HBV coinfection (DHHS, 2013).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Oral: 150 mg/dose twice daily or 300 mg/dose once daily, in combination with other antiretrovirals in an antiretroviral (ARV) regimen (DHHS, 2013)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F186659\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/0/36871?source=see_link\">",
"      see \"Lamivudine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      HIV:",
"     </b>",
"     Oral (use with at least two other antiretroviral agents)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants 1-3 months (DHHS [pediatric], 2010): 4 mg/kg/dose twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants and Children 3 months to 16 years: 4 mg/kg/dose twice daily (maximum: 150 mg/dose twice daily)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Alternate weight-based dosing using scored 150 mg tablets (DHHS [pediatric], 2010):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     14-21 kg: 75 mg/dose twice daily (150 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     22-29 kg: 75 mg in the morning, 150 mg in the evening (225 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &ge;30 kg: 150 mg/dose twice daily (300 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &gt;16 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Postexposure prophylaxis for HIV exposure (unlabeled use [CDC, 2005]):",
"     </b>",
"     Adolescents &ge;16 years; Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Treatment of hepatitis B/HIV coinfection (in patients with both infections requiring treatment):",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     The formulation and dosage of Epivir-HBV&reg; are not appropriate for patients infected with both HBV and HIV. Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants and Children: 4 mg/kg/dose (maximum: 150 mg/dose) twice daily, in combination with other antiretrovirals in an ARV regimen (CDC, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adolescents: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Treatment of hepatitis B (Epivir-HBV&reg;):",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     Not a preferred agent in chronic HBV treatment due to high rates of resistance; consider alternative agents: Oral: Children 2-17 years: 3 mg/kg/dose once daily (maximum: 100 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Treatment duration (AASLD practice guidelines):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Hepatitis Be antigen (HBeAg) positive chronic hepatitis: Treat &ge;1 year until HBeAg seroconversion and undetectable serum HBV DNA; continue therapy for &ge;6 months after HBeAg seroconversion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     HBeAg negative chronic hepatitis: Treat &gt;1 year until hepatitis B surface antigen (HBsAg) clearance",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Patients not achieving &lt;2 log decrease in serum HBV DNA after at least 6 months of therapy should either receive additional treatment or be switched to an alternative therapy (Lok, 2009).",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F186642\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F186643\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      HIV:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Patients &le;16 years: Insufficient data; however, dose reduction should be considered.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Patients &gt;16 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30-49 mL/minute: Administer 150 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     15-29 mL/minute: Administer 150 mg first dose, then 100 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     5-14 mL/minute: Administer 150 mg first dose, then 50 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;5 mL/minute: Administer 50 mg first dose, then 25 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Treatment of hepatitis B patients:",
"     </b>",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30-49 mL/minute: Administer 100 mg first dose, then 50 mg once daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     15-29 mL/minute: Administer 100 mg first dose, then 25 mg once daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     5-14 mL/minute: Administer 35 mg first dose, then 15 mg once daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;5 mL/minute: Administer 35 mg first dose, then 10 mg once daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dialysis: Negligible amounts are removed by 4-hour hemodialysis or peritoneal dialysis. Supplemental dosing not needed; however, dosing after dialysis is recommended (DHHS, 2013).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F16160258\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment necessary. However, has not been studied in the setting of decompensated liver disease.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F186610\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Epivir-HBV&reg;: 5 mg/mL [contains propylene glycol, sucrose 200 mg/mL; strawberry-banana flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Epivir&reg;: 10 mg/mL [DSC] [contains propylene glycol, sucrose 200 mg/mL; strawberry-banana flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Epivir&reg;: 10 mg/mL [ethanol free; contains propylene glycol, sucrose 200 mg/mL; strawberry-banana flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 150 mg, 300 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Epivir-HBV&reg;: 100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Epivir&reg;: 150 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Epivir&reg;: 300 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F186595\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Tablet",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F186613\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered without regard to meals. Adjust dosage in renal failure.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F186611\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Epivir&reg;: Treatment of HIV infection when antiretroviral therapy is warranted; should always be used as part of a multidrug regimen (at least three antiretroviral agents)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Epivir-HBV&reg;: Treatment of chronic hepatitis B associated with evidence of hepatitis B viral replication and active liver inflammation. Resistance develops rapidly in hepatitis B; consider use only if other anti-HBV antiviral agents with more favorable resistance patterns cannot be used.",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F186672\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Postexposure prophylaxis for HIV exposure as part of a multidrug regimen",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F186683\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       LamiVUDine may be confused with lamoTRIgine",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Epivir&reg; may be confused with Combivir&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F186674\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Incidence data include patients on combination therapy with other antiretroviral agents.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (21% to 35%), fatigue (24% to 27%), insomnia (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (15% to 33%), diarrhea (14% to 18%), pancreatitis (range: 0.3% to 18%; higher percentage in pediatric patients), abdominal pain (9% to 16%), vomiting (13% to 15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Neutropenia (7% to 15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Transaminases increased (2% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Myalgia (8% to 14%), neuropathy (12%), musculoskeletal pain (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Nasal signs and symptoms (20%), cough (18%), sore throat (13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Infections (25%; includes ear, nose, and throat)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness (10%), depression (9%), fever (7% to 10%), chills (7% to 10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (5% to 9%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Anorexia (10%), lipase increased (10%), abdominal cramps (6%),  dyspepsia (5%), amylase increased (&lt;1% to 4%), heartburn",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Thrombocytopenia (1% to 4%), hemoglobinemia (2% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Creatine phosphokinase increased (9%), arthralgia (5% to 7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Alopecia, anaphylaxis, anemia, body fat redistribution, hepatitis B exacerbation, hepatomegaly, hyperbilirubinemia, hyperglycemia, immune reconstitution syndrome, lactic acidosis, lymphadenopathy, muscle weakness, paresthesia, peripheral neuropathy, pruritus, red cell aplasia, rhabdomyolysis, splenomegaly, steatosis, stomatitis, urticaria, weakness, wheezing",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F186616\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to lamivudine or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F186599\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Fat redistribution: May cause redistribution of fat (eg, buffalo hump, peripheral wasting with increased abdominal girth, cushingoid appearance).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Immune reconstitution syndrome: Patients may develop immune reconstitution syndrome resulting in the occurrence of an inflammatory response to an indolent or residual opportunistic infection during initial HIV treatment or activation of autoimmune disorders (eg, Graves&rsquo; disease, polymyositis, Guillain-Barr&eacute; syndrome) later in therapy; further evaluation and treatment may be required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Lactic acidosis/hepatomegaly:",
"     <b>",
"      [U.S Boxed Warning]: Lactic acidosis and severe hepatomegaly with steatosis have been reported with nucleoside analogues, including fatal cases;",
"     </b>",
"     use with caution in patients with risk factors for liver disease (risk may be increased with female gender, obesity, pregnancy or prolonged exposure) and suspend treatment in any patient who develops clinical or laboratory findings suggestive of lactic acidosis or hepatotoxicity (transaminase elevation may/may not accompany hepatomegaly and steatosis).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pancreatitis: Has been reported, particularly in HIV-infected children with a history of nucleoside use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Chronic hepatitis B:",
"     <b>",
"      [U.S. Boxed Warning]: Monitor patients closely for several months following discontinuation of therapy for chronic hepatitis B;",
"     </b>",
"     clinical exacerbations may occur. Treatment of HBV in patients with unrecognized/untreated HIV may lead to rapid HIV resistance;",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; dosage reduction recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Duplicate therapy: Concomitant use of other lamivudine-containing products should be avoided.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Emtricitabine: Concomitant use of emtricitabine-containing products should be avoided; cross-resistance may develop.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Interferon alfa: Use with caution in combination with interferon alfa with or without ribavirin in HIV/HBV coinfected patients; monitor closely for hepatic decompensation, anemia, or neutropenia; dose reduction or discontinuation of interferon and/or ribavirin may be required if toxicity evident.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Use with extreme caution in children with history of pancreatitis or risk factors for development of pancreatitis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate product selection: Epivir-HBV&reg;:",
"     <b>",
"      [U.S. Boxed Warning]: Do not use Epivir-HBV&reg; tablets or Epivir-HBV&reg; oral solution for the treatment of HIV.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     - HIV: Do not use as monotherapy in treatment of HIV. Treatment of HIV in patients with unrecognized/untreated HBV may lead to rapid HBV resistance. Lamivudine combined with emtricitabine is not recommended as a dual-NRTI combination due to similar resistance patterns and negligible additive antiviral activity; lamivudine and tenofovir combination is preferred as the NRTIs in a fully suppressive antiretroviral regimen (DHHS, 2013).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     - HBV: Not recommended as first line therapy of chronic HBV due to high rate of resistance; consider use only if other anti-HBV antiviral agents with more favorable resistance patterns cannot be used. Use may be appropriate in short-term treatment of acute HBV (Lok, 2009). Potential compliance problems, frequency of administration, and adverse effects should be discussed with patients before initiating therapy to help prevent the emergence of resistance.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     - HIV/HBV coinfection: Lamivudine and tenofovir are a preferred NRTI backbone in a fully suppressive antiretroviral regimen to provide activity against both HIV and HBV (DHHS, 2013).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299572\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F186604\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Emtricitabine: LamiVUDine may enhance the adverse/toxic effect of Emtricitabine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ganciclovir-Valganciclovir: May enhance the adverse/toxic effect of Reverse Transcriptase Inhibitors (Nucleoside). Hematologic toxicity is of specific concern.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ribavirin: May enhance the hepatotoxic effect of Reverse Transcriptase Inhibitors (Nucleoside). Lactic acidosis may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trimethoprim: May decrease the excretion of LamiVUDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F186632\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food: Food decreases the rate of absorption and C",
"     <sub>",
"      max",
"     </sub>",
"     ; however, there is no change in the systemic AUC. Therefore, may be taken with or without food.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F186606\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F186620\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in some animal reproduction studies. Lamivudine crosses the human placenta. No increased risk of overall birth defects has been observed following first trimester exposure according to data collected by the antiretroviral pregnancy registry. The pharmacokinetics of lamivudine during pregnancy are not significantly altered and dosage adjustment is not required. Cases of lactic acidosis/hepatic steatosis syndrome related to mitochondrial toxicity have been reported in pregnant women with prolonged use of nucleoside analogues. It is not known if pregnancy itself potentiates this known side effect; however, women may be at increased risk of lactic acidosis and liver damage. In addition, these adverse events are similar to other rare but life-threatening syndromes which occur during pregnancy (eg, HELLP syndrome). Hepatic enzymes and electrolytes should be monitored in women receiving nucleoside analogues and clinicians should watch for early signs of the syndrome. In addition, mitochondrial dysfunction may develop in infants following in utero exposure The DHHS Perinatal HIV Guidelines recommend lamivudine for use during pregnancy; the combination of lamivudine with zidovudine is the recommended dual combination NRTI in pregnancy. The DHHS Perinatal HIV Guidelines consider lamivudine plus tenofovir a recommended dual NRTI/NtRTI backbone for HIV/HBV coinfected pregnant women. Use caution with hepatitis B coinfection; hepatitis B flare may occur if lamivudine is discontinued postpartum.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Regardless of CD4 count or HIV RNA copy number, all HIV-infected pregnant women should receive a combination antepartum antiretroviral (ARV) drug regimen; this includes women who require therapy for their own health, as well as women who do not yet require therapy for their own health. ARV therapy should be started as soon as possible if required for the woman&rsquo;s health. Although earlier initiation may be more effective in reducing the perinatal transmission of HIV), also consider maternal conditions (eg, nausea and vomiting) and the potential risks of first trimester fetal exposure for specific agents. Plasma HIV RNA levels should be assessed at ~34-36 weeks gestation in order to help determine mode of delivery. If ARV therapy must be interrupted for &lt;24 hours during the peripartum period, stop then restart all medications simultaneously in order to decrease the chance of developing resistance. Long-term follow-up is recommended for all infants exposed to ARV medications.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Healthcare providers are encouraged to enroll pregnant women exposed to antiretroviral medications in the Antiretroviral Pregnancy Registry (1-800-258-4263 or www.APRegistry.com). Healthcare providers caring for HIV-infected women and their infants may contact the National Perinatal HIV Hotline (888-448-8765) for clinical consultation (DHHS [perinatal], 2012).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F186647\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/contraindicated",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F186621\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Lamivudine is excreted into breast milk and can be detected in the serum of nursing infants.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Maternal or infant antiretroviral therapy does not completely eliminate the risk of postnatal HIV transmission. In addition, multiclass-resistant virus has been detected in breast-feeding infants despite maternal therapy. Therefore, in the United States, where formula is accessible, affordable, safe, and sustainable, and the risk of infant mortality due to diarrhea and respiratory infections is low, complete avoidance of breast-feeding by HIV-infected women is recommended to decrease potential transmission of HIV (DHHS [perinatal], 2012).",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F186622\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken without regard to meals. Some products may contain sucrose.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F186619\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Epivir HBV Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg/mL (240 mL): $195.29",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Epivir Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg/mL (240 mL): $133.04",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Epivir HBV Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (60): $976.44",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Epivir Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150 mg (60): $498.89",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300 mg (30): $498.89",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (LamiVUDine Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150 mg (60): $429.19",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300 mg (30): $429.19",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F186608\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Amylase, bilirubin, liver enzymes (every 3 months during therapy), hematologic parameters, HIV viral load, and CD4 count; signs/symptoms of pancreatitis, HBV DNA (every 3-6 months during therapy), HBeAg and anti-HBe (after 1 year of therapy and every 3-6 months thereafter); signs/symptoms of HBV relapse/exacerbation (every 1-3 months for 6 months after discontinuation and every 3-6 months thereafter)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F186623\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      3TC (AR, AU, BB, BM, BS, BZ, GY, HK, ID, JM, MX, NZ, SR, TT, UY);",
"     </li>",
"     <li>",
"      3TC-HBV (ID);",
"     </li>",
"     <li>",
"      Epivir (AE, AT, BE, BH, BR, CY, CZ, DE, DK, EE, EG, ES, FI, FR, GB, GR, HN, HR, IE, IL, IQ, IR, IT, JO, KW, LB, LU, LY, MT, NL, NO, OM, PE, PL, PT, PY, QA, RU, SA, SE, SG, SK, SY, TH, TR, VE, YE);",
"     </li>",
"     <li>",
"      epivir 3TC (CN);",
"     </li>",
"     <li>",
"      Heptodin (CL);",
"     </li>",
"     <li>",
"      Inhavir (CO);",
"     </li>",
"     <li>",
"      Ladiwin (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Lamidac (IN);",
"     </li>",
"     <li>",
"      Lamidine (TW);",
"     </li>",
"     <li>",
"      Lamivir (PE, TH);",
"     </li>",
"     <li>",
"      Zeffix (AT, AU, BE, BG, BR, CH, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HN, IE, IL, IT, KP, MT, MY, NL, NO, NZ, PH, PK, PL, PT, RU, SE, SG, SK, TH, TR, TW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F186598\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Lamivudine is a cytosine analog. After lamivudine is triphosphorylated, the principle mode of action is inhibition of HIV reverse transcription via viral DNA chain termination; inhibits RNA- and DNA-dependent DNA polymerase activities of reverse transcriptase. The monophosphate form of lamivudine is incorporated into the viral DNA by hepatitis B virus polymerase, resulting in DNA chain termination.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F186615\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 1.3 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding, plasma: &lt;36%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: 4.2% to trans-sulfoxide metabolite",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Absolute; Cp",
"     <sub>",
"      max",
"     </sub>",
"     decreased with food although AUC not significantly affected",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 66%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 86% to 87%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Children: 2 hours; Adults: 5-7 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, plasma: Fed: 3.2 hours; Fasted: 0.9 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Primarily urine (as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention, &ldquo;Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children: Recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2009, 58(RR-11):1-166. Available at",
"      <a href=\"file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf\" target=\"_blank\">",
"       file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf",
"      </a>",
"      .",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/7/38007/abstract-text/19730409/pubmed\" id=\"19730409\" target=\"_blank\">",
"        19730409",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention, &ldquo;Notice to Readers: Updated Information Regarding Antiretroviral Agents Used as HIV Postexposure Prophylaxis for Occupational HIV Exposures,&rdquo;",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 2007, 56(49):1291-2. Available at",
"      <a href=\"file://www.cdc.gov/mmwr/preview/mmwrhtml/mm5649a4.htm\" target=\"_blank\">",
"       file://www.cdc.gov/mmwr/preview/mmwrhtml/mm5649a4.htm",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents, &ldquo;Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents, Department of Health and Human Services,&rdquo; February 12, 2013;1-267. Available at",
"      <a href=\"file://aidsinfo.nih.gov/Guidelines/GuidelineDetail.aspx?GuidelineID=7&amp;ClassID=1\" target=\"_blank\">",
"       file://www.aidsinfo.nih.gov",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DHHS Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission, \"Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States,\"  July 31, 2012. Available at",
"      <a href=\"file://aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf\" target=\"_blank\">",
"       file://aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dienstag JL, Perrillo, RP, Schiff, ER, et al, &ldquo;A Preliminary Trial of Lamivudine for Chronic Hepatitis B Infection,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1995, 333(25):1657-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/7/38007/abstract-text/7477217/pubmed\" id=\"7477217\" target=\"_blank\">",
"        7477217",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Eron JJ, Benoit SL, Jemsek J, et al, &ldquo;Treatment With Lamivudine, Zidovudine, or Both in HIV-Positive Patients With 200 to 500 CD4",
"      <sup>",
"       +",
"      </sup>",
"      Cells Per Cubic Millimeter,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1995, 333(25):1662-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/7/38007/abstract-text/7477218/pubmed\" id=\"7477218\" target=\"_blank\">",
"        7477218",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hilts AE and Fish DN, &ldquo;Dosage Adjustment of Antiretroviral Agents in Patients With Organ Dysfunction,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 1998, 55:2528-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/7/38007/abstract-text/9853641/pubmed\" id=\"9853641\" target=\"_blank\">",
"        9853641",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Johnson MA, Verpooten GA, Daniel MJ, et al, &ldquo;Single Dose Pharmacokinetics of Lamivudine in Subjects With Impaired Renal Function and the Effect of Haemodialysis,&rdquo;",
"      <i>",
"       Br J Clin Pharmacol",
"      </i>",
"      , 1998, 46(1):21-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/7/38007/abstract-text/9690945/pubmed\" id=\"9690945\" target=\"_blank\">",
"        9690945",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lai CL, Chien RN, Leung NW, et al, &ldquo;A One-Year Trial of Lamivudine for Chronic Hepatitis B,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1998, 339(2):61-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/7/38007/abstract-text/9654535/pubmed\" id=\"9654535\" target=\"_blank\">",
"        9654535",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lewis LL, Mueller B, Schock R, et al, &ldquo;A Phase I/II Study to Evaluate the Safety, Toxicity, and Preliminary Efficacy of Combinations of Lamivudine (3TC), Zidovudine (AZT) and Didanosine (ddI) in Children With HIV Infection,&rdquo;",
"      <i>",
"       Natl Conf Hum Retroviruses Relat Infect (2nd)",
"      </i>",
"      , 1995, Jan 29-Feb 2:103.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lewis LL, Venzon D, Church J, et al, &ldquo;Lamivudine in Children With Human Immunodeficiency Virus Infection: A Phase I/II Study,&rdquo;",
"      <i>",
"       J Infect Dis",
"      </i>",
"      , 1996, 174(1):16-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/7/38007/abstract-text/8655986/pubmed\" id=\"8655986\" target=\"_blank\">",
"        8655986",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lok AS and McMahon BJ, &ldquo;Chronic Hepatitis B: Update 2009,&rdquo;",
"      <i>",
"       Hepatology",
"      </i>",
"      , 2009, 50(3):661-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/7/38007/abstract-text/19714720/pubmed\" id=\"19714720\" target=\"_blank\">",
"        19714720",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Panlilio AL, Cardo DM, Grohskopf LA, et al, &ldquo;Updated U.S. Public Health Service Guidelines for the Management of Occupational Exposures to HIV and Recommendations for Postexposure Prophylaxis,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2005, 54(RR-9):1-17. Available at",
"      <a href=\"file://www.cdc.gov/mmwr/preview/mmwrhtml/rr5409a1.htm\" target=\"_blank\">",
"       file://www.cdc.gov/mmwr/preview/mmwrhtml/rr5409a1.htm",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/7/38007/abstract-text/16195697/pubmed\" id=\"16195697\" target=\"_blank\">",
"        16195697",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Perry CM and Faulds D, &ldquo;Lamivudine. A Review of Its Antiviral Activity, Pharmacokinetic Properties and Therapeutic Efficacy in the Management of HIV Infection,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1997, 53(4):657-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/7/38007/abstract-text/9098665/pubmed\" id=\"9098665\" target=\"_blank\">",
"        9098665",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tremoulet AH, Capparelli EV, Patel P, et al, &ldquo;Population Pharmacokinetics of Lamivudine in Human Immunodeficiency Virus-Exposed and -Infected Infants,&rdquo;",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      ,  2007, 51(12):4297-302.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/7/38007/abstract-text/17893155/pubmed\" id=\"17893155\" target=\"_blank\">",
"        17893155",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children, &ldquo;Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection,&rdquo; August 16, 2010. Available at",
"      <a href=\"file://www.aidsinfo.nih.gov\" target=\"_blank\">",
"       file://www.aidsinfo.nih.gov",
"      </a>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9544 Version 44.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-27.109.116.13-B2EFA6BE5C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_7_38007=[""].join("\n");
var outline_f37_7_38007=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709005\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186636\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186637\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186676\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186641\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186659\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186642\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186643\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16160258\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186610\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186595\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186613\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186611\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186672\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186683\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186674\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186616\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186599\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299572\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186604\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186632\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186606\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186620\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186647\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186621\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186622\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186619\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186608\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186623\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186598\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186615\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9544\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9544|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?19/53/20309?source=related_link\">",
"      Lamivudine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/0/36871?source=related_link\">",
"      Lamivudine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_7_38008="Intermediate case 2";
var content_f37_7_38008=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F72945&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F72945&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1120px;\">",
"  <div class=\"figure\" style=\"width: 550px\">",
"   <div class=\"ttl\">",
"    Intermediate case 2",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 530px; height: 155px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCACbAhIDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD13RNK06TRdOeTTrBna1s2Zm0wsSSeST3J7n+LoKL3StOSxt2XTrAMWsQSNMOTmcA898jgn+IcCjRLu2TRdOVrdywtbMEjSZ2yc88gYOfUcN0FF9d2z2NuBbvndYnLaTP/AM91zzjkn1/j6Dmn7vKfXN1vbPWVuZdH3XkW30fTN0X/ABLNP/1j/wDMMI/5bKPx9Mdh8vU1UudJ04X8ajTrAKbW9YgaYRyJI8H2IycH+HODVt7213Rf6PJ/rH/5g84/5bKPTnjjHYfL1NVbm7tvt8biB8C1vR/yCZwc+ZHjHHbHXonQ9RTfKRSda61l16Ps/ItXOj6YJbzGmaeMRyYxphXHyR9B/D9T05P8QqOz0nTW1S+VtN08qt8FUHSjgD7MhwF9Mknb6ndUlze2olvALeQYjkxjR51x8kfQY+X6npyf4hUdndWq6pfZt2w18MAaNOePsycFcZHIzt6/xdKHy6Exdbkesvh7PuvIksdH0wrb50zTzmReumF8/uc9uvPOO5+bpVTRNK06TRdOeTTrBna1s2Zm0wsSSeST3J7n+LoKt2N7albfNvIcyL10ed8/uc9l59cdz83SqmiXdsmi6crW7lha2YJGkztk555Awc+o4boKHy3Kbrcr1lvHo/PyC90rTksbdl06wDFrEEjTDk5nAPPfI4J/iHAq2+j6Zui/4lmn/wCsf/mGEf8ALZR+PpjsPl6mql9d2z2NuBbvndYnLaTP/wA91zzjkn1/j6Dmrb3trui/0eT/AFj/APMHnH/LZR6c8cY7D5epo924N1rLWW76PsvIqXOk6cL+NRp1gFNresQNMI5EkeD7EZOD/DnBq3c6PpglvMaZp4xHJjGmFcfJH0H8P1PTk/xCqtzd232+NxA+Ba3o/wCQTODnzI8Y47Y69E6HqKtXN7aiW8At5BiOTGNHnXHyR9Bj5fqenJ/iFC5bg3W93WWz6Pv6EdnpOmtql8rabp5Vb4KoOlHAH2ZDgL6ZJO31O6pLHR9MK2+dM085kXrphfP7nPbrzzjufm6VHZ3VquqX2bdsNfDAGjTnj7MnBXGRyM7ev8XSpLG9tStvm3kOZF66PO+f3Oey8+uO5+bpQuWxM3WtvL4V0fb0KmiaVp0mi6c8mnWDO1rZszNphYkk8knuT3P8XQUXulacljbsunWAYtYgkaYcnM4B575HBP8AEOBRol3bJounK1u5YWtmCRpM7ZOeeQMHPqOG6Ci+u7Z7G3At3zusTltJn/57rnnHJPr/AB9BzS93lNW63tnrK3Muj7ryLb6Ppm6L/iWaf/rH/wCYYR/y2Ufj6Y7D5epqpc6Tpwv41GnWAU2t6xA0wjkSR4PsRk4P8OcGrb3trui/0eT/AFj/APMHnH/LZR6c8cY7D5epqrc3dt9vjcQPgWt6P+QTODnzI8Y47Y69E6HqKb5SKTrXWsuvR9n5Fq50fTBLeY0zTxiOTGNMK4+SPoP4fqenJ/iFR2ek6a2qXytpunlVvgqg6UcAfZkOAvpkk7fU7qkub21Et4BbyDEcmMaPOuPkj6DHy/U9OT/EKjs7q1XVL7Nu2GvhgDRpzx9mTgrjI5GdvX+LpQ+XQmLrcj1l8PZ915Eljo+mFbfOmaecyL10wvn9znt155x3PzdKqaJpWnSaLpzyadYM7WtmzM2mFiSTySe5Pc/xdBVuxvbUrb5t5DmReujzvn9znsvPrjufm6VU0S7tk0XTla3csLWzBI0mdsnPPIGDn1HDdBQ+W5Tdblest49H5+QXulacljbsunWAYtYgkaYcnM4B575HBP8AEOBVt9H0zdF/xLNP/wBY/wDzDCP+Wyj8fTHYfL1NVL67tnsbcC3fO6xOW0mf/nuuecck+v8AH0HNW3vbXdF/o8n+sf8A5g84/wCWyj0544x2Hy9TR7twbrWWst30fZeRUudJ04X8ajTrAKbW9YgaYRyJI8H2IycH+HODVu50fTBLeY0zTxiOTGNMK4+SPoP4fqenJ/iFVbm7tvt8biB8C1vR/wAgmcHPmR4xx2x16J0PUVaub21Et4BbyDEcmMaPOuPkj6DHy/U9OT/EKFy3But7ustn0ff0I7PSdNbVL5W03Tyq3wVQdKOAPsyHAX0ySdvqd1SWOj6YVt86Zp5zIvXTC+f3Oe3XnnHc/N0qOzurVdUvs27Ya+GANGnPH2ZOCuMjkZ29f4ulSWN7albfNvIcyL10ed8/uc9l59cdz83ShctiZutbeXwro+3oVNE0rTpNF055NOsGdrWzZmbTCxJJ5JPcnuf4ugovdK05LG3ZdOsAxaxBI0w5OZwDz3yOCf4hwKNEu7ZNF05Wt3LC1swSNJnbJzzyBg59Rw3QUX13bPY24Fu+d1ictpM//Pdc845J9f4+g5pe7ymrdb2z1lbmXR915Ft9H0zdF/xLNP8A9Y//ADDCP+Wyj8fTHYfL1NVLnSdOF/Go06wCm1vWIGmEciSPB9iMnB/hzg1be9td0X+jyf6x/wDmDzj/AJbKPTnjjHYfL1NVbm7tvt8biB8C1vR/yCZwc+ZHjHHbHXonQ9RTfKRSda61l16Ps/ItXOj6YJbzGmaeMRyYxphXHyR9B/D9T05P8QqOz0nTW1S+VtN08qt8FUHSjgD7MhwF9Mknb6ndUlze2olvALeQYjkxjR51x8kfQY+X6npyf4hUdndWq6pfZt2w18MAaNOePsycFcZHIzt6/wAXSh8uhMXW5HrL4ez7ryJLHR9MK2+dM085kXrphfP7nPbrzzjufm6VU0TStOk0XTnk06wZ2tbNmZtMLEknkk9ye5/i6Crdje2pW3zbyHMi9dHnfP7nPZefXHc/N0qpol3bJounK1u5YWtmCRpM7ZOeeQMHPqOG6Ch8tym63K9Zbx6Pz8gvdK05LG3ZdOsAxaxBI0w5OZwDz3yOCf4hwKtvo+mbov8AiWaf/rH/AOYYR/y2Ufj6Y7D5epqpfXds9jbgW753WJy2kz/891zzjkn1/j6Dmrb3trui/wBHk/1j/wDMHnH/AC2UenPHGOw+XqaPduDday1lu+j7LyKlzpOnC/jUadYBTa3rEDTCORJHg+xGTg/w5wat3Oj6YJbzGmaeMRyYxphXHyR9B/D9T05P8Qqrc3dt9vjcQPgWt6P+QTODnzI8Y47Y69E6HqKtXN7aiW8At5BiOTGNHnXHyR9Bj5fqenJ/iFC5bg3W93WWz6Pv6EdnpOmtql8rabp5Vb4KoOlHAH2ZDgL6ZJO31O6pLHR9MK2+dM085kXrphfP7nPbrzzjufm6VHZ3VquqX2bdsNfDAGjTnj7MnBXGRyM7ev8AF0qSxvbUrb5t5DmReujzvn9znsvPrjufm6ULlsTN1rby+FdH29CpomladJounPJp1gzta2bMzaYWJJPJJ7k9z/F0FF7pWnJY27Lp1gGLWIJGmHJzOAee+RwT/EOBRol3bJounK1u5YWtmCRpM7ZOeeQMHPqOG6Ci+u7Z7G3At3zusTltJn/57rnnHJPr/H0HNL3eU1bre2esrcy6PuvItvo+mbov+JZp/wDrH/5hhH/LZR+PpjsPl6mqlzpOnC/jUadYBTa3rEDTCORJHg+xGTg/w5watve2u6L/AEeT/WP/AMwecf8ALZR6c8cY7D5epqrc3dt9vjcQPgWt6P8AkEzg58yPGOO2OvROh6im+Uik611rLr0fZ+RaudH0wS3mNM08YjkxjTCuPkj6D+H6npyf4hUdnpOmtql8rabp5Vb4KoOlHAH2ZDgL6ZJO31O6pLm9tRLeAW8gxHJjGjzrj5I+gx8v1PTk/wAQqOzurVdUvs27Ya+GANGnPH2ZOCuMjkZ29f4ulD5dCYutyPWXw9n3XkSWOj6YVt86Zp5zIvXTC+f3Oe3XnnHc/N0qpomladJounPJp1gzta2bMzaYWJJPJJ7k9z/F0FW7G9tStvm3kOZF66PO+f3Oey8+uO5+bpVTRLu2TRdOVrdywtbMEjSZ2yc88gYOfUcN0FD5blN1uV6y3j0fn5Be6VpyWNuy6dYBi1iCRphyczgHnvkcE/xDgVbfR9M3Rf8AEs0//WP/AMwwj/lso/H0x2Hy9TVS+u7Z7G3At3zusTltJn/57rnnHJPr/H0HNW3vbXdF/o8n+sf/AJg84/5bKPTnjjHYfL1NHu3ButZay3fR9l5FS50nThfxqNOsAptb1iBphHIkjwfYjJwf4c4NW7nR9MEt5jTNPGI5MY0wrj5I+g/h+p6cn+IVVubu2+3xuIHwLW9H/IJnBz5keMcdsdeidD1FWrm9tRLeAW8gxHJjGjzrj5I+gx8v1PTk/wAQoXLcG63u6y2fR9/Qjs9J01tUvlbTdPKrfBVB0o4A+zIcBfTJJ2+p3VJY6PphW3zpmnnMi9dML5/c57deecdz83So7O6tV1S+zbthr4YA0ac8fZk4K4yORnb1/i6VJY3tqVt828hzIvXR53z+5z2Xn1x3PzdKFy2Jm61t5fCuj7ehU0TStOk0XTnk06wZ2tbNmZtMLEknkk9ye5/i6Ci90rTksbdl06wDFrEEjTDk5nAPPfI4J/iHAo0S7tk0XTla3csLWzBI0mdsnPPIGDn1HDdBRfXds9jbgW753WJy2kz/APPdc845J9f4+g5pe7ymrdb2z1lbmXR915Ft9H0zdF/xLNP/ANY//MMI/wCWyj8fTHYfL1NVLnSdOF/Go06wCm1vWIGmEciSPB9iMnB/hzg1be9td0X+jyf6x/8AmDzj/lso9OeOMdh8vU1Vubu2+3xuIHwLW9H/ACCZwc+ZHjHHbHXonQ9RTfKRSda61l16Ps/ItXOj6YJbzGmaeMRyYxphXHyR9B/D9T05P8QqOz0nTW1S+VtN08qt8FUHSjgD7MhwF9Mknb6ndUlze2olvALeQYjkxjR51x8kfQY+X6npyf4hUdndWq6pfZt2w18MAaNOePsycFcZHIzt6/xdKHy6Exdbkesvh7PuvIksdH0wrb50zTzmReumF8/uc9uvPOO5+bpVTRNK06TRdOeTTrBna1s2Zm0wsSSeST3J7n+LoKt2N7albfNvIcyL10ed8/uc9l59cdz83SqmiXdsmi6crW7lha2YJGkztk555Awc+o4boKHy3Kbrcr1lvHo/PyC90rTksbdl06wDFrEEjTDk5nAPPfI4J/iHAq2+j6Zui/4lmn/6x/8AmGEf8tlH4+mOw+XqaqX13bPY24Fu+d1ictpM/wDz3XPOOSfX+PoOatve2u6L/R5P9Y//ADB5x/y2UenPHGOw+XqaPduDday1lu+j7LyMS+0rTxe3AFhaACRuBbhAOf7pHH07UUX2oQC9uAI7kASNgCylQDn+6V4+naitVynoQ9vyrf8AE29BZv7C0z91N/x6WfSWb1/3e/bHA/hyaNQZvsFv+6mPz2H/AC1m/wCe6+i9+2OB/Dk1U0Se6Gi6cEjsCotbMAtqsing9xs4PqP4eopb64uvsMAeOwUbrHpqsmcideMbOO2R/AORmsr+6ee6T9s9PtLqu68zWdjui/dTf6x/+Ws3/PZf9n8OOc8n5sCqd0zf2lF+6mH+iX3/AC1m/wCesX+z2754P8WDQ9xebov3Wn/6x/8AmLSn/lsp/wCefHHOe4+bqKqXM90b+P8Ad2G/7LegAarIQcyR/wCx16YH8XU4xTbM6VJ3Wnfquz8zXuWbzrz91MP3cnWWY4+SPrlefxwORngDMVi7f2rqP7if/j/HHnXGf+PWPj7uc989ccYxzUFzcXhlvMRaecxyYxq0rZ+SPofL+b6Hrgj+EVHZ3Fz/AGpflU08/wCnAtnWJQB/oyDhvL5HT5uufl6c0N7ExpPken2e67rzNCxYhbf91McSL0lmGf3Psv48c44+7zVPQWb+wtM/dTf8eln0lm9f93v2xwP4cmixuLwLb5i08YkXOdWlTH7nHaPj0z2Py9KqaJPdDRdOCR2BUWtmAW1WRTwe42cH1H8PUUN6lOk+V+seq8/Mt6gzfYLf91MfnsP+Ws3/AD3X0Xv2xwP4cmrjsd0X7qb/AFj/APLWb/nsv+z+HHOeT82BWTfXF19hgDx2CjdY9NVkzkTrxjZx2yP4ByM1ae4vN0X7rT/9Y/8AzFpT/wAtlP8Azz445z3HzdRRfUHSfKtOr6rsvMLpm/tKL91MP9Evv+Ws3/PWL/Z7d88H+LBq5cs3nXn7qYfu5Ossxx8kfXK8/jgcjPAGci5nujfx/u7Df9lvQANVkIOZI/8AY69MD+LqcYq3c3F4ZbzEWnnMcmMatK2fkj6Hy/m+h64I/hFCeoOk/d06Pqu/qT2Lt/auo/uJ/wDj/HHnXGf+PWPj7uc989ccYxzUtixC2/7qY4kXpLMM/ufZfx45xx93ms+zuLn+1L8qmnn/AE4Fs6xKAP8ARkHDeXyOnzdc/L05qSxuLwLb5i08YkXOdWlTH7nHaPj0z2Py9KE9CZ0nbb7K+0u3qGgs39haZ+6m/wCPSz6Szev+737Y4H8OTRqDN9gt/wB1MfnsP+Ws3/PdfRe/bHA/hyaqaJPdDRdOCR2BUWtmAW1WRTwe42cH1H8PUUt9cXX2GAPHYKN1j01WTOROvGNnHbI/gHIzSv7ps6T9s9PtLqu68zWdjui/dTf6x/8AlrN/z2X/AGfw45zyfmwKp3TN/aUX7qYf6Jff8tZv+esX+z2754P8WDQ9xebov3Wn/wCsf/mLSn/lsp/558cc57j5uoqpcz3Rv4/3dhv+y3oAGqyEHMkf+x16YH8XU4xTbM6VJ3Wnfquz8zXuWbzrz91MP3cnWWY4+SPrlefxwORngDMVi7f2rqP7if8A4/xx51xn/j1j4+7nPfPXHGMc1Bc3F4ZbzEWnnMcmMatK2fkj6Hy/m+h64I/hFR2dxc/2pflU08/6cC2dYlAH+jIOG8vkdPm65+XpzQ3sTGk+R6fZ7ruvM0LFiFt/3UxxIvSWYZ/c+y/jxzjj7vNU9BZv7C0z91N/x6WfSWb1/wB3v2xwP4cmixuLwLb5i08YkXOdWlTH7nHaPj0z2Py9KqaJPdDRdOCR2BUWtmAW1WRTwe42cH1H8PUUN6lOk+V+seq8/Mt6gzfYLf8AdTH57D/lrN/z3X0Xv2xwP4cmrjsd0X7qb/WP/wAtZv8Ansv+z+HHOeT82BWTfXF19hgDx2CjdY9NVkzkTrxjZx2yP4ByM1ae4vN0X7rT/wDWP/zFpT/y2U/88+OOc9x83UUX1B0nyrTq+q7LzC6Zv7Si/dTD/RL7/lrN/wA9Yv8AZ7d88H+LBq5cs3nXn7qYfu5Ossxx8kfXK8/jgcjPAGci5nujfx/u7Df9lvQANVkIOZI/9jr0wP4upxirdzcXhlvMRaecxyYxq0rZ+SPofL+b6Hrgj+EUJ6g6T93To+q7+pPYu39q6j+4n/4/xx51xn/j1j4+7nPfPXHGMc1LYsQtv+6mOJF6SzDP7n2X8eOccfd5rPs7i5/tS/Kpp5/04Fs6xKAP9GQcN5fI6fN1z8vTmpLG4vAtvmLTxiRc51aVMfucdo+PTPY/L0oT0JnSdtvsr7S7eoaCzf2Fpn7qb/j0s+ks3r/u9+2OB/Dk0agzfYLf91MfnsP+Ws3/AD3X0Xv2xwP4cmqmiT3Q0XTgkdgVFrZgFtVkU8HuNnB9R/D1FLfXF19hgDx2CjdY9NVkzkTrxjZx2yP4ByM0r+6bOk/bPT7S6ruvM1nY7ov3U3+sf/lrN/z2X/Z/DjnPJ+bAqndM39pRfuph/ol9/wAtZv8AnrF/s9u+eD/Fg0PcXm6L91p/+sf/AJi0p/5bKf8AnnxxznuPm6iqlzPdG/j/AHdhv+y3oAGqyEHMkf8AsdemB/F1OMU2zOlSd1p36rs/M17lm868/dTD93J1lmOPkj65Xn8cDkZ4AzFYu39q6j+4n/4/xx51xn/j1j4+7nPfPXHGMc1Bc3F4ZbzEWnnMcmMatK2fkj6Hy/m+h64I/hFR2dxc/wBqX5VNPP8ApwLZ1iUAf6Mg4by+R0+brn5enNDexMaT5Hp9nuu68y/YuwS3xDM37xfuyzDP7kei/jxzjj7vNVNBZv7C0z91N/x6WfSWb1/3e/bHA/hyaLG4vAtvmLTxiRc51aVMfucdo+PTPY/L0qpok90NF04JHYFRa2YBbVZFPB7jZwfUfw9RQ3qU6T5Xp1j1Xn5lvUGb7Bb/ALqY/PYf8tZv+e6+i9+2OB/Dk1cdjui/dTf6x/8AlrN/z2X/AGfw45zyfmwKyb64uvsMAeOwUbrHpqsmcideMbOO2R/AORmrT3F5ui/daf8A6x/+YtKf+Wyn/nnxxznuPm6ii+oOk+VadX1XZeYXTN/aUX7qYf6Jff8ALWb/AJ6xf7Pbvng/xYNXLlm868/dTD93J1lmOPkj65Xn8cDkZ4AzkXM90b+P93Yb/st6ABqshBzJH/sdemB/F1OMVbubi8Mt5iLTzmOTGNWlbPyR9D5fzfQ9cEfwihPUHSfu6dH1Xf1J7F2/tXUf3E//AB/jjzrjP/HrHx93Oe+euOMY5qWxYhbf91McSL0lmGf3Psv48c44+7zWfZ3Fz/al+VTTz/pwLZ1iUAf6Mg4by+R0+brn5enNSWNxeBbfMWnjEi5zq0qY/c47R8emex+XpQnoTOk7bfZX2l29Q0Fm/sLTP3U3/HpZ9JZvX/d79scD+HJo1Bm+wW/7qY/PYf8ALWb/AJ7r6L37Y4H8OTVTRJ7oaLpwSOwKi1swC2qyKeD3Gzg+o/h6ilvri6+wwB47BRusemqyZyJ14xs47ZH8A5GaV/dNnSftnp9pdV3Xmazsd0X7qb/WP/y1m/57L/s/hxznk/NgVTumb+0ov3Uw/wBEvv8AlrN/z1i/2e3fPB/iwaHuLzdF+60//WP/AMxaU/8ALZT/AM8+OOc9x83UVUuZ7o38f7uw3/Zb0ADVZCDmSP8A2OvTA/i6nGKbZnSpO6079V2fma9yzedefuph+7k6yzHHyR9crz+OByM8AZisXb+1dR/cT/8AH+OPOuM/8esfH3c575644xjmoLm4vDLeYi085jkxjVpWz8kfQ+X830PXBH8IqOzuLn+1L8qmnn/TgWzrEoA/0ZBw3l8jp83XPy9OaG9iY0nyPT7Pdd15mhYsQtv+6mOJF6SzDP7n2X8eOccfd5qnoLN/YWmfupv+PSz6Szev+737Y4H8OTRY3F4Ft8xaeMSLnOrSpj9zjtHx6Z7H5elVNEnuhounBI7AqLWzALarIp4PcbOD6j+HqKG9SnSfK/WPVefmW9QZvsFv+6mPz2H/AC1m/wCe6+i9+2OB/Dk1cdjui/dTf6x/+Ws3/PZf9n8OOc8n5sCsm+uLr7DAHjsFG6x6arJnInXjGzjtkfwDkZq09xebov3Wn/6x/wDmLSn/AJbKf+efHHOe4+bqKL6g6T5Vp1fVdl5hdM39pRfuph/ol9/y1m/56xf7Pbvng/xYNXLlm868/dTD93J1lmOPkj65Xn8cDkZ4AzkXM90b+P8Ad2G/7LegAarIQcyR/wCx16YH8XU4xVu5uLwy3mItPOY5MY1aVs/JH0Pl/N9D1wR/CKE9QdJ+7p0fVd/UnsXb+1dR/cT/APH+OPOuM/8AHrHx93Oe+euOMY5qWxYhbf8AdTHEi9JZhn9z7L+PHOOPu81n2dxc/wBqX5VNPP8ApwLZ1iUAf6Mg4by+R0+brn5enNSWNxeBbfMWnjEi5zq0qY/c47R8emex+XpQnoTOk7bfZX2l29Q0Fm/sLTP3U3/HpZ9JZvX/AHe/bHA/hyaNQZvsFv8Aupj89h/y1m/57r6L37Y4H8OTVTRJ7oaLpwSOwKi1swC2qyKeD3Gzg+o/h6ilvri6+wwB47BRusemqyZyJ14xs47ZH8A5GaV/dNnSftnp9pdV3Xmazsd0X7qb/WP/AMtZv+ey/wCz+HHOeT82BVO6Zv7Si/dTD/RL7/lrN/z1i/2e3fPB/iwaHuLzdF+60/8A1j/8xaU/8tlP/PPjjnPcfN1FVLme6N/H+7sN/wBlvQANVkIOZI/9jr0wP4upxim2Z0qTutO/Vdn5mvcs3nXn7qYfu5Ossxx8kfXK8/jgcjPAGYrF2/tXUf3E/wDx/jjzrjP/AB6x8fdznvnrjjGOagubi8Mt5iLTzmOTGNWlbPyR9D5fzfQ9cEfwio7O4uf7Uvyqaef9OBbOsSgD/RkHDeXyOnzdc/L05ob2JjSfI9Ps913XmaFixC2/7qY4kXpLMM/ufZfx45xx93mqegs39haZ+6m/49LPpLN6/wC737Y4H8OTRY3F4Ft8xaeMSLnOrSpj9zjtHx6Z7H5elVNEnuhounBI7AqLWzALarIp4PcbOD6j+HqKG9SnSfK/WPVefmW9QZvsFv8Aupj89h/y1m/57r6L37Y4H8OTVx2O6L91N/rH/wCWs3/PZf8AZ/DjnPJ+bArJvri6+wwB47BRusemqyZyJ14xs47ZH8A5GatPcXm6L91p/wDrH/5i0p/5bKf+efHHOe4+bqKL6g6T5Vp1fVdl5mffHN7cZBH7xuCSSOfU8/nzRVS+lvze3BFvaEGRsEXbuDz/AHinP170VqmehCm+Vbfev8zb0GeQaFpg+2QjFpZjHnpxg8D7nbqfTvu6UahPILC3AvIRh7AY89BjE64H3O3U+nfd0qPQ7W9bRNNZb/VVU2lkQqrbYAzwBlM49M8/3qL21vVsLc/btVYZ08AbbbH+vG0j5M9eVz3+9xWN/d2OFxh7Z6x+Jd+68jQeeTdF/pkJxI5/16cfvlOfuevP0GeAMGndTyHUogbyE5tL4Y89OcyxZH3O/Uevbb0rhviJfX2mfED4a25v9SJutUvFAkEHXGwlQF2lsyfxAgHpgV2t1a3v25FN9qvNpfncVtuB5se4cJ0z175A28Zpt+Rz0JQlUcdNL/k/I0LmeQzXhN5C26OQEidDuykfA+TnOMcYzg9MEmKxuZf7V1A/b4M/bwd32hMZ+yxjOfL6ds4xnjGeaLu0vvPv92o6tnypd25bXONkWc4Tp0zjnGMc5plna351a/Av9XDDUACQtruJ+ypyfkxux+GB60N7aFRjDkesfh8+68ixYzyKtvi8hTEinmdBj9zjPKHHHHfnjrzVPQZ5BoWmD7ZCMWlmMeenGDwPudup9O+7pU+nWl9sttuo6t/rVxsW16/Zx0ynXHrxj3qpodretommst/qqqbSyIVVtsAZ4Aymcemef71DeuxTjDlesd49/PyJNQnkFhbgXkIw9gMeegxidcD7nbqfTvu6VceeTdF/pkJxI5/16cfvlOfuevP0GeAMHPvbW9Wwtz9u1VhnTwBttsf68bSPkz15XPf73FW5LS+3wf8AEx1b/WyYytr1+0J0+TrnHtnGOM0X12BxhZax3ffsvIgup5DqUQN5Cc2l8MeenOZYsj7nfqPXtt6VcuZ5DNeE3kLbo5ASJ0O7KR8D5Oc4xxjOD0wSc+6tb37cim+1Xm0vzuK23A82PcOE6Z698gbeM1bu7S+8+/3ajq2fKl3bltc42RZzhOnTOOcYxzmhPV6A4w93WOz7/wA3oFjcy/2rqB+3wZ+3g7vtCYz9ljGc+X07ZxjPGM81LYzyKtvi8hTEinmdBj9zjPKHHHHfnjrzVeztb86tfgX+rhhqABIW13E/ZU5PyY3Y/DA9afp1pfbLbbqOrf61cbFtev2cdMp1x68Y96UXpsTOMLbx+Fd+3oQaDPINC0wfbIRi0sxjz04weB9zt1Pp33dKNQnkFhbgXkIw9gMeegxidcD7nbqfTvu6VHodretommst/qqqbSyIVVtsAZ4Aymcemef71F7a3q2Fuft2qsM6eANttj/XjaR8mevK57/e4ov7uxs4w9s9Y/Eu/deRoPPJui/0yE4kc/69OP3ynP3PXn6DPAGDTup5DqUQN5Cc2l8MeenOZYsj7nfqPXtt6VPJaX2+D/iY6t/rZMZW16/aE6fJ1zj2zjHGaqXVre/bkU32q82l+dxW24Hmx7hwnTPXvkDbxmm35GdKMLrWPXv2fkaFzPIZrwm8hbdHICROh3ZSPgfJznGOMZwemCTFY3Mv9q6gft8Gft4O77QmM/ZYxnPl9O2cYzxjPNF3aX3n3+7UdWz5Uu7ctrnGyLOcJ06ZxzjGOc0yztb86tfgX+rhhqABIW13E/ZU5PyY3Y/DA9aG9tCYxhyPWPw+fdeRYsZ5FW3xeQpiRTzOgx+5xnlDjjjvzx15qnoM8g0LTB9shGLSzGPPTjB4H3O3U+nfd0qfTrS+2W23UdW/1q42La9fs46ZTrj14x71U0O1vW0TTWW/1VVNpZEKq22AM8AZTOPTPP8Aeob12KcYcr1jvHv5+RJqE8gsLcC8hGHsBjz0GMTrgfc7dT6d93Srjzybov8ATITiRz/r04/fKc/c9efoM8AYOfe2t6thbn7dqrDOngDbbY/142kfJnryue/3uKtyWl9vg/4mOrf62TGVtev2hOnydc49s4xxmi+uwOMLLWO779l5EF1PIdSiBvITm0vhjz05zLFkfc79R69tvSrlzPIZrwm8hbdHICROh3ZSPgfJznGOMZwemCTn3Vre/bkU32q82l+dxW24Hmx7hwnTPXvkDbxmrd3aX3n3+7UdWz5Uu7ctrnGyLOcJ06ZxzjGOc0J6vQHGHu6x2ff+b0CxuZf7V1A/b4M/bwd32hMZ+yxjOfL6ds4xnjGealsZ5FW3xeQpiRTzOgx+5xnlDjjjvzx15rm/AurXniO716aO51aF7LxDc6e202rF2hhCbuYwNxUDgfKB6nk7+nWl9sttuo6t/rVxsW16/Zx0ynXHrxj3oT02M37Kcbpx+Fd+it2INBnkGhaYPtkIxaWYx56cYPA+526n077ulGoTyCwtwLyEYewGPPQYxOuB9zt1Pp33dKj0O1vW0TTWW/1VVNpZEKq22AM8AZTOPTPP96i9tb1bC3P27VWGdPAG22x/rxtI+TPXlc9/vcUr+7sdDjD2z1j8S7915Gg88m6L/TITiRz/AK9OP3ynP3PXn6DPAGDTup5DqUQN5Cc2l8MeenOZYsj7nfqPXtt6VPJaX2+D/iY6t/rZMZW16/aE6fJ1zj2zjHGaqXVre/bkU32q82l+dxW24Hmx7hwnTPXvkDbxmm35GdKMLrWPXv2fkaFzPIZrwm8hbdHICROh3ZSPgfJznGOMZwemCTFY3Mv9q6gft8Gft4O77QmM/ZYxnPl9O2cYzxjPNF3aX3n3+7UdWz5Uu7ctrnGyLOcJ06ZxzjGOc0yztb86tfgX+rhhqABIW13E/ZU5PyY3Y/DA9aG9tCYxhyPWPw+fdeRYsZ5FW3xeQpiRTzOgx+5xnlDjjjvzx15qnoM8g0LTB9shGLSzGPPTjB4H3O3U+nfd0qfTrS+2W23UdW/1q42La9fs46ZTrj14x71U0O1vW0TTWW/1VVNpZEKq22AM8AZTOPTPP96hvXYpxhyvWO8e/n5EmoTyCwtwLyEYewGPPQYxOuB9zt1Pp33dKuPPJui/0yE4kc/69OP3ynP3PXn6DPAGDn3trerYW5+3aqwzp4A222P9eNpHyZ68rnv97irclpfb4P8AiY6t/rZMZW16/aE6fJ1zj2zjHGaL67A4wstY7vv2XkQXU8h1KIG8hObS+GPPTnMsWR9zv1Hr229KuXM8hmvCbyFt0cgJE6HdlI+B8nOcY4xnB6YJPmXgbdffFb4stDc36vb/AGWPejRkg+Syy7gw2fM0S52jPyjHFekXdpfeff7tR1bPlS7ty2ucbIs5wnTpnHOMY5zQn5GVKpTqpNWVr/nft5hY3Mv9q6gft8Gft4O77QmM/ZYxnPl9O2cYzxjPNS2M8irb4vIUxIp5nQY/c4zyhxxx354681Xs7W/OrX4F/q4YagASFtdxP2VOT8mN2PwwPWn6daX2y226jq3+tXGxbXr9nHTKdcevGPelF6bFzjC28fhXft6EGgzyDQtMH2yEYtLMY89OMHgfc7dT6d93SjUJ5BYW4F5CMPYDHnoMYnXA+526n077ulR6Ha3raJprLf6qqm0siFVbbAGeAMpnHpnn+9Re2t6thbn7dqrDOngDbbY/142kfJnryue/3uKL+7sbOMPbPWPxLv3XkaDzybov9MhOJHP+vTj98pz9z15+gzwBg07qeQ6lEDeQnNpfDHnpzmWLI+536j17belTyWl9vg/4mOrf62TGVtev2hOnydc49s4xxmql1a3v25FN9qvNpfncVtuB5se4cJ0z175A28Zpt+RnSjC61j179n5GhczyGa8JvIW3RyAkTod2Uj4Hyc5xjjGcHpgkxWNzL/auoH7fBn7eDu+0JjP2WMZz5fTtnGM8YzzRd2l959/u1HVs+VLu3La5xsiznCdOmcc4xjnNMs7W/OrX4F/q4YagASFtdxP2VOT8mN2PwwPWhvbQmMYcj1j8Pn3XkWLGeRVt8XkKYkU8zoMfucZ5Q444788deap6DPINC0wfbIRi0sxjz04weB9zt1Pp33dKn060vtltt1HVv9auNi2vX7OOmU649eMe9VNDtb1tE01lv9VVTaWRCqttgDPAGUzj0zz/AHqG9dinGHK9Y7x7+fkSahPILC3AvIRh7AY89BjE64H3O3U+nfd0q488m6L/AEyE4kc/69OP3ynP3PXn6DPAGDy/j3U7jwv4GvdbuLzVJorC3s5xGfsyhyJhsGQhIBbGDg8/eBHFbOnNc6lp2m31vqOrGG6BnjJW16NNGRj5OvI698ds0X12JbpNqF43T8+q9PIfdTyHUogbyE5tL4Y89OcyxZH3O/Uevbb0q5czyGa8JvIW3RyAkTod2Uj4Hyc5xjjGcHpgk591a3v25FN9qvNpfncVtuB5se4cJ0z175A28Zq3d2l959/u1HVs+VLu3La5xsiznCdOmcc4xjnNCer0KcYe7rHZ9/5vQLG5l/tXUD9vgz9vB3faExn7LGM58vp2zjGeMZ5qWxnkVbfF5CmJFPM6DH7nGeUOOOO/PHXmq9na351a/Av9XDDUACQtruJ+ypyfkxux+GB60/TrS+2W23UdW/1q42La9fs46ZTrj14x70ovTYmcYW3j8K79vQg0GeQaFpg+2QjFpZjHnpxg8D7nbqfTvu6UahPILC3AvIRh7AY89BjE64H3O3U+nfd0qPQ7W9bRNNZb/VVU2lkQqrbYAzwBlM49M8/3qL21vVsLc/btVYZ08AbbbH+vG0j5M9eVz3+9xRf3djZxh7Z6x+Jd+68jQeeTdF/pkJxI5/16cfvlOfuevP0GeAMGndTyHUogbyE5tL4Y89OcyxZH3O/Uevbb0qeS0vt8H/Ex1b/WyYytr1+0J0+TrnHtnGOM1UurW9+3IpvtV5tL87ittwPNj3DhOmevfIG3jNNvyM6UYXWsevfs/I0LmeQzXhN5C26OQEidDuykfA+TnOMcYzg9MEmKxuZf7V1A/b4M/bwd32hMZ+yxjOfL6ds4xnjGeaLu0vvPv92o6tnypd25bXONkWc4Tp0zjnGMc5plna351a/Av9XDDUACQtruJ+ypyfkxux+GB60N7aExjDkesfh8+68ixYzyKtvi8hTEinmdBj9zjPKHHHHfnjrzVPQZ5BoWmD7ZCMWlmMeenGDwPudup9O+7pU+nWl9sttuo6t/rVxsW16/Zx0ynXHrxj3ry/RorlvjXo6reX6ufBlqVKiDcq/bEwoyuNvQjPzZxk4zQ3rsE+SKteOrj+vkek6hPILC3AvIRh7AY89BjE64H3O3U+nfd0q488m6L/TITiRz/r04/fKc/c9efoM8AYOfe2t6thbn7dqrDOngDbbY/wBeNpHyZ68rnv8Ae4q3JaX2+D/iY6t/rZMZW16/aE6fJ1zj2zjHGaL67FOMLLWO779l5GTfMWvbhiwcmRiWBBB565AGfyFFVNRtLj+0LrdqF7u81s71hznJ64TGfpxRWqfkelCEeVe8vx/yNrQbRToWmH7PMc2lmc7Iedxx39e3c/xcUahaKbC3P2eY5ewOQkPO6dR39e2eT/FxVTRNK06TRdOeTTrBna1s2Zm0wsSSeST3J7n+LoKL3StOSxt2XTrAMWsQSNMOTmcA898jgn+IcCsbvlONuPtnq/iX2fNeZ598XbVR8UPhOvkSgPqd2uCsQ3YkhGBjgn/e49OK9MurQDUoj9nmGLS+OSkPG2WIdvTv3H8PFeRfGGG1t/if8LLaG1to4W1SffGlpsRg00S8p/FwMY9Pl6ivUrnSdOF/Go06wCm1vWIGmEciSPB9iMnB/hzg0Ns4sI0609er6eT8zXubRVmvB9nmG2OQ4KQ8YSM84+vbnkY5zUVjYr/auor9ln/4/wALjy7fP/HrGceme/pj3qC50fTBLeY0zTxiOTGNMK4+SPoP4fqenJ/iFZWoy+GdBlvrvXhothZLqKwrJdaf5aAm2QhQD75O3r1bpTbehupRVNtyfw/y+a8zobGzDrb/AOjzNukUcJCc/ud3f8+eMf7VU9BtFOhaYfs8xzaWZzsh53HHf17dz/FxRY6PphW3zpmnnMi9dML5/c57deecdz83SqmiaVp0mi6c8mnWDO1rZszNphYkk8knuT3P8XQUNu5TceV6veP2fXzLeoWimwtz9nmOXsDkJDzunUd/Xtnk/wAXFXHtAGi/0eYZkcfch5xMo/rjnjJ4+XNZF7pWnJY27Lp1gGLWIJGmHJzOAee+RwT/ABDgVbfR9M3Rf8SzT/8AWP8A8wwj/lso/H0x2Hy9TRd3BuPKtXu/s+S8wurQDUoj9nmGLS+OSkPG2WIdvTv3H8PFXLm0VZrwfZ5htjkOCkPGEjPOPr255GOc1kXOk6cL+NRp1gFNresQNMI5EkeD7EZOD/DnBq3c6PpglvMaZp4xHJjGmFcfJH0H8P1PTk/xChN3YNx93V7P7Pn6k9jYr/auor9ln/4/wuPLt8/8esZx6Z7+mPepbGzDrb/6PM26RRwkJz+53d/z54x/tVn2ek6a2qXytpunlVvgqg6UcAfZkOAvpkk7fU7qksdH0wrb50zTzmReumF8/uc9uvPOO5+bpQm7Ezcbbv4V9ny9Tm/hVrEniTQNQ8/TXtpdI1EaOyr5RLGIoCzBlBUneBjnkHcccDpNQtFNhbn7PMcvYHISHndOo7+vbPJ/i4ryv9mx4PEHgrX9R1C2guJbnxFLOTcWpuCC4gLc9s55/vdK9JvdK05LG3ZdOsAxaxBI0w5OZwDz3yOCf4hwKV3ykYWt7a1ST1cu3mvM13tAGi/0eYZkcfch5xMo/rjnjJ4+XNU7q0A1KI/Z5hi0vjkpDxtliHb079x/DxQ+j6Zui/4lmn/6x/8AmGEf8tlH4+mOw+Xqa8T8Xae/iXVPHd/ZXUmnaX4fsryLTv7Nhlti93AqtOzqMdpnhycgISMDqW2wdVU9Y3b10tbSzv16fie8XNoqzXg+zzDbHIcFIeMJGecfXtzyMc5qKxsV/tXUV+yz/wDH+Fx5dvn/AI9Yzj0z39Me9ZenQ6HrGmjUrCw057S7tWuIWXTCvytHEwIH8J56npyf4hVmz0nTW1S+VtN08qt8FUHSjgD7MhwF9Mknb6ndQ29C4uPI/efw/wAvmvM0LGzDrb/6PM26RRwkJz+53d/z54x/tVT0G0U6Fph+zzHNpZnOyHnccd/Xt3P8XFFjo+mFbfOmaecyL10wvn9znt155x3PzdKqaJpWnSaLpzyadYM7WtmzM2mFiSTySe5Pc/xdBQ27lNx5Xq94/Z9fMt6haKbC3P2eY5ewOQkPO6dR39e2eT/FxVx7QBov9HmGZHH3IecTKP6454yePlzWRe6VpyWNuy6dYBi1iCRphyczgHnvkcE/xDgVbfR9M3Rf8SzT/wDWP/zDCP8Also/H0x2Hy9TRd3BuPKtXu/s+S8wurQDUoj9nmGLS+OSkPG2WIdvTv3H8PFXLm0VZrwfZ5htjkOCkPGEjPOPr255GOc1kXOk6cL+NRp1gFNresQNMI5EkeD7EZOD/DnBrG+IuqaJ4Q02a5k0Wzurq6lNlY2kWm7GnuHVNiDP3O5yc45OCWAIm9RTnCKi3J7P7Pn6nL/sxTvrnhPWNTuIJXmvfEdzM5VYmyWgRyPmGc5OeePxr1ixsw62/wDo8zbpFHCQnP7nd3/PnjH+1XlPwC8LxaHpmp6HrGnWh1Gzv4XnWez89kMljE5Q46gNu4zgnkcDn0qx0fTCtvnTNPOZF66YXz+5z268847n5ulCbscmGa9jq3t29fMNBtFOhaYfs8xzaWZzsh53HHf17dz/ABcVV1eWxg/syyuJEjvr17RraBzbiSfbMpcop5bC8nGT/e4qPStP0lPD9lc3dnpiItnaSSzTafhVGcszOePqx4YV5Zp3hJfH2hX/AIivzd6U11cQL4d8iCSM2EJmjRLlUXgSyGNXY5JYABWHBCu+U6a9VxqtU9Zc21rdvM9te0AaL/R5hmRx9yHnEyj+uOeMnj5c1TurQDUoj9nmGLS+OSkPG2WIdvTv3H8PFc78P59L8T+DdC1VtP0w3M8f+lKmlkBJhKgkTHfDbgB6cfxA1e12HQ9JEl5qFrp1tYwWV9LNI2mMAoWSPB4B5GSBgErnHJNNt2KpTg7S5nbX7Pk/M6C5tFWa8H2eYbY5DgpDxhIzzj69ueRjnNRWNiv9q6iv2Wf/AI/wuPLt8/8AHrGceme/pj3rjvAWp2XizSdQub/wpb6HqNs00Nxp9xp2WhPlxMpHAIBVwQSBgluoINdNZ6TprapfK2m6eVW+CqDpRwB9mQ4C+mSTt9TuobehMJwdNtSfw/y+a8zQsbMOtv8A6PM26RRwkJz+53d/z54x/tVT0G0U6Fph+zzHNpZnOyHnccd/Xt3P8XFFjo+mFbfOmaecyL10wvn9znt155x3PzdKqaJpWnSaLpzyadYM7WtmzM2mFiSTySe5Pc/xdBQ27ltx5Xq94/Z9fMt6haKbC3P2eY5ewOQkPO6dR39e2eT/ABcVce0AaL/R5hmRx9yHnEyj+uOeMnj5c1kXulacljbsunWAYtYgkaYcnM4B575HBP8AEOBVHxrPonhbwxf65d6VpzxWSSy+WdP8vzWEyhU3EHG4kL0+XOD1ou7hKUVFNydrv7PkvM85+Cm6X4nfF+N0kYJeucbY8rslnUZzwMD+7z6V7Xc2irNeD7PMNschwUh4wkZ5x9e3PIxzmvGfhb4XGieLdUtdZhEupahoEep30Vzaq6xXTXE4cIqAKgB4BGQOfoPWrnR9MEt5jTNPGI5MY0wrj5I+g/h+p6cn+IURucWCso2ba1fT08yexsV/tXUV+yz/APH+Fx5dvn/j1jOPTPf0x71n65qmm+GfDk2t6ys0dhabXldY4CWzCMKoPVmYjAPByP4qls9J01tUvlbTdPKrfBVB0o4A+zIcBfTJJ2+p3V5xeDSfGvj3S/DGl2VrNpWkzre61cwWR2GRIv3VqSv+szICzocA7Cc5BAE3Y3xFRRjo9eVW08vU7n4f39h4i8GaPqemR3EltLbWy5MUKkOHMbggjP3lZc98ckjBrS1C0U2Fufs8xy9gchIed06jv69s8n+LivOfh7Y2GheIrjw/qNlatHrMUGs6XNc2rSmXcE+0wIWxyr5k2Juyrk8V3d7pWnJY27Lp1gGLWIJGmHJzOAee+RwT/EOBSu+U1pT5qnvP3lJX063Xma72gDRf6PMMyOPuQ84mUf1xzxk8fLmqd1aAalEfs8wxaXxyUh42yxDt6d+4/h4rkr/xD4dt/iNpfg9dFtpr66EkjTR6cvlwnezqjjO7JSFzjHAIHOSV6K50nThfxqNOsAptb1iBphHIkjwfYjJwf4c4NNthRnByspbX+z5PzNe5tFWa8H2eYbY5DgpDxhIzzj69ueRjnNRWNiv9q6iv2Wf/AI/wuPLt8/8AHrGceme/pj3qC50fTBLeY0zTxiOTGNMK4+SPoP4fqenJ/iFR2ek6a2qXytpunlVvgqg6UcAfZkOAvpkk7fU7qG3oKLjyPV/D/L5rzNCxsw62/wDo8zbpFHCQnP7nd3/PnjH+1VPQbRToWmH7PMc2lmc7Iedxx39e3c/xcUWOj6YVt86Zp5zIvXTC+f3Oe3XnnHc/N0qpomladJounPJp1gzta2bMzaYWJJPJJ7k9z/F0FDbuU3Hler3j9n18zi/2iBBb/BnWfNVo5JorJYtyxDexnVjjAzyqsfXg57V1fgDzL/wH4UvLlbiee6sIZZJXETGRiYskluSeTy3c+ma8w/aLsbK+0LRfDujw2set3ZS7WC3smSSWOOGbIO0Eks5jUcYdsdNpI7/4b6Vpsnw78IO1hZSM2nW5Lvp5dm5i5Lfxf/XK9TTu7nLG3t27u2nTy9TpLq0A1KI/Z5hi0vjkpDxtliHb079x/DxVy5tFWa8H2eYbY5DgpDxhIzzj69ueRjnNZFzpOnC/jUadYBTa3rEDTCORJHg+xGTg/wAOcGrdzo+medeD+zdOAEcmP+JZtA+SP1+79T05P8QpJu7OpuKUbyez+z5+pPY2K/2rqK/ZZ/8Aj/C48u3z/wAesZx6Z7+mPepbGzDrb/6PM26RRwkJz+53d/z54x/tV4P4L8Q3kvizSNf1q2sW8JeJNQnsra1bSlxp8hx9mVsIC+9OgBxzvNe2WOj6YVt86Zp5zIvXTC+f3Oe3XnnHc/N0oi3YxVaFRN3asl9ny9eoaDaKdC0w/Z5jm0sznZDzuOO/r27n+LijULRTYW5+zzHL2ByEh53TqO/r2zyf4uKqaJpWnSaLpzyadYM7WtmzM2mFiSTySe5Pc/xdBRe6VpyWNuy6dYBi1iCRphyczgHnvkcE/wAQ4FK75Tqbj7Z6v4l9nzXma72gDRf6PMMyOPuQ84mUf1xzxk8fLmqd1aAalEfs8wxaXxyUh42yxDt6d+4/h4ofR9M3Rf8AEs0//WP/AMwwj/lso/H0x2Hy9TVS50nThfxqNOsAptb1iBphHIkjwfYjJwf4c4NNtmdJxutX1+z5PzNe5tFWa8H2eYbY5DgpDxhIzzj69ueRjnNRWNiv9q6iv2Wf/j/C48u3z/x6xnHpnv6Y96gudH0wS3mNM08YjkxjTCuPkj6D+H6npyf4hUdnpOmtql8rabp5Vb4KoOlHAH2ZDgL6ZJO31O6ht6ExceR6v4f5fNeZoWNmHW3/ANHmbdIo4SE5/c7u/wCfPGP9qvGfBs8N38fJLZYyWtfC1pCy7UzuaS3fj+HkSd/XnvXrNlpGl7LctpunkeYud2mF/wDlhnnHX1x6/N0rwv4V2Ed1450vXpFjuIfECXojD22A9pBNbRQ74gOWzGScFs5HOc0O90Y4iUfdim94vbpqu/mtD3XULRTYW5+zzHL2ByEh53TqO/r2zyf4uKuPaANF/o8wzI4+5DziZR/XHPGTx8uayL3StOSxt2XTrAMWsQSNMOTmcA898jgn+IcCrb6Ppm6L/iWaf/rH/wCYYR/y2Ufj6Y7D5epou7nQ3HlWr3f2fJeZn3y7L24QKV2yMMEAEc+3H5cUVUvtK08XtwBYWgAkbgW4QDn+6Rx9O1Faq56EFDlWr+7/AIJoaJd2yaLpytbuWFrZgkaTO2TnnkDBz6jhugovru2extwLd87rE5bSZ/8Anuuecck+v8fQc1b0Fm/sLTP3U3/HpZ9JZvX/AHe/bHA/hyaNQZvsFv8Aupj89h/y1m/57r6L37Y4H8OTWOvKcba9s9H8S6ruvI8R+Mmowv8AGL4cwxoVWO+RmQ2ciEhr1P8AlmfmbhMYA/2eoNeyXN3bfb43ED4Frej/AJBM4OfMjxjjtjr0Toeorxn4q2LXfx98KXaRzE2f9nSMoMjYV9ScbiSNyjLKMgdWHc4r2vU7qK1uhPdboII7K+Z5JZ5lVB5kWSSVxgd88H+LBo1OHCNe1m7Pd9V2fkS3N7aiW8At5BiOTGNHnXHyR9Bj5fqenJ/iFeaX1hp/i/4zX9rrGkC70DSIGUZ0qcA3VxBECGjAyQsceR0Ks24HpjT1n4taQ9/fWfhSw1LxTfbGQppckskUZZFwXmIxt+U5PI9eFrV+E2jaloWl3keutNc61d6q97fOHmQedLboxQBVP3cgZHJx/dNDu9Ac41VyRTaS11Xl5b3sZHwc1B9N05vCutWl2L3SLgrbyXGmSytdWTK4glAUfdwhXb2K5znIEPhjx79p8UafocOkxT6MYYbAanFb79t9DCJ5YmUNk5QkdMsyMADyV6LxD4J0zxLPZXsv9pafq0QWBNS026mguBH5Qby9wQgru+YDBx24JJyJfBENx8M00/QVNprEi2uqQalP5s0v9ob9/wBodivLuflLc4ViF3fdp2dxTVWMGoJ2TXVedlt/Vjqr67tnsbcC3fO6xOW0mf8A57rnnHJPr/H0HNW3vbXdF/o8n+sf/mDzj/lso9OeOMdh8vU15/c+NfFVjpsZ8Q/DzWgiSWapNpV79rEpSYHIjBDKr4AXOeTxg1c/4W94WjEK6n/aul3m87rO8trsTIWkVgpCoRnAPQnOM9QMq7vua/WaLSTutXu0ui7o6q5u7b7fG4gfAtb0f8gmcHPmR4xx2x16J0PUVaub21Et4BbyDEcmMaPOuPkj6DHy/U9OT/EK4PVfF3iLWLlF8GeE9RDeVcp9v1ppba28p3jfzUQkSyIACDhRyyk5zip5PBfiTUzcTeJfG2vLeL5jiPRmazgjUhG8sho2eRRnGZDkqFzjAJav0D28ZKPs4t79UuvodjZ3VquqX2bdsNfDAGjTnj7MnBXGRyM7ev8AF0rxeHxVqNt8XLbxNLbXKeFZbxfDJtvsTj7VIkb4YqcqWE5fBB3Y3cDkHsYvh1eXmqX0l1438di4+2AO1tqTwqzfZ0JIRYMA844H3QBjHzVuW3gPQpfANr4Qk0+Z9GVk+XzZd5YIJC4IQgOWyxK+pAG00kpNGOIjUqK1mrJdV28kjkf2fTDY+EL2CWHdmexlGzTnl+/Z2rH/AFY4znnPL/UmvQr67tnsbcC3fO6xOW0mf/nuuecck+v8fQc1y/wrMUOp+KLW0tTBBDJpIjhikmAjX7FbhR0JPC8FiT6Fjyc67vvFXi7U7n+xNRfw/wCH9Lu4tLlPkPPc3k6TIjOu9CkaKzPtIyQ0fAJPBrylYV+xioNNyUraNbp+hv8AxD8WRaDoIOnWyy63eTPaaZayabLF9ouWmUIuXABA5OCeACvUim+EtJsfC2kadpkYnuZILK98+5l0mfzbiYyxlpGJGck55OdgwCelL4X+H+maBrMGsTPqur64oeFdR1O7mmmRfNAIQ7Bt4ZhkDPzt0Jwemumb+0ov3Uw/0S+/5azf89Yv9nt3zwf4sGm0zWgm6nNNPrbVdnfoeW+D/Eum+AFuvCfim3m0i1hkvv7Iv9QtX8u6g3ho13k5SQKw4YfKCvdgKxviP4l1XXtR1eb4f6kkelaLGNXub2wQqtwxgGyBlB3bNsEzHOVPfqufbdasbTVIr611PTlu7ZkctDc+bKmQsZBIZecEA8+2cALnLsPDWix2+u6Pa6HBZ6beXTwzW9ossCsj2q7l+RB/fbnGQDgDbQ09DD2c3TcY3tbyv00++3yuX9M1PTrmC0mtVNzbSujRzLpE8iyIYAQwIGGB64HX73Sq+iXdsmi6crW7lha2YJGkztk555Awc+o4boK4TwvqfjTwPp1rpOqeFb/xLpWnuqwanpVzsla3EQWOP7PwWkVMZKnkDqwyxuaL8TbFLS005fD3iqTUba0txcWsdlcmSEocHcoHGSMDGQOxzSu7mixNNQcZ3T93ql3v0Ovvru2extwLd87rE5bSZ/8Anuuecck+v8fQc1be9td0X+jyf6x/+YPOP+Wyj0544x2Hy9TXneoa14y8WW8Fro2iap4R0/NsG1TVEaS43rIAgS1zxmQqQWONqtt5wDem+GNvqjw/8JfrXiTxFCzEy2V3eyxWjSBwu9Yoo12nk9CeTzzwX719CnW5kvZxbV31S6LyNW58ZeE11nyZ9d0O1mitbtWS6QW7Bmlj2D94w5+Vsf3cEGsN9a0fxJ8XTLpL22p2Gg6TcSfbtOtnmhjuLgRoEBjyAfLSTnJUZPfIGr/wgHg+2mtbaLwfpHlR2l3gvas7ErJGFZmaPLFQSMse/wAxBrpdP0nTtEhvbXRdIg062KyuYbVZIkBKR5JAQZ6DOcZ4zwFyJMmUak3Dm210079/+Act4TuIV+JnjpmjUwPfWYSNdNkZlIsVyWhHzoDxjcAGIJGdrVc1fx74X8N/ZItYu4YruSSMpatpsrzyBosAhMZZdwPPTdznkCszwUzf8Lv+JR8mbPmaX8vmzZ/49JO+3d+Yz6cZNJ8JNFjF9rfiW8tftWq32s3cEV9vkL/ZYi0SRIyAgKPK/hOTgZ4AIFcwjO0OWKd3ft3fS36mFe6te+NtDs/Dmg6Ze2mizW1vBqetS6VMmYd2xkthtYu7jcC7ADC46kV6C7afbaPZWtnZmG3hFgkcf9k3BCosyjAJHPAxnPz9BzWhoLN/YWmfupv+PSz6Szev+737Y4H8OTRqDN9gt/3Ux+ew/wCWs3/PdfRe/bHA/hyaVnynbThy1m53cuZa6LqumpwGqeDpoNbvdR8I+JNU0B9TuXmu7b+wHubcyeYi70jdPlY9WwTnhT75F74Y8R6rfWml+KdZt9V0CJ5ryWddCltrq4Ebofs7xqnl+UXWNieSOVJGQD7E7HdF+6m/1j/8tZv+ey/7P4cc55PzYFU7pm/tKL91MP8ARL7/AJazf89Yv9nt3zwf4sGm0yIUabe0uvVdn0OB1W6fwl8QfEGuyaddXHhrV7aNbqaLSpd1hcRRqvmGMgMsPl8s4DkMBwAwDX9C+KPgC91K6aLxHokaTXwKG4tHgUr9nRckPjC7gRg9+eld3cs3nXn7qYfu5Ossxx8kfXK8/jgcjPAGascMV3e6pBdWbzwSXyh4pHnZWxbRkAgpzyAemeBxjmiz0MlCpGMvZuyt1s+qv1X+Rzdt8RvA8TKkniPQmMMg8wiMygARYJLKcMNwPTqfm6VjWfxO8NQ6db2WkRXHiHULWG1hmttH0l7llYfe+fIRumCQx3dB610dl4F8IFYt3g3Q5N8gDE2AO79znHEZ7ndxz+GDWp4ZijtvDmlQ21q0UKWdmFSN5lUc9gFwM9scD+HJo1uaT9q4vl027Pv6W/E5PU/FOqPo1tPbeAtaZWe1/wBdbWyMSJAw+Xzy3zkBckDdnHHfGNzrnjPXtFh8ReD5vD+i6be/2gztC873kquAkRWMYCKzFiGznaqjB6+k6gzfYLf91MfnsP8AlrN/z3X0Xv2xwP4cmrjsd0X7qb/WP/y1m/57L/s/hxznk/NgUWbYez5oJVLvV9ktl5M4KJ7dvi3rF35Fztj8OrEAuky7ATd3Bye6N8vynGMbgSCvNzxj460vRNVXSbWwm1HXr5ZFtNNg05opD8ikSN5hURoNrZc524ZsEZxmGRh+0Bdr5cmG8JSkjzJcj/Tm5+7nHJ4PB7kHIq1oUMt18WvH+p3MRcW9rb6batul3xIIUlkUttyQWkU4bjgZOAKFe5gpNNqN7tvt/kcumg+JvHd/PJ4uubjwzo09xibQ9JsJnmJ8kqUmmVBwyhCUUkENnCnmvRfClloehaZaWOkaWtrarIvyJo07bj5A5Y4y54Gc5JI3ZxWxYu39q6j+4n/4/wAcedcZ/wCPWPj7uc989ccYxzUtixC2/wC6mOJF6SzDP7n2X8eOccfd5oSdjodOEbu0m7Lqu3ocfe6LoniLwvp9tqVnMLiOztfs97b6XOtxaSEj97DMoyrghTuHD7QMEcVy9x4a8RaVbiTQ/GepXdrF9mmgsNZ0BrgyyGQbUkuQqvtLAcqMkHADHg+maCzf2Fpn7qb/AI9LPpLN6/7vftjgfw5NGoM32C3/AHUx+ew/5azf8919F79scD+HJpWfLc0qUoTrt2knzLZpdV5HkGr6Dfaf4XuvE+rWsl94rTV49emtbKxmggYW8iRrb72TmNYTKORkFiDuJ59E0vxJouvJbajpEsN1bvZXRJt7B5DGzGFwrFMgMFYZ/wCeecNya6d2O6L91N/rH/5azf8APZf9n8OOc8n5sCvN9f8AhP4M1LWjO3h/7LLNBcyyG1mnhUtG8aqdoUKMA88DJ5Yg5y2mjCnB05XpRb33a89b2/rQ7y5vbUS3gFvIMRyYxo864+SPoMfL9T05P8QrLvPEmgaFeXs+tXVnp9u98CHutNliXH2aMYw2MckfL1yQ3QiucT4S+H7T7bFDJryI3mSMo1O5XgIBtOFGQFkdecHDkEgHJXw18JvBem6tcu3htL+WC68hTfvPcDYbdW2lGTbwTkHbuH05pPm0CM6nI7Qe38y8v7psaf8AEHwQ1tDK3ifw4qiUBhKV3f6kclSwJGfbBPPtVLTviF4Is9EiWfxJ4f8AMs7a3WVFAdiyAlwuG+c4U5K53cAckZ19K8GeFraSKa38KaTHK5MbPFaFCyPBhlysfRgTkDqCRgrzVbw54Q8MwabpN1B4U0iK6jt7WRbiOzKSbmPzNuEect06/wC7npT1uD9tyy9V+v3/AIHmqXF7qnh7xh46vLK70yW7sbeLRQ1qwkitI3yJRIvEZeRS/wAxyeMEgqT6F8Nby2X4c+DlaCQsNNtwT/Zcz5/1Q+8Bh/w7cd6n+J6+d8NdcieOZVewhQt5kvA3dcFdv0B4HbNU/D1/LoPwT0TU1t2naw8OpehPOlRXCRRyYzjC8DHB6nPUAE1THHlppKV92+nZX+R0Fzd232+NxA+Ba3o/5BM4OfMjxjjtjr0Toeorgvil4xstTXUfBvhXyLzxBqSS2ksa2DqtnCVTzZJAeVwgkwACwOTj5hVSx+H+oeItPsZvHXibxNqNxeWj3k9nHcNbWqMgQNGYkjKnl+WVlyQScFq9A8MeE9D8H2t/Z+HNIFjFLG/mlJJy8mFXBdiuWA3MQG4G89BjIrsmUp1YpcrSs+qel/RHO+IfCun6t4E1fwlaC5ijzFb2sv8AZlwrK0VrEYt5CEgbo1LLjJGWxgis7Q/i9oemxW9l8QbdfDeuwiN54J9PknjkBiwJEaPOUOA204ILdWwTXpli7f2rqP7if/j/ABx51xn/AI9Y+Pu5z3z1xxjHNJFBFdQQRXNmZ4zIpKO0xBxCMcBSOwPHP/AeaIpjrwd+andPlXZ9PlqeT6/8QdI1D4dWOneDdTsLvX9VjtdJt0ghZZ7aVgQ8rKD5g2gH51U5JXA61e+Fuu3N94Pm03Xj9o1jRdSg0+eZrKSV5lW4VklbADDcjAAsN0m3uc11/hzw9osP9n61FoNmusNbW7tfrE4nLPw7bwmcsOM56EgE5Irj/GOgeJNG8Sf8JT4OH2qG8/s7+1NHdnRr1o32xMkxXCHG0AZAGMgt0C1sH72Ff2lS797p+i11ueive2u6L/R5P9Y//MHnH/LZR6c8cY7D5epqrc3dt9vjcQPgWt6P+QTODnzI8Y47Y69E6HqK4uXxX8R9rOvw3bLtIIIzrYLRN5inLnow3YGFwc9cHBqvt+KWrXCRXsmg6ArwXTieCO6ubiJAy7k2s3lNltgJPQAk88FtsqniIp6Ql17dn5HoOp6rp1ot/Pcr5EEcUjNJJpU8ap8kfPI+Xr1PTJP8Qrl7v4neAtIu557vxHockVzdLNF9ltmuMp9nVeVjLFfmUja2DnmsxfhWuo3M8/j/AFvVvFdxGJJFjuHlt7ZHCptcQqOCAQDk4PfAxnsfDnh3RNI1vUZtI8PWWny/bRHm0hkhIX7OjbAVjBAyS2OvPTHNGulyL1ZQfIradbPt6HmXiv4lad4q8NXXh/wFa3WsavqCi1WWDS5dkKvGEkZmPzDapZshTzhq29PisNO8U/D60s7eRLa10KVApsZMt89qMkBR5pPJLKMNntXptixC2/7qY4kXpLMM/ufZfx45xx93mvPZJinjv4cjZIN+jTLjdId3NseCRkDj+HI9M0O9w9m1FzqXbvFdFpf5m34q8S6JomhRXusSpZ2yvZEyT6XMASJgzYOPmO1WJx94A46VzVx8YPDd7cRWnhCzuPE+qOZClrYaa8Yz5q7PMeTG1DwNwDbQ2CDmm+M7aTxV4/0LSLm1Wfw/osNpqF9BJ5kiXE8sphhRuMrhTI4xlTyMHIr0iCCG0SGK1szBGJHwkbTKP9cg6BfYDjnpn5gBQr3FKVSppDSN32bvbXseCjwb4q1AfbdS+I3irS765/fXFhb2FwI7WRuWiTbMBtUkqMADA4FFeyXxze3GQR+8bgkkjn1PP580VXszqjluFaTcX9//AACXRJ7oaLpwSOwKi1swC2qyKeD3Gzg+o/h6ilvri6+wwB47BRusemqyZyJ14xs47ZH8A5GataDPINC0wfbIRi0sxjz04weB9zt1Pp33dKNQnkFhbgXkIw9gMeegxidcD7nbqfTvu6VFnymjf75+6viXV90eWaz4K0bwh/ZNx4b0yy01rnWrCOYQatNKJFS9j2qxdcoucHcM/dBxxV3xjY3Hi74jabo2p2Wmz6Po9lNrDxSXjyRzzPLJHEjOydtrMEAw4HzZzgdL8SVuJ7Lw/JHcRSLb6/ZyuwnT92DfRLuPyjgsy9j64A4rI8N6reT/ABi8ewGfbax2MMG9pF2ysu6TCsV5/wCPg/KMZznjihqx50aac+SMUte76cz/ACR1djZRaNb3Vno2l6JYWYSUrDaag6R5Kx5wFiAYk5478g/dFWbO4uf7Uvyqaef9OBbOsSgD/RkHDeXyOnzdc/L05rQuZ5DNeE3kLbo5ASJ0O7KR8D5Oc4xxjOD0wSYrG5l/tXUD9vgz9vB3faExn7LGM58vp2zjGeMZ5ptPQ64/A/dXw95d0QWNxeBbfMWnjEi5zq0qY/c47R8emex+XpVTRJ7oaLpwSOwKi1swC2qyKeD3Gzg+o/h6itexnkVbfF5CmJFPM6DH7nGeUOOOO/PHXmqegzyDQtMH2yEYtLMY89OMHgfc7dT6d93Shp3Kb91+6t49X5lW+uLr7DAHjsFG6x6arJnInXjGzjtkfwDkZq09xebov3Wn/wCsf/mLSn/lsp/558cc57j5uoo1CeQWFuBeQjD2Ax56DGJ1wPudup9O+7pVx55N0X+mQnEjn/Xpx++U5+568/QZ4AwSzvuDfur3Vu+r7IyLme6N/H+7sN/2W9AA1WQg5kj/ANjr0wP4upxirdzcXhlvMRaecxyYxq0rZ+SPofL+b6Hrgj+EUXU8h1KIG8hObS+GPPTnMsWR9zv1Hr229KuXM8hmvCbyFt0cgJE6HdlI+B8nOcY4xnB6YJIk7vUG/h91bPq+5n2dxc/2pflU08/6cC2dYlAH+jIOG8vkdPm65+XpzUljcXgW3zFp4xIuc6tKmP3OO0fHpnsfl6VPY3Mv9q6gft8Gft4O77QmM/ZYxnPl9O2cYzxjPNS2M8irb4vIUxIp5nQY/c4zyhxxx354680JOxM3p8K+FdZdjzL4ZSTp4m8YNGto2TpAIk1B4+BaRdMIc8df7nbOKX4Uy3p+F+kXFz9lknvJ4byWWTUJI5JHkvmkyy7T/eGTkkDDdTioPh7q407X/iBPNOBDaW+j3LhZF3MFs0OFGw5ICfh33V0ngdjD8L/CaR3cCL9h0lsCdRg+Yjd0PIJJPpnuOKlL3TOn/vO32n1f8y/r8zo3uLzdF+60/wD1j/8AMWlP/LZT/wA8+OOc9x83UVUuZ7o38f7uw3/Zb0ADVZCDmSP/AGOvTA/i6nGK13nk3Rf6ZCcSOf8AXpx++U5+568/QZ4Awad1PIdSiBvITm0vhjz05zLFkfc79R69tvSqafc2pPVe6uvV9mFzcXhlvMRaecxyYxq0rZ+SPofL+b6Hrgj+EVHZ3Fz/AGpflU08/wCnAtnWJQB/oyDhvL5HT5uufl6c1oXM8hmvCbyFt0cgJE6HdlI+B8nOcY4xnB6YJMVjcy/2rqB+3wZ+3g7vtCYz9ljGc+X07ZxjPGM80NPQmL9x+6vh7y7ogsbi8C2+YtPGJFznVpUx+5x2j49M9j8vSqmiT3Q0XTgkdgVFrZgFtVkU8HuNnB9R/D1Fa9jPIq2+LyFMSKeZ0GP3OM8occcd+eOvNU9BnkGhaYPtkIxaWYx56cYPA+526n077ulDTuU37r91bx6vzKt9cXX2GAPHYKN1j01WTOROvGNnHbI/gHIzVp7i83RfutP/ANY//MWlP/LZT/zz445z3HzdRRqE8gsLcC8hGHsBjz0GMTrgfc7dT6d93Srjzybov9MhOJHP+vTj98pz9z15+gzwBglnfcG/dXurd9X2RkXM90b+P93Yb/st6ABqshBzJH/sdemB/F1OMVbubi8Mt5iLTzmOTGNWlbPyR9D5fzfQ9cEfwii6nkOpRA3kJzaXwx56c5liyPud+o9e23pVy5nkM14TeQtujkBInQ7spHwPk5zjHGM4PTBJEnd6g38PurZ9X3OK0KCe0+Lfi6522vmXsOmz4OoSCLaI7qPPnbdxOUH8Pcjp1pfAmS8i+Gmgs0dn+9mmuMy6jJAf3hkf7oQ4HzYDZyeB3rWvb+Sw+LWp38kpa3h0C2mlnjdWGVlvMANtC5IDADAzj8at/C2UxfD7wkIrmCECxtGx56jBNouWOUOO47jPGO9CTPPovV6dJdX3/r9S1ok90NF04JHYFRa2YBbVZFPB7jZwfUfw9RS31xdfYYA8dgo3WPTVZM5E68Y2cdsj+AcjNWtBnkGhaYPtkIxaWYx56cYPA+526n077ulGoTyCwtwLyEYewGPPQYxOuB9zt1Pp33dKVnynqN/vn7q+JdX3QPcXm6L91p/+sf8A5i0p/wCWyn/nnxxznuPm6iqlzPdG/j/d2G/7LegAarIQcyR/7HXpgfxdTjFa7zybov8ATITiRz/r04/fKc/c9efoM8AYNO6nkOpRA3kJzaXwx56c5liyPud+o9e23pTafczpPVe6uvV9mFzcXhlvMRaecxyYxq0rZ+SPofL+b6Hrgj+EVHZ3Fz/al+VTTz/pwLZ1iUAf6Mg4by+R0+brn5enNaFzPIZrwm8hbdHICROh3ZSPgfJznGOMZwemCTFY3Mv9q6gft8Gft4O77QmM/ZYxnPl9O2cYzxjPNDT0Ji/cfur4e8u6ILG4vAtvmLTxiRc51aVMfucdo+PTPY/L0qpok90NF04JHYFRa2YBbVZFPB7jZwfUfw9RWvYzyKtvi8hTEinmdBj9zjPKHHHHfnjrzVPQZ5BoWmD7ZCMWlmMeenGDwPudup9O+7pQ07lN+6/dW8er8yrfXF19hgDx2CjdY9NVkzkTrxjZx2yP4ByM1ae4vN0X7rT/APWP/wAxaU/8tlP/ADz445z3HzdRRqE8gsLcC8hGHsBjz0GMTrgfc7dT6d93Srjzybov9MhOJHP+vTj98pz9z15+gzwBglnfcG/dXurd9X2R5m73P/C97mUR2hlPhSdSo1CQpt+2nB37OSSfukYPBJycVZ+G97e3E/jqcx2jF9dv0DSai652JBGAuEO8fIQCcbsHPSp9ev5NO+L+gvLNZyJq2kalYRMjr5iukizsWYR8qwXCgnqWI25wdD4fL5Gla+6XUYNzq2sSPmZfnP2pl4+TnIQYxjODjHcSdzip3dX4dm+r7I3LO4uf7Uvyqaef9OBbOsSgD/RkHDeXyOnzdc/L05qSxuLwLb5i08YkXOdWlTH7nHaPj0z2Py9KnsbmX+1dQP2+DP28Hd9oTGfssYzny+nbOMZ4xnmpbGeRVt8XkKYkU8zoMfucZ5Q444788deaEnY65vT4V8K6y7GRok90NF04JHYFRa2YBbVZFPB7jZwfUfw9RS31xdfYYA8dgo3WPTVZM5E68Y2cdsj+AcjNWtBnkGhaYPtkIxaWYx56cYPA+526n077ulGoTyCwtwLyEYewGPPQYxOuB9zt1Pp33dKVnymzf75+6viXV90D3F5ui/daf/rH/wCYtKf+Wyn/AJ58cc57j5uoqpcz3Rv4/wB3Yb/st6ABqshBzJH/ALHXpgfxdTjFa7zybov9MhOJHP8Ar04/fKc/c9efoM8AYNO6nkOpRA3kJzaXwx56c5liyPud+o9e23pTafczpPVe6uvV9mFzcXhlvMRaecxyYxq0rZ+SPofL+b6Hrgj+EVHZ3Fz/AGpflU08/wCnAtnWJQB/oyDhvL5HT5uufl6c1oXM8hmvCbyFt0cgJE6HdlI+B8nOcY4xnB6YJMVjcy/2rqB+3wZ+3g7vtCYz9ljGc+X07ZxjPGM80NPQmL9x+6vh7y7ogsbi8C2+YtPGJFznVpUx+5x2j49M9j8vSqmiT3Q0XTgkdgVFrZgFtVkU8HuNnB9R/D1Fa9jPIq2+LyFMSKeZ0GP3OM8occcd+eOvNU9BnkGhaYPtkIxaWYx56cYPA+526n077ulDTuU37r91bx6vzMzX0uL7QXs547FUnSziO3UXkPMoGNhQA9eV6L1Ga868RPf3/wCzdpNrYJb7p9JsbRT9sffl5baPBi24Gc9M8j5uoxXq+ozv/Z9uPtkIG+wGPPQEYnXA+5xjqfTvu6V4noeoXmofCn4PJDMvOvQQsnmr8kcM0hJb5flH7oNzu6fgU1qcmJ2vb+bq+0f67HsNxNci+iAisAwtL0Ko1WQjBkj/ANj6YH8XU4xVy5uLwy3mItPOY5MY1aVs/JH0Pl/N9D1wR/CKLqeQ6lEDeQnNpfDHnpzmWLI+536j17belXLmeQzXhN5C26OQEidDuykfA+TnOMcYzg9MElpO71Otv4fdWz6vuZ9ncXP9qX5VNPP+nAtnWJQB/oyDhvL5HT5uufl6c1JY3F4Ft8xaeMSLnOrSpj9zjtHx6Z7H5elT2NzL/auoH7fBn7eDu+0JjP2WMZz5fTtnGM8YzzUtjPIq2+LyFMSKeZ0GP3OM8occcd+eOvNCTsTN6fCvhXWXYyNEnuhounBI7AqLWzALarIp4PcbOD6j+HqKW+uLr7DAHjsFG6x6arJnInXjGzjtkfwDkZq1oM8g0LTB9shGLSzGPPTjB4H3O3U+nfd0o1CeQWFuBeQjD2Ax56DGJ1wPudup9O+7pSs+U2b/AHz91fEur7oHuLzdF+60/wD1j/8AMWlP/LZT/wA8+OOc9x83UVUuZ7o38f7uw3/Zb0ADVZCDmSP/AGOvTA/i6nGK13nk3Rf6ZCcSOf8AXpx++U5+568/QZ4Awad1PIdSiBvITm0vhjz05zLFkfc79R69tvSm0+5nSeq91der7MLm4vDLeYi085jkxjVpWz8kfQ+X830PXBH8IqOzuLn+1L8qmnn/AE4Fs6xKAP8ARkHDeXyOnzdc/L05rQuZ5DNeE3kLbo5ASJ0O7KR8D5Oc4xxjOD0wSYrG5l/tXUD9vgz9vB3faExn7LGM58vp2zjGeMZ5oaehMX7j91fD3l3RBY3F4Ft8xaeMSLnOrSpj9zjtHx6Z7H5elec39zcJ8QPhkFjtTnTJ0U/bnIxthJ3Nt/dngcDIFepWM8irb4vIUxIp5nQY/c4zyhxxx3546815lqUxX4g/Cl3mU/8AEvniRwwKo3lxMFLbcKcKx5z0PWhp3FUfuP3VvHq+7HeHIL5PGHjfUJRbiOa90a2VX1CRApijhchfk5H74E9NmSRmu/e4vN0X7rT/APWP/wAxaU/8tlP/ADz445z3HzdRXCfDm4vHs/FstzMkHmeKVCI0oX5YpoYQcMp5Hlc+nv0r0d55N0X+mQnEjn/Xpx++U5+568/QZ4AwRJ3FS0pp8qfvPq+3qcxfS35vbgi3tCDI2CLt3B5/vFOfr3oq5fMWvbhiwcmRiWBBB565AGfyFFapPuepCa5V7q/H/Mt6Ha3raJprLf6qqm0siFVbbAGeAMpnHpnn+9Re2t6thbn7dqrDOngDbbY/142kfJnryue/3uKk0G0U6Fph+zzHNpZnOyHnccd/Xt3P8XFGoWimwtz9nmOXsDkJDzunUd/Xtnk/xcVjZcpwua9s/h+JdF3RzfxSluNJ8I/2jdX9+0Npf287icW4TC6jbkk7FDdRzg9cY4zWX4De61LxB40u3+129wdT1O2aeNYd0scCWcQ3ZGOqknaByTjvWj8adFXUPhZ4kh8qVPLtLi53FYR/qZVfsM/w4P1wOM1T+FJGpeE9N1RrWRWv4tXvchIwpDXgYMN3zAYI9D6d6Glc4acr4pbbPorfaO6u7S+8+/3ajq2fKl3bltc42RZzhOnTOOcYxzmmWdrfnVr8C/1cMNQAJC2u4n7KnJ+TG7H4YHrVi5tFWa8H2eYbY5DgpDxhIzzj69ueRjnNRWNiv9q6iv2Wf/j/AAuPLt8/8esZx6Z7+mPehpaHRGa5H8Pw9l3QadaX2y226jq3+tXGxbXr9nHTKdcevGPeqmh2t62iaay3+qqptLIhVW2wBngDKZx6Z5/vVoWNmHW3/wBHmbdIo4SE5/c7u/588Y/2qp6DaKdC0w/Z5jm0sznZDzuOO/r27n+Lim0rlOouV/DvHovMjvbW9Wwtz9u1VhnTwBttsf68bSPkz15XPf73FW5LS+3wf8THVv8AWyYytr1+0J0+TrnHtnGOM1BqFopsLc/Z5jl7A5CQ87p1Hf17Z5P8XFXHtAGi/wBHmGZHH3IecTKP6454yePlzRZXBzVl8O76LsjPurW9+3IpvtV5tL87ittwPNj3DhOmevfIG3jNW7u0vvPv92o6tnypd25bXONkWc4Tp0zjnGMc5qC6tANSiP2eYYtL45KQ8bZYh29O/cfw8VcubRVmvB9nmG2OQ4KQ8YSM84+vbnkY5zQkrg5r3fh2fRfzFeztb86tfgX+rhhqABIW13E/ZU5PyY3Y/DA9afp1pfbLbbqOrf61cbFtev2cdMp1x68Y96LGxX+1dRX7LP8A8f4XHl2+f+PWM49M9/THvUtjZh1t/wDR5m3SKOEhOf3O7v8Anzxj/apRirEzmrfZ+FdF2PENT099MsviQsupXAm1fwlY6kkAEXzRRwywENkZ2gquCuDh13c816pa6PdaV4b0qwivtUMVrFplugxbYAWZVXHy54x8vPX72RXkXxw/tHRNA8Oano9kpbU9GOg3EjLHvYXCqyAYHIIilwTyMnPWvbNQtFNhbn7PMcvYHISHndOo7+vbPJ/i4pWXKRTdsVJO2kuy6u5PJaX2+D/iY6t/rZMZW16/aE6fJ1zj2zjHGaqXVre/bkU32q82l+dxW24Hmx7hwnTPXvkDbxmtB7QBov8AR5hmRx9yHnEyj+uOeMnj5c1TurQDUoj9nmGLS+OSkPG2WIdvTv3H8PFU0jWlUV18PXouzJ7u0vvPv92o6tnypd25bXONkWc4Tp0zjnGMc5plna351a/Av9XDDUACQtruJ+ypyfkxux+GB61YubRVmvB9nmG2OQ4KQ8YSM84+vbnkY5zUVjYr/auor9ln/wCP8Ljy7fP/AB6xnHpnv6Y96TS0JjNcj+H4ey7oNOtL7ZbbdR1b/WrjYtr1+zjplOuPXjHvVTQ7W9bRNNZb/VVU2lkQqrbYAzwBlM49M8/3q0LGzDrb/wCjzNukUcJCc/ud3f8APnjH+1VPQbRToWmH7PMc2lmc7Iedxx39e3c/xcU2lcp1Fyv4d49F5kd7a3q2Fuft2qsM6eANttj/AF42kfJnryue/wB7irclpfb4P+Jjq3+tkxlbXr9oTp8nXOPbOMcZqDULRTYW5+zzHL2ByEh53TqO/r2zyf4uKuPaANF/o8wzI4+5DziZR/XHPGTx8uaLK4Oasvh3fRdkZ91a3v25FN9qvNpfncVtuB5se4cJ0z175A28Zq3d2l959/u1HVs+VLu3La5xsiznCdOmcc4xjnNQXVoBqUR+zzDFpfHJSHjbLEO3p37j+HirlzaKs14Ps8w2xyHBSHjCRnnH17c8jHOaElcHNe78Oz6L+Y8c+K1v/Z/jHXdSutSvkvbjw7qlijzzQIzCO3t5FRR0OTM5IQBscjkMa9P8H6LqGl+H9E083uqxvaRwQFI1tsKVtVXA3JnoO/br81eVftJ6JJeeHY0sbScX0niOCzjcIgKiWzAKYT+8dvbHTuTn2mxsw62/+jzNukUcJCc/ud3f8+eMf7VKKWpyp2qSeluVdF1SZn6Ha3raJprLf6qqm0siFVbbAGeAMpnHpnn+9Re2t6thbn7dqrDOngDbbY/142kfJnryue/3uKk0G0U6Fph+zzHNpZnOyHnccd/Xt3P8XFGoWimwtz9nmOXsDkJDzunUd/Xtnk/xcUWXKdzmvbP4fiXRd0TyWl9vg/4mOrf62TGVtev2hOnydc49s4xxmql1a3v25FN9qvNpfncVtuB5se4cJ0z175A28ZrQe0AaL/R5hmRx9yHnEyj+uOeMnj5c1TurQDUoj9nmGLS+OSkPG2WIdvTv3H8PFNpGdKorr4evRdmT3dpfeff7tR1bPlS7ty2ucbIs5wnTpnHOMY5zTLO1vzq1+Bf6uGGoAEhbXcT9lTk/Jjdj8MD1qxc2irNeD7PMNschwUh4wkZ5x9e3PIxzmorGxX+1dRX7LP8A8f4XHl2+f+PWM49M9/THvSaWhMZrkfw/D2XdBp1pfbLbbqOrf61cbFtev2cdMp1x68Y96qaHa3raJprLf6qqm0siFVbbAGeAMpnHpnn+9WhY2Ydbf/R5m3SKOEhOf3O7v+fPGP8AaqnoNop0LTD9nmObSzOdkPO447+vbuf4uKbSuU6i5X8O8ei8yO9tb1bC3P27VWGdPAG22x/rxtI+TPXlc9/vcVbktL7fB/xMdW/1smMra9ftCdPk65x7ZxjjNQahaKbC3P2eY5ewOQkPO6dR39e2eT/FxVx7QBov9HmGZHH3IecTKP6454yePlzRZXBzVl8O76Lsjzj4szX2map4InVr25c6xNCZZhCGhWbdAxXYuOTMudwPIG3Aqb4My3mrfDsaiL+/H2uTUp28pYdp3XBJPzqWwcgnvyMd6ufFfQNT1fw7Pa+H7d/7VEM1xb7zDGN0N5bv94EYwEIzkYOMcZrQ+H/hyTw94G0zS7q0nju7XT/36N5LlJfLjZxnngMzdDnGMc5pJatGCaVZNW1Tey/mt+hu2drfnVr8C/1cMNQAJC2u4n7KnJ+TG7H4YHrT9OtL7ZbbdR1b/WrjYtr1+zjplOuPXjHvRY2K/wBq6iv2Wf8A4/wuPLt8/wDHrGceme/pj3qWxsw62/8Ao8zbpFHCQnP7nd3/AD54x/tURirGs5q32fhXRdjP0O1vW0TTWW/1VVNpZEKq22AM8AZTOPTPP96i9tb1bC3P27VWGdPAG22x/rxtI+TPXlc9/vcVJoNop0LTD9nmObSzOdkPO447+vbuf4uKNQtFNhbn7PMcvYHISHndOo7+vbPJ/i4osuU2c17Z/D8S6LuieS0vt8H/ABMdW/1smMra9ftCdPk65x7ZxjjNVLq1vftyKb7VebS/O4rbcDzY9w4Tpnr3yBt4zWg9oA0X+jzDMjj7kPOJlH9cc8ZPHy5qndWgGpRH7PMMWl8clIeNssQ7enfuP4eKbSM6VRXXw9ei7Mnu7S+8+/3ajq2fKl3bltc42RZzhOnTOOcYxzmmWdrfnVr8C/1cMNQAJC2u4n7KnJ+TG7H4YHrVi5tFWa8H2eYbY5DgpDxhIzzj69ueRjnNRWNiv9q6iv2Wf/j/AAuPLt8/8esZx6Z7+mPek0tCYzXI/h+Hsu6DTrS+2W23UdW/1q42La9fs46ZTrj14x71U0O1vW0TTWW/1VVNpZEKq22AM8AZTOPTPP8AerQsbMOtv/o8zbpFHCQnP7nd3/PnjH+1VPQbRToWmH7PMc2lmc7Iedxx39e3c/xcU2lcp1Fyv4d49F5kd7a3q2Fuft2qsM6eANttj/XjaR8mevK57/e4ryjwXbz6Fp/wu8K3s9xNcwa3qqERhAkclubqMtESvPzSq3z5GcDjkD1vULRTYW5+zzHL2ByEh53TqO/r2zyf4uK8l8N6bZf8L61TTLSNlfTry91KSMhN3+kLYIfblmk4+7+tJpXOXFWkoN2+K2y/u/5Hq11a3v25FN9qvNpfncVtuB5se4cJ0z175A28Zq3d2l959/u1HVs+VLu3La5xsiznCdOmcc4xjnNQXVoBqUR+zzDFpfHJSHjbLEO3p37j+HirlzaKs14Ps8w2xyHBSHjCRnnH17c8jHOaaSudTmvd+HZ9F/MV7O1vzq1+Bf6uGGoAEhbXcT9lTk/Jjdj8MD1p+nWl9sttuo6t/rVxsW16/Zx0ynXHrxj3osbFf7V1Ffss/wDx/hceXb5/49Yzj0z39Me9S2NmHW3/ANHmbdIo4SE5/c7u/wCfPGP9qlGKsTOat9n4V0XYz9Dtb1tE01lv9VVTaWRCqttgDPAGUzj0zz/eovbW9Wwtz9u1VhnTwBttsf68bSPkz15XPf73FSaDaKdC0w/Z5jm0sznZDzuOO/r27n+LijULRTYW5+zzHL2ByEh53TqO/r2zyf4uKLLlNnNe2fw/Eui7onktL7fB/wATHVv9bJjK2vX7QnT5Ouce2cY4zVS6tb37cim+1Xm0vzuK23A82PcOE6Z698gbeM1oPaANF/o8wzI4+5DziZR/XHPGTx8uap3VoBqUR+zzDFpfHJSHjbLEO3p37j+Him0jOlUV18PXouzJ7u0vvPv92o6tnypd25bXONkWc4Tp0zjnGMc5plna351a/Av9XDDUACQtruJ+ypyfkxux+GB61YubRVmvB9nmG2OQ4KQ8YSM84+vbnkY5zUVjYr/auor9ln/4/wALjy7fP/HrGceme/pj3pNLQmM1yP4fh7Lug060vtltt1HVv9auNi2vX7OOmU649eMe9ef+LI9QsbL4faxb3F5/ot9p0byOLb9xBPHJAxTjP/LRQN2fVs4Fei2NmHW3/wBHmbdIo4SE5/c7u/588Y/2q8/+JGl3Fz8EtQaxEkFzb6XZ3qSlIuDE6y5GBu58vA75+9xQ0rk15Xoz26dF5kXwqnudX+Gtjq6teW0mo34upUgWHazvqcpDfOCcjIA7fKMjHX0CS0vt8H/Ex1b/AFsmMra9ftCdPk65x7ZxjjNc54V0xrb4deF4Z7G5hmjstIWSN4ogyuXjDZDcgk54POeG4rqHtAGi/wBHmGZHH3IecTKP6454yePlzQkrioyUaMFpv2X8qOZ1G0uP7Qut2oXu7zWzvWHOcnrhMZ+nFFWr5dl7cIFK7ZGGCACOfbj8uKK2SPXhUfKtvuRLomladJounPJp1gzta2bMzaYWJJPJJ7k9z/F0FF7pWnJY27Lp1gGLWIJGmHJzOAee+RwT/EOBRol3bJounK1u5YWtmCRpM7ZOeeQMHPqOG6Ci+u7Z7G3At3zusTltJn/57rnnHJPr/H0HNYe7ynM3W9s9ZW5l0fdeRX8VeG7bUvDeqafp1rY2t3e2t1aRzJp7RlDI3l5yATjDY46DK8k1R8NeGLXRtC0HSruzsZbi00eeGd/sLSB5YzCpbewBPO7DEDaDgiuhe9td0X+jyf6x/wDmDzj/AJbKPTnjjHYfL1NVbm7tvt8biB8C1vR/yCZwc+ZHjHHbHXonQ9RTfKY04VPaKb5r+8tn5+RaudH0wS3mNM08YjkxjTCuPkj6D+H6npyf4hUdnpOmtql8rabp5Vb4KoOlHAH2ZDgL6ZJO31O6pLm9tRLeAW8gxHJjGjzrj5I+gx8v1PTk/wAQqOzurVdUvs27Ya+GANGnPH2ZOCuMjkZ29f4ulD5dBxdbkesvh7PuvIksdH0wrb50zTzmReumF8/uc9uvPOO5+bpVTRNK06TRdOeTTrBna1s2Zm0wsSSeST3J7n+LoKt2N7albfNvIcyL10ed8/uc9l59cdz83SqmiXdsmi6crW7lha2YJGkztk555Awc+o4boKHy3Kbrcr1lvHo/PyC90rTksbdl06wDFrEEjTDk5nAPPfI4J/iHAq2+j6Zui/4lmn/6x/8AmGEf8tlH4+mOw+XqaqX13bPY24Fu+d1ictpM/wDz3XPOOSfX+PoOatve2u6L/R5P9Y//ADB5x/y2UenPHGOw+XqaPduDday1lu+j7LyKlzpOnC/jUadYBTa3rEDTCORJHg+xGTg/w5wat3Oj6YJbzGmaeMRyYxphXHyR9B/D9T05P8Qqrc3dt9vjcQPgWt6P+QTODnzI8Y47Y69E6HqKtXN7aiW8At5BiOTGNHnXHyR9Bj5fqenJ/iFC5bg3W93WWz6Pv6EdnpOmtql8rabp5Vb4KoOlHAH2ZDgL6ZJO31O6pLHR9MK2+dM085kXrphfP7nPbrzzjufm6VHZ3VquqX2bdsNfDAGjTnj7MnBXGRyM7ev8XSpLG9tStvm3kOZF66PO+f3Oey8+uO5+bpQuWxM3WtvL4V0fb0ML/hEdE1zRvD731hB5lp9gvkaOydS0q5+8R94Hcc54fjHIrSvdK05LG3ZdOsAxaxBI0w5OZwDz3yOCf4hwKNEu7ZNF05Wt3LC1swSNJnbJzzyBg59Rw3QUX13bPY24Fu+d1ictpM//AD3XPOOSfX+PoOaXu8pfLUVdyXNrJdH3XkW30fTN0X/Es0//AFj/APMMI/5bKPx9Mdh8vU1UudJ04X8ajTrAKbW9YgaYRyJI8H2IycH+HODVt7213Rf6PJ/rH/5g84/5bKPTnjjHYfL1NVbm7tvt8biB8C1vR/yCZwc+ZHjHHbHXonQ9RTfKKk611rLr0fZ+RaudH0wS3mNM08YjkxjTCuPkj6D+H6npyf4hUdnpOmtql8rabp5Vb4KoOlHAH2ZDgL6ZJO31O6pLm9tRLeAW8gxHJjGjzrj5I+gx8v1PTk/xCo7O6tV1S+zbthr4YA0ac8fZk4K4yORnb1/i6UPl0Ji63I9ZfD2fdeRJY6PphW3zpmnnMi9dML5/c57deecdz83SqmiaVp0mi6c8mnWDO1rZszNphYkk8knuT3P8XQVbsb21K2+beQ5kXro875/c57Lz647n5ulVNEu7ZNF05Wt3LC1swSNJnbJzzyBg59Rw3QUPluU3W5XrLePR+fkF7pWnJY27Lp1gGLWIJGmHJzOAee+RwT/EOBVt9H0zdF/xLNP/ANY//MMI/wCWyj8fTHYfL1NVL67tnsbcC3fO6xOW0mf/AJ7rnnHJPr/H0HNW3vbXdF/o8n+sf/mDzj/lso9OeOMdh8vU0e7cG61lrLd9H2XkVLnSdOF/Go06wCm1vWIGmEciSPB9iMnB/hzg1budH0wS3mNM08YjkxjTCuPkj6D+H6npyf4hVW5u7b7fG4gfAtb0f8gmcHPmR4xx2x16J0PUVaub21Et4BbyDEcmMaPOuPkj6DHy/U9OT/EKFy3But7ustn0ff0DTdPso9V1ER2Vkg+2eVhdLYDYbVMrj+6cn5fU7ulFjo+mFbfOmaecyL10wvn9znt155x3PzdKjs7q1XVL7Nu2GvhgDRpzx9mTgrjI5GdvX+LpUlje2pW3zbyHMi9dHnfP7nPZefXHc/N0oXLYiftVdpy+FdH29CpomladJounPJp1gzta2bMzaYWJJPJJ7k9z/F0FF7pWnJY27Lp1gGLWIJGmHJzOAee+RwT/ABDgUaJd2yaLpytbuWFrZgkaTO2TnnkDBz6jhugovru2extwLd87rE5bSZ/+e655xyT6/wAfQc0vd5TZut7Z6ytzLo+68i2+j6Zui/4lmn/6x/8AmGEf8tlH4+mOw+XqaqXOk6cL+NRp1gFNresQNMI5EkeD7EZOD/DnBq297a7ov9Hk/wBY/wDzB5x/y2UenPHGOw+Xqaq3N3bfb43ED4Frej/kEzg58yPGOO2OvROh6im+Uik611rLr0fZ+RaudH0wS3mNM08YjkxjTCuPkj6D+H6npyf4hUdnpOmtql8rabp5Vb4KoOlHAH2ZDgL6ZJO31O6pLm9tRLeAW8gxHJjGjzrj5I+gx8v1PTk/xCo7O6tV1S+zbthr4YA0ac8fZk4K4yORnb1/i6UPl0Ji63I9ZfD2fdeRJY6PphW3zpmnnMi9dML5/c57deecdz83SqmiaVp0mi6c8mnWDO1rZszNphYkk8knuT3P8XQVbsb21K2+beQ5kXro875/c57Lz647n5ulVNEu7ZNF05Wt3LC1swSNJnbJzzyBg59Rw3QUPluU3W5XrLePR+fkF7pWnJY27Lp1gGLWIJGmHJzOAee+RwT/ABDgVbfR9M3Rf8SzT/8AWP8A8wwj/lso/H0x2Hy9TVS+u7Z7G3At3zusTltJn/57rnnHJPr/AB9BzVt7213Rf6PJ/rH/AOYPOP8Also9OeOMdh8vU0e7cG61lrLd9H2XkVLnSdOF/Go06wCm1vWIGmEciSPB9iMnB/hzg1budH0wS3mNM08YjkxjTCuPkj6D+H6npyf4hVW5u7b7fG4gfAtb0f8AIJnBz5keMcdsdeidD1FWrm9tRLeAW8gxHJjGjzrj5I+gx8v1PTk/xChctwbre7rLZ9H39COz0nTW1S+VtN08qt8FUHSjgD7MhwF9Mknb6ndUljo+mFbfOmaecyL10wvn9znt155x3PzdKjs7q1XVL7Nu2GvhgDRpzx9mTgrjI5GdvX+LpUlje2pW3zbyHMi9dHnfP7nPZefXHc/N0oXLYmbrW3l8K6Pt6FTRNK06TRdOeTTrBna1s2Zm0wsSSeST3J7n+LoKL3StOSxt2XTrAMWsQSNMOTmcA898jgn+IcCjRLu2TRdOVrdywtbMEjSZ2yc88gYOfUcN0FF9d2z2NuBbvndYnLaTP/z3XPOOSfX+PoOaXu8pq3W9s9ZW5l0fdeRbfR9M3Rf8SzT/APWP/wAwwj/lso/H0x2Hy9TVS50nThfxqNOsAptb1iBphHIkjwfYjJwf4c4NW3vbXdF/o8n+sf8A5g84/wCWyj0544x2Hy9TVW5u7b7fG4gfAtb0f8gmcHPmR4xx2x16J0PUU3ykUnWutZdej7PyLVzo+mCW8xpmnjEcmMaYVx8kfQfw/U9OT/EKjs9J01tUvlbTdPKrfBVB0o4A+zIcBfTJJ2+p3VJc3tqJbwC3kGI5MY0edcfJH0GPl+p6cn+IVHZ3VquqX2bdsNfDAGjTnj7MnBXGRyM7ev8AF0ofLoTF1uR6y+Hs+68iSx0fTCtvnTNPOZF66YXz+5z268847n5ulVNE0rTpNF055NOsGdrWzZmbTCxJJ5JPcnuf4ugq3Y3tqVt828hzIvXR53z+5z2Xn1x3PzdKqaJd2yaLpytbuWFrZgkaTO2TnnkDBz6jhugofLcputyvWW8ej8/IL3StOSxt2XTrAMWsQSNMOTmcA898jgn+IcCsOw+HOjWHj/UvE4RJZdRjWD7JJp58mHZMikqvuFTjthhyW43L67tnsbcC3fO6xOW0mf8A57rnnHJPr/H0HNW3vbXdF/o8n+sf/mDzj/lso9OeOMdh8vU0e7cmcaslG/NpJ9H2XkVLnSdOF/Go06wCm1vWIGmEciSPB9iMnB/hzg1budH0wS3mNM08YjkxjTCuPkj6D+H6npyf4hVW5u7b7fG4gfAtb0f8gmcHPmR4xx2x16J0PUVaub21Et4BbyDEcmMaPOuPkj6DHy/U9OT/ABChctym63u6y2fR9/Qjs9J01tUvlbTdPKrfBVB0o4A+zIcBfTJJ2+p3VJY6PphW3zpmnnMi9dML5/c57deecdz83So7O6tV1S+zbthr4YA0ac8fZk4K4yORnb1/i6VJY3tqVt828hzIvXR53z+5z2Xn1x3PzdKFy2Jm61t5fCuj7ehU0TStOk0XTnk06wZ2tbNmZtMLEknkk9ye5/i6Ci90rTksbdl06wDFrEEjTDk5nAPPfI4J/iHAo0S7tk0XTla3csLWzBI0mdsnPPIGDn1HDdBRfXds9jbgW753WJy2kz/891zzjkn1/j6Dml7vKat1vbPWVuZdH3XkW30fTN0X/Es0/wD1j/8AMMI/5bKPx9Mdh8vU1UudJ04X8ajTrAKbW9YgaYRyJI8H2IycH+HODVt7213Rf6PJ/rH/AOYPOP8Also9OeOMdh8vU1Vubu2+3xuIHwLW9H/IJnBz5keMcdsdeidD1FN8pFJ1rrWXXo+z8i1c6PpglvMaZp4xHJjGmFcfJH0H8P1PTk/xCo7PSdNbVL5W03Tyq3wVQdKOAPsyHAX0ySdvqd1SXN7aiW8At5BiOTGNHnXHyR9Bj5fqenJ/iFR2d1arql9m3bDXwwBo054+zJwVxkcjO3r/ABdKHy6Exdbkesvh7PuvIksdH0wrb50zTzmReumF8/uc9uvPOO5+bpVTRNK06TRdOeTTrBna1s2Zm0wsSSeST3J7n+LoKt2N7albfNvIcyL10ed8/uc9l59cdz83SqmiXdsmi6crW7lha2YJGkztk555Awc+o4boKHy3Kbrcr1lvHo/PyC90rTksbdl06wDFrEEjTDk5nAPPfI4J/iHAq2+j6Zui/wCJZp/+sf8A5hhH/LZR+PpjsPl6mql9d2z2NuBbvndYnLaTP/z3XPOOSfX+PoOatve2u6L/AEeT/WP/AMwecf8ALZR6c8cY7D5epo924N1rLWW76PsvIxL7StPF7cAWFoAJG4FuEA5/ukcfTtRRfahAL24AjuQBI2ALKVAOf7pXj6dqK1XKehD2/Kt/xNvQWb+wtM/dTf8AHpZ9JZvX/d79scD+HJo1Bm+wW/7qY/PYf8tZv+e6+i9+2OB/Dk1U0Se6Gi6cEjsCotbMAtqsing9xs4PqP4eopb64uvsMAeOwUbrHpqsmcideMbOO2R/AORmsr+6ee6T9s9PtLqu68zWdjui/dTf6x/+Ws3/AD2X/Z/DjnPJ+bAqndM39pRfuph/ol9/y1m/56xf7Pbvng/xYND3F5ui/daf/rH/AOYtKf8Alsp/558cc57j5uoqpcz3Rv4/3dhv+y3oAGqyEHMkf+x16YH8XU4xTbM6VJ3Wnfquz8zXuWbzrz91MP3cnWWY4+SPrlefxwORngDMVi7f2rqP7if/AI/xx51xn/j1j4+7nPfPXHGMc1Bc3F4ZbzEWnnMcmMatK2fkj6Hy/m+h64I/hFR2dxc/2pflU08/6cC2dYlAH+jIOG8vkdPm65+XpzQ3sTGk+R6fZ7ruvM0LFiFt/wB1McSL0lmGf3Psv48c44+7zVPQWb+wtM/dTf8AHpZ9JZvX/d79scD+HJosbi8C2+YtPGJFznVpUx+5x2j49M9j8vSqmiT3Q0XTgkdgVFrZgFtVkU8HuNnB9R/D1FDepTpPlfrHqvPzLeoM32C3/dTH57D/AJazf8919F79scD+HJq47HdF+6m/1j/8tZv+ey/7P4cc55PzYFZN9cXX2GAPHYKN1j01WTOROvGNnHbI/gHIzVp7i83RfutP/wBY/wDzFpT/AMtlP/PPjjnPcfN1FF9QdJ8q06vquy8wumb+0ov3Uw/0S+/5azf89Yv9nt3zwf4sGrlyzedefuph+7k6yzHHyR9crz+OByM8AZyLme6N/H+7sN/2W9AA1WQg5kj/ANjr0wP4upxirdzcXhlvMRaecxyYxq0rZ+SPofL+b6Hrgj+EUJ6g6T93To+q7+pPYu39q6j+4n/4/wAcedcZ/wCPWPj7uc989ccYxzUtixC2/wC6mOJF6SzDP7n2X8eOccfd5rPs7i5/tS/Kpp5/04Fs6xKAP9GQcN5fI6fN1z8vTmpLG4vAtvmLTxiRc51aVMfucdo+PTPY/L0oT0JnSdtvsr7S7eoaCzf2Fpn7qb/j0s+ks3r/ALvftjgfw5NGoM32C3/dTH57D/lrN/z3X0Xv2xwP4cmqmiT3Q0XTgkdgVFrZgFtVkU8HuNnB9R/D1FLfXF19hgDx2CjdY9NVkzkTrxjZx2yP4ByM0r+6bOk/bPT7S6ruvM1nY7ov3U3+sf8A5azf89l/2fw45zyfmwKp3TN/aUX7qYf6Jff8tZv+esX+z2754P8AFg0PcXm6L91p/wDrH/5i0p/5bKf+efHHOe4+bqKqXM90b+P93Yb/ALLegAarIQcyR/7HXpgfxdTjFNszpUndad+q7PzNe5ZvOvP3Uw/dydZZjj5I+uV5/HA5GeAMxWLt/auo/uJ/+P8AHHnXGf8Aj1j4+7nPfPXHGMc1Bc3F4ZbzEWnnMcmMatK2fkj6Hy/m+h64I/hFR2dxc/2pflU08/6cC2dYlAH+jIOG8vkdPm65+XpzQ3sTGk+R6fZ7ruvM0LFiFt/3UxxIvSWYZ/c+y/jxzjj7vNU9BZv7C0z91N/x6WfSWb1/3e/bHA/hyaLG4vAtvmLTxiRc51aVMfucdo+PTPY/L0qpok90NF04JHYFRa2YBbVZFPB7jZwfUfw9RQ3qU6T5X6x6rz8y3qDN9gt/3Ux+ew/5azf8919F79scD+HJq47HdF+6m/1j/wDLWb/nsv8As/hxznk/NgVk31xdfYYA8dgo3WPTVZM5E68Y2cdsj+AcjNWnuLzdF+60/wD1j/8AMWlP/LZT/wA8+OOc9x83UUX1B0nyrTq+q7LzC6Zv7Si/dTD/AES+/wCWs3/PWL/Z7d88H+LBq5cs3nXn7qYfu5Ossxx8kfXK8/jgcjPAGci5nujfx/u7Df8AZb0ADVZCDmSP/Y69MD+LqcYq3c3F4ZbzEWnnMcmMatK2fkj6Hy/m+h64I/hFCeoOk/d06Pqu/qT2Lt/auo/uJ/8Aj/HHnXGf+PWPj7uc989ccYxzUtixC2/7qY4kXpLMM/ufZfx45xx93ms+zuLn+1L8qmnn/TgWzrEoA/0ZBw3l8jp83XPy9Oaksbi8C2+YtPGJFznVpUx+5x2j49M9j8vShPQmdJ22+yvtLt6hoLN/YWmfupv+PSz6Szev+737Y4H8OTRqDN9gt/3Ux+ew/wCWs3/PdfRe/bHA/hyaqaJPdDRdOCR2BUWtmAW1WRTwe42cH1H8PUUt9cXX2GAPHYKN1j01WTOROvGNnHbI/gHIzSv7ps6T9s9PtLqu68zWdjui/dTf6x/+Ws3/AD2X/Z/DjnPJ+bAqndM39pRfuph/ol9/y1m/56xf7Pbvng/xYND3F5ui/daf/rH/AOYtKf8Alsp/558cc57j5uoqpcz3Rv4/3dhv+y3oAGqyEHMkf+x16YH8XU4xTbM6VJ3Wnfquz8zXuWbzrz91MP3cnWWY4+SPrlefxwORngDMVi7f2rqP7if/AI/xx51xn/j1j4+7nPfPXHGMc1Bc3F4ZbzEWnnMcmMatK2fkj6Hy/m+h64I/hFR2dxc/2pflU08/6cC2dYlAH+jIOG8vkdPm65+XpzQ3sTGk+R6fZ7ruvM0LFiFt/wB1McSL0lmGf3Psv48c44+7zVPQWb+wtM/dTf8AHpZ9JZvX/d79scD+HJosbi8C2+YtPGJFznVpUx+5x2j49M9j8vSqmiT3Q0XTgkdgVFrZgFtVkU8HuNnB9R/D1FDepTpPlfrHqvPzLeoM32C3/dTH57D/AJazf8919F79scD+HJq47HdF+6m/1j/8tZv+ey/7P4cc55PzYFZN9cXX2GAPHYKN1j01WTOROvGNnHbI/gHIzVp7i83RfutP/wBY/wDzFpT/AMtlP/PPjjnPcfN1FF9QdJ8q06vquy8wumb+0ov3Uw/0S+/5azf89Yv9nt3zwf4sGrlyzedefuph+7k6yzHHyR9crz+OByM8AZyLme6N/H+7sN/2W9AA1WQg5kj/ANjr0wP4upxirdzcXhlvMRaecxyYxq0rZ+SPofL+b6Hrgj+EUJ6g6T93To+q7+pPYu39q6j+4n/4/wAcedcZ/wCPWPj7uc989ccYxzUtixC2/wC6mOJF6SzDP7n2X8eOccfd5rPs7i5/tS/Kpp5/04Fs6xKAP9GQcN5fI6fN1z8vTmpLG4vAtvmLTxiRc51aVMfucdo+PTPY/L0oT0JnSdtvsr7S7eoaCzf2Fpn7qb/j0s+ks3r/ALvftjgfw5NGoM32C3/dTH57D/lrN/z3X0Xv2xwP4cmqmiT3Q0XTgkdgVFrZgFtVkU8HuNnB9R/D1FLfXF19hgDx2CjdY9NVkzkTrxjZx2yP4ByM0r+6bOk/bPT7S6ruvM1nY7ov3U3+sf8A5azf89l/2fw45zyfmwKp3TN/aUX7qYf6Jff8tZv+esX+z2754P8AFg0PcXm6L91p/wDrH/5i0p/5bKf+efHHOe4+bqKqXM90b+P93Yb/ALLegAarIQcyR/7HXpgfxdTjFNszpUndad+q7PzNe5ZvOvP3Uw/dydZZjj5I+uV5/HA5GeAMxWLt/auo/uJ/+P8AHHnXGf8Aj1j4+7nPfPXHGMc1Bc3F4ZbzEWnnMcmMatK2fkj6Hy/m+h64I/hFR2dxc/2pflU08/6cC2dYlAH+jIOG8vkdPm65+XpzQ3sTGk+R6fZ7ruvM0LFiFt/3UxxIvSWYZ/c+y/jxzjj7vNU9BZv7C0z91N/x6WfSWb1/3e/bHA/hyaLG4vAtvmLTxiRc51aVMfucdo+PTPY/L0qpok90NF04JHYFRa2YBbVZFPB7jZwfUfw9RQ3qU6T5X6x6rz8y3qDN9gt/3Ux+ew/5azf8919F79scD+HJq47HdF+6m/1j/wDLWb/nsv8As/hxznk/NgVk31xdfYYA8dgo3WPTVZM5E68Y2cdsj+AcjNWnuLzdF+60/wD1j/8AMWlP/LZT/wA8+OOc9x83UUX1B0nyrTq+q7LzC6Zv7Si/dTD/AES+/wCWs3/PWL/Z7d88H+LBq5cs3nXn7qYfu5Ossxx8kfXK8/jgcjPAGci5nujfx/u7Df8AZb0ADVZCDmSP/Y69MD+LqcYq3c3F4ZbzEWnnMcmMatK2fkj6Hy/m+h64I/hFCeoOk/d06Pqu/qT2Lt/auo/uJ/8Aj/HHnXGf+PWPj7uc989ccYxzUtixC2/7qY4kXpLMM/ufZfx45xx93ms+zuLn+1L8qmnn/TgWzrEoA/0ZBw3l8jp83XPy9Oaksbi8C2+YtPGJFznVpUx+5x2j49M9j8vShPQmdJ22+yvtLt6hoLN/YWmfupv+PSz6Szev+737Y4H8OTRqDN9gt/3Ux+ew/wCWs3/PdfRe/bHA/hyaqaJPdDRdOCR2BUWtmAW1WRTwe42cH1H8PUUt9cXX2GAPHYKN1j01WTOROvGNnHbI/gHIzSv7ps6T9s9PtLqu68zWdjui/dTf6x/+Ws3/AD2X/Z/DjnPJ+bAqndM39pRfuph/ol9/y1m/56xf7Pbvng/xYND3F5ui/daf/rH/AOYtKf8Alsp/558cc57j5uoqpcz3Rv4/3dhv+y3oAGqyEHMkf+x16YH8XU4xTbM6VJ3Wnfquz8zXuWbzrz91MP3cnWWY4+SPrlefxwORngDMVi7f2rqP7if/AI/xx51xn/j1j4+7nPfPXHGMc1Bc3F4ZbzEWnnMcmMatK2fkj6Hy/m+h64I/hFR2dxc/2pflU08/6cC2dYlAH+jIOG8vkdPm65+XpzQ3sTGk+R6fZ7ruvM0LFiFt/wB1McSL0lmGf3Psv48c44+7zVPQWb+wtM/dTf8AHpZ9JZvX/d79scD+HJosbi8C2+YtPGJFznVpUx+5x2j49M9j8vSqmiT3Q0XTgkdgVFrZgFtVkU8HuNnB9R/D1FDepTpPlfrHqvPzLeoM32C3/dTH57D/AJazf8919F79scD+HJq47HdF+6m/1j/8tZv+ey/7P4cc55PzYFZN9cXX2GAPHYKN1j01WTOROvGNnHbI/gHIzVp7i83RfutP/wBY/wDzFpT/AMtlP/PPjjnPcfN1FF9QdJ8q06vquy8zPvjm9uMgj943BJJHPqefz5oqpfS35vbgi3tCDI2CLt3B5/vFOfr3orVM9CFN8q2+9f5m3oM8g0LTB9shGLSzGPPTjB4H3O3U+nfd0o1CeQWFuBeQjD2Ax56DGJ1wPudup9O+7pXllv418QW9vFBDqG2KJI40XyYzhYzlB93t/wDrok8a+IHiSNtQyieVgeTHx5bbk/h7EZ9++a5fbRtax1PIMR7Rz93e+78v7p6+88m6L/TITiRz/r04/fKc/c9efoM8AYNO6nkOpRA3kJzaXwx56c5liyPud+o9e23pXl58deIyVJ1HlWLD9xH1LBz/AA/3gDTH8a+IHfe2oZYRyx58mP7shDOPu9yo+mOKbrR7Ew4fxEXd8vXq+qf93zPX7meQzXhN5C26OQEidDuykfA+TnOMcYzg9MEmKxuZf7V1A/b4M/bwd32hMZ+yxjOfL6ds4xnjGea8ok8deI5GlZ9RyZVZX/cR8hgoP8Poq/lQnjnxFHPJMmo4kkl85j5EfL7BHn7v90Af/XpOtHTQlcPYhRa93a278v7vkeuWM8irb4vIUxIp5nQY/c4zyhxxx354681T0GeQaFpg+2QjFpZjHnpxg8D7nbqfTvu6V5fD468RwhBHqOAjBl/cR8EJsH8P93imW/jXxBb28UEOobYokjjRfJjOFjOUH3e3/wCun7aN72KfD+Is17vTq+l/7p6nqE8gsLcC8hGHsBjz0GMTrgfc7dT6d93Srjzybov9MhOJHP8Ar04/fKc/c9efoM8AYPkEnjXxA8SRtqGUTysDyY+PLbcn8PYjPv3zTz468RkqTqPKsWH7iPqWDn+H+8AaPbRvewPh/EWS93e+77JfynqF1PIdSiBvITm0vhjz05zLFkfc79R69tvSrlzPIZrwm8hbdHICROh3ZSPgfJznGOMZwemCT5A/jXxA7721DLCOWPPkx/dkIZx93uVH0xxT5PHXiORpWfUcmVWV/wBxHyGCg/w+ir+VCrR7B/q/iNPh0v1fe/8AKer2NzL/AGrqB+3wZ+3g7vtCYz9ljGc+X07ZxjPGM81LYzyKtvi8hTEinmdBj9zjPKHHHHfnjrzXkaeOfEUc8kyajiSSXzmPkR8vsEefu/3QB/8AXoh8deI4Qgj1HARgy/uI+CE2D+H+7xSVaNtiZcPYhr7OyW76L/CeoaDPINC0wfbIRi0sxjz04weB9zt1Pp33dKNQnkFhbgXkIw9gMeegxidcD7nbqfTvu6V5Zb+NfEFvbxQQ6htiiSONF8mM4WM5Qfd7f/rok8a+IHiSNtQyieVgeTHx5bbk/h7EZ9++aPbRtaxo8gxHtHP3d77vy/unr7zybov9MhOJHP8Ar04/fKc/c9efoM8AYNO6nkOpRA3kJzaXwx56c5liyPud+o9e23pXl58deIyVJ1HlWLD9xH1LBz/D/eANMfxr4gd97ahlhHLHnyY/uyEM4+73Kj6Y4putHsTDh/ERd3y9er6p/wB3zPX7meQzXhN5C26OQEidDuykfA+TnOMcYzg9MEmKxuZf7V1A/b4M/bwd32hMZ+yxjOfL6ds4xnjGea8ok8deI5GlZ9RyZVZX/cR8hgoP8Poq/lQnjnxFHPJMmo4kkl85j5EfL7BHn7v90Af/AF6TrR00JXD2IUWvd2tu/L+75HrljPIq2+LyFMSKeZ0GP3OM8occcd+eOvNU9BnkGhaYPtkIxaWYx56cYPA+526n077uleXw+OvEcIQR6jgIwZf3EfBCbB/D/d4plv418QW9vFBDqG2KJI40XyYzhYzlB93t/wDrp+2je9inw/iLNe706vpf+6ep6hPILC3AvIRh7AY89BjE64H3O3U+nfd0q488m6L/AEyE4kc/69OP3ynP3PXn6DPAGD5BJ418QPEkbahlE8rA8mPjy23J/D2Iz79808+OvEZKk6jyrFh+4j6lg5/h/vAGj20b3sD4fxFkvd3vu+yX8p6hdTyHUogbyE5tL4Y89OcyxZH3O/Uevbb0q5czyGa8JvIW3RyAkTod2Uj4Hyc5xjjGcHpgk+QP418QO+9tQywjljz5Mf3ZCGcfd7lR9McU+Tx14jkaVn1HJlVlf9xHyGCg/wAPoq/lQq0ewf6v4jT4dL9X3v8Aynq9jcy/2rqB+3wZ+3g7vtCYz9ljGc+X07ZxjPGM81LYzyKtvi8hTEinmdBj9zjPKHHHHfnjrzXkaeOfEUc8kyajiSSXzmPkR8vsEefu/wB0Af8A16IfHXiOEII9RwEYMv7iPghNg/h/u8UlWjbYmXD2Ia+zslu+i/wnqGgzyDQtMH2yEYtLMY89OMHgfc7dT6d93SjUJ5BYW4F5CMPYDHnoMYnXA+526n077uleWW/jXxBb28UEOobYokjjRfJjOFjOUH3e3/66JPGviB4kjbUMonlYHkx8eW25P4exGffvmj20bWsaPIMR7Rz93e+78v7p6+88m6L/AEyE4kc/69OP3ynP3PXn6DPAGDTup5DqUQN5Cc2l8MeenOZYsj7nfqPXtt6V5efHXiMlSdR5Viw/cR9Swc/w/wB4A0x/GviB33tqGWEcsefJj+7IQzj7vcqPpjim60exMOH8RF3fL16vqn/d8z1+5nkM14TeQtujkBInQ7spHwPk5zjHGM4PTBJisbmX+1dQP2+DP28Hd9oTGfssYzny+nbOMZ4xnmvKJPHXiORpWfUcmVWV/wBxHyGCg/w+ir+VCeOfEUc8kyajiSSXzmPkR8vsEefu/wB0Af8A16TrR00JXD2IUWvd2tu/L+75HrljPIq2+LyFMSKeZ0GP3OM8occcd+eOvNU9BnkGhaYPtkIxaWYx56cYPA+526n077uleXw+OvEcIQR6jgIwZf3EfBCbB/D/AHeKZb+NfEFvbxQQ6htiiSONF8mM4WM5Qfd7f/rp+2je9inw/iLNe706vpf+6ep6hPILC3AvIRh7AY89BjE64H3O3U+nfd0q488m6L/TITiRz/r04/fKc/c9efoM8AYPkEnjXxA8SRtqGUTysDyY+PLbcn8PYjPv3zTz468RkqTqPKsWH7iPqWDn+H+8AaPbRvewPh/EWS93e+77JfynqF1PIdSiBvITm0vhjz05zLFkfc79R69tvSrlzPIZrwm8hbdHICROh3ZSPgfJznGOMZwemCT5A/jXxA7721DLCOWPPkx/dkIZx93uVH0xxT5PHXiORpWfUcmVWV/3EfIYKD/D6Kv5UKtHsH+r+I0+HS/V97/ynq9jcy/2rqB+3wZ+3g7vtCYz9ljGc+X07ZxjPGM81LYzyKtvi8hTEinmdBj9zjPKHHHHfnjrzXkaeOfEUc8kyajiSSXzmPkR8vsEefu/3QB/9eiHx14jhCCPUcBGDL+4j4ITYP4f7vFJVo22Jlw9iGvs7Jbvov8ACeoaDPINC0wfbIRi0sxjz04weB9zt1Pp33dKNQnkFhbgXkIw9gMeegxidcD7nbqfTvu6V5Zb+NfEFvbxQQ6htiiSONF8mM4WM5Qfd7f/AK6JPGviB4kjbUMonlYHkx8eW25P4exGffvmj20bWsaPIMR7Rz93e+78v7p6+88m6L/TITiRz/r04/fKc/c9efoM8AYNO6nkOpRA3kJzaXwx56c5liyPud+o9e23pXl58deIyVJ1HlWLD9xH1LBz/D/eANMfxr4gd97ahlhHLHnyY/uyEM4+73Kj6Y4putHsTDh/ERd3y9er6p/3fM9fuZ5DNeE3kLbo5ASJ0O7KR8D5Oc4xxjOD0wSYrG5l/tXUD9vgz9vB3faExn7LGM58vp2zjGeMZ5ryiTx14jkaVn1HJlVlf9xHyGCg/wAPoq/lQnjnxFHPJMmo4kkl85j5EfL7BHn7v90Af/XpOtHTQlcPYhRa93a278v7vkeuWM8irb4vIUxIp5nQY/c4zyhxxx354681T0GeQaFpg+2QjFpZjHnpxg8D7nbqfTvu6V5fD468RwhBHqOAjBl/cR8EJsH8P93imW/jXxBb28UEOobYokjjRfJjOFjOUH3e3/66fto3vYp8P4izXu9Or6X/ALp6nqE8gsLcC8hGHsBjz0GMTrgfc7dT6d93Srjzybov9MhOJHP+vTj98pz9z15+gzwBg+QSeNfEDxJG2oZRPKwPJj48ttyfw9iM+/fNPPjrxGSpOo8qxYfuI+pYOf4f7wBo9tG97A+H8RZL3d77vsl/KeoXU8h1KIG8hObS+GPPTnMsWR9zv1Hr229KuXM8hmvCbyFt0cgJE6HdlI+B8nOcY4xnB6YJPkD+NfEDvvbUMsI5Y8+TH92QhnH3e5UfTHFPk8deI5GlZ9RyZVZX/cR8hgoP8Poq/lQq0ewf6v4jT4dL9X3v/Ker2NzL/auoH7fBn7eDu+0JjP2WMZz5fTtnGM8YzzUtjPIq2+LyFMSKeZ0GP3OM8occcd+eOvNeRp458RRzyTJqOJJJfOY+RHy+wR5+7/dAH/16IfHXiOEII9RwEYMv7iPghNg/h/u8UlWjbYmXD2Ia+zslu+i/wnqGgzyDQtMH2yEYtLMY89OMHgfc7dT6d93SjUJ5BYW4F5CMPYDHnoMYnXA+526n077uleWW/jXxBb28UEOobYokjjRfJjOFjOUH3e3/AOuiTxr4geJI21DKJ5WB5MfHltuT+HsRn375o9tG1rGjyDEe0c/d3vu/L+6evvPJui/0yE4kc/69OP3ynP3PXn6DPAGDTup5DqUQN5Cc2l8MeenOZYsj7nfqPXtt6V5efHXiMlSdR5Viw/cR9Swc/wAP94A0x/GviB33tqGWEcsefJj+7IQzj7vcqPpjim60exMOH8RF3fL16vqn/d8z1+5nkM14TeQtujkBInQ7spHwPk5zjHGM4PTBJisbmX+1dQP2+DP28Hd9oTGfssYzny+nbOMZ4xnmvKJPHXiORpWfUcmVWV/3EfIYKD/D6Kv5UJ458RRzyTJqOJJJfOY+RHy+wR5+7/dAH/16TrR00JXD2IUWvd2tu/L+75HrljPIq2+LyFMSKeZ0GP3OM8occcd+eOvNU9BnkGhaYPtkIxaWYx56cYPA+526n077uleXw+OvEcIQR6jgIwZf3EfBCbB/D/d4plv418QW9vFBDqG2KJI40XyYzhYzlB93t/8Arp+2je9inw/iLNe706vpf+6ep6hPILC3AvIRh7AY89BjE64H3O3U+nfd0q488m6L/TITiRz/AK9OP3ynP3PXn6DPAGD5BJ418QPEkbahlE8rA8mPjy23J/D2Iz79808+OvEZKk6jyrFh+4j6lg5/h/vAGj20b3sD4fxFkvd3vu+yX8p6DfMWvbhiwcmRiWBBB565AGfyFFeZzeKdYmleWS8y7sWY+UnJPXtRV/WInXHJq6SV1+P+R//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal rhythm strip",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 165px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal rhythm strip in lead II. The PR interval is 0.15 sec and the QRS duration is 0.08 sec. Both the P and T waves are upright.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Morton F Arnsdorf, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_7_38008=[""].join("\n");
var outline_f37_7_38008=null;
var title_f37_7_38009="Second and third line chemotherapy regimens and biologic therapy for relapsing or resistant classical Hodgkin lymphoma";
var content_f37_7_38009=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Second and third line chemotherapy regimens and biologic therapy for relapsing or resistant classical Hodgkin lymphoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/7/38009/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/7/38009/contributors\">",
"     George P Canellos, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/7/38009/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/7/38009/contributors\">",
"     Arnold S Freedman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/7/38009/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/7/38009/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/7/38009/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 29, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The likelihood of relapse of Hodgkin lymphoma (formerly called Hodgkin's disease, HL) from initial therapy in the current era of systemic or combined modality therapy is approximately 10 to 15 percent for localized HL and 20 to 40 percent for more advanced stages (ie, IIIB or IV), dependent on prognostic factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38009/abstract/1\">",
"     1",
"    </a>",
"    ]. Approximately 40 to 50 percent of these relapses will occur in the first 12 months from induction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38009/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. In addition, approximately 10 to 15 percent will have disease resistant to initial therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38009/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Salvage therapy can achieve durable responses and remissions in approximately one-half of these patients. Patients with high risk disease, a second relapse, or progressive, resistant disease are candidates for high dose chemotherapy and autologous hematopoietic cell transplantation (HCT). Patients who relapse following autologous HCT can only achieve palliation with conventional dose chemotherapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/17/37145?source=see_link\">",
"     \"Treatment of relapse of classical Hodgkin lymphoma after initial chemotherapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/49/21274?source=see_link\">",
"     \"Hematopoietic cell transplantation in classical Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A number of regimens have been developed which incorporate drugs not used in initial treatment in an attempt to anticipate and avoid resistance while minimizing toxicity. These regimens have been used as second or third line therapy and as cytoreductive regimens prior to high dose chemotherapy. The trials evaluating the use of these regimens will be reviewed here. Some of the less commonly used regimens and newer attempts not mentioned in this topic are summarized in other reviews [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38009/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. In addition, the initial treatment of Hodgkin lymphoma is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/31/11770?source=see_link\">",
"     \"Treatment of favorable prognosis early (stage I-II) classical Hodgkin lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/54/27496?source=see_link\">",
"     \"Treatment of unfavorable prognosis early (stage I-II) classical Hodgkin lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/54/39786?source=see_link\">",
"     \"Initial treatment of advanced (stage III-IV) classical Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Second and third-line chemotherapy combinations generally achieve complete remission (CR) in 30 to 40 percent of patients with aggressive or resistant disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38009/abstract/6\">",
"     6",
"    </a>",
"    ]. They are frequently used as cytoreductive agents prior to proceeding to high dose chemotherapy and autologous HCT. Salvage chemotherapy without progression to high-dose chemotherapy and autologous HCT results in 8- to 10-year overall survival rates of 21 to 27 percent with freedom from treatment failure of 16 percent. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/17/37145?source=see_link&amp;anchor=H3#H3\">",
"     \"Treatment of relapse of classical Hodgkin lymphoma after initial chemotherapy\", section on 'Achieving a second complete response'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There has been a multitude of regimens designed for relapsing HL. The major new agents incorporated into salvage regimens include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    , cisplatinum,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    , and, most recently,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    . Although the list of various regimens from single groups or institutions is long, this review will refer exclusively to those regimens that have had a wider application and common acceptable utility. The long-term assessment of salvage regimens has been made difficult because the majority of patients go on to autologous HCT.",
"   </p>",
"   <p>",
"    The vast majority of patients in community practice with relapsed disease will have had ABVD (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/3/4152?source=see_link\">",
"     vinblastine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/49/4887?source=see_link\">",
"     dacarbazine",
"    </a>",
"    ) as their primary chemotherapy. The general standards for salvage chemotherapy include any of the regimens mentioned below which are given usually for a minimum of two cycles, although some patients may require more. A potential limitation of excessive chemotherapy is the impairment of the peripheral stem cell collection process which could be compromised by excess bone marrow suppression. However, it appears that more than 60 to 70 percent of patients are able to proceed to HCT after salvage therapy; in general, approximately 40 to 60 percent of those remain in a second remission, especially if they demonstrate sensitivity to salvage chemotherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H111154724\">",
"    <span class=\"h2\">",
"     Choice of regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of chemotherapy in the patient with relapsed or refractory HL is to achieve an at least partial response prior to proceeding with autologous hematopoietic cell transplantation (HCT). The ideal chemotherapy regimen would have a high response rate, low toxicity, and allow for subsequent stem cell mobilization. There is no agreed upon preferred regimen in this setting, and clinical practice varies widely. No agent or regimen has demonstrated superiority to another in a randomized trial. As such, a choice among regimens is largely based upon side effect profiles and clinical experience.",
"   </p>",
"   <p>",
"    The most commonly used regimens are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      ICE (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/25/38297?source=see_link\">",
"       ifosfamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      ) &mdash; Hematologic toxicity is universal with approximately 35 percent of patients requiring transfusion of blood products. Severe (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      nonhematologic side effects include infection (23 percent) and nephrotoxicity (1 percent). Stem cell mobilization appears adequate. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'ICE regimen'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      GDP (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      ) &mdash; Hematologic toxicity is universal. Febrile neutropenia is seen in approximately 15 percent of patients. Stem cell mobilization appears adequate [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/7/38009/abstract/8\">",
"       8",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'GDP regimen'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Mini-BEAM (BCNU,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/54/22376?source=see_link\">",
"       melphalan",
"      </a>",
"      , each at reduced doses) &mdash; Hematologic toxicity is universal and virtually all patients require transfusion of platelets and red cells and approximately half of patients require antibiotics. Stem cell mobilization may be impaired [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/7/38009/abstract/8\">",
"       8",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Mini-BEAM'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      DHAP (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      , high dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      ) &mdash; Hematologic toxicity is universal with more than half of patients requiring transfusion of blood products. Severe (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      nonhematologic side effects include infection (24 percent) and nephrotoxicity (6 percent). Stem cell mobilization appears adequate. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'DHAP regimen'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In phase II studies, response rates for these regimens have ranged from 60 to 85 percent following initial therapy with ABVD. Response rates are lower following more dose-intense initial chemotherapy, such as escalated BEACOPP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38009/abstract/9\">",
"     9",
"    </a>",
"    ]. For most patients with relapsed or refractory HL who are candidates for HCT, we prefer the use of ICE chemotherapy rather than another regimen. This preference is largely based upon presumed equal efficacy to other regimens, decreased toxicity when compared with DHAP and mini-BEAM, and our familiarity with the regimen.",
"   </p>",
"   <p>",
"    A chemotherapy regimen is generally administered for two to three cycles. Disease response to therapy is assessed by combined positron emission",
"    <span class=\"nowrap\">",
"     tomography/computed",
"    </span>",
"    tomography scans three weeks after completion of the second or third chemotherapy cycle. Patients with a negative PET scan proceed to hematopoietic cell transplantation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/17/37145?source=see_link\">",
"     \"Treatment of relapse of classical Hodgkin lymphoma after initial chemotherapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Prognostic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The impact of salvage therapy appears to be determined by clinical characteristics such as age, stage, symptoms, duration of first remission (&lt;12 months or &gt;12 months), anemia, and extent of prior therapy. As an example, the most favorable setting would be a late (&gt;12 months) asymptomatic relapse from complete remission in an isolated, usually nodal, site. Three series demonstrate that salvage therapy with conventional dose chemotherapy with or without radiation therapy in this circumstance results in long-term survival in 50 to 80 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38009/abstract/2,3,10\">",
"     2,3,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A multivariate analysis derived from 422 relapsed patients of the German Hodgkin Study Group (GHSG) identified three features as independent risk factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38009/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Time to relapse (&gt; or &lt;12 months)",
"     </li>",
"     <li>",
"      Clinical stage at relapse",
"     </li>",
"     <li>",
"      Anemia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    At a median follow-up of 45 months, patients with none or one of these factors had a freedom from second progression of 30 percent (24 of 79 patients) as compared with 74 percent (25 of 34 patients) for patients with two or three factors.",
"   </p>",
"   <p>",
"    A high clinical response rate as well as a reversion to a negative PET scan are the goals of salvage therapy in preparation for an autologous HCT. It appears clear that a negative scan prior to transplant predicts that HCT will result in a more favorable progression-free survival in lymphomas. As an example, in one series of aggressive lymphomas, progression-free survival of the PET-negative group after conventional dose chemotherapy followed by HCT salvage was 72 percent versus 23 percent for the PET-positive group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38009/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clearly, primary progressive disease (ie, a circumstance of not responding to first induction therapy or relapse from complete remission within three months) represents the worse prognostic group. For such patients, second-line chemotherapy has only a 33 percent overall response rate. The five-year survival rate is low, approximately 19 percent, without HCT, but increases to 53 percent following HCT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38009/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Myeloablative high-dose chemotherapy associated with HCT is absolutely required in the circumstance of primary progressive disease. With this approach, the five-year freedom-from-second-failure rate is still only 31 percent and overall survival of 43 percent in the GHSG series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38009/abstract/14\">",
"     14",
"    </a>",
"    ]. Significant negative factors were low Karnofsky score, age over 50 years, and failure to attain a secondary remission with salvage therapy. Absence of these factors resulted in an overall survival rate of 55 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     GEMCITABINE-CONTAINING REGIMENS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with relapsed HL,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    has single agent activity of 39 percent overall lasting approximately 6.7 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38009/abstract/15\">",
"     15",
"    </a>",
"    ]. Gemcitabine has been incorporated into several salvage regimens, such as:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"       Gemcitabine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       Cisplatin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"       Methylprednisolone",
"      </a>",
"      (GEM-P) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/7/38009/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"       Gemcitabine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       Dexamethasone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       Cisplatin",
"      </a>",
"      (GDP) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/7/38009/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"       Gemcitabine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/59/953?source=see_link\">",
"       Vinorelbine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/13/10458?source=see_link\">",
"       Pegylated Liposomal Doxorubicin",
"      </a>",
"      (GVD) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/7/38009/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/25/38297?source=see_link\">",
"       Ifosfamide",
"      </a>",
"      with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/0/41989?source=see_link\">",
"       MESNA",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"       Gemcitabine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/59/953?source=see_link\">",
"       Vinorelbine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/48/33536?source=see_link\">",
"       Prednisolone",
"      </a>",
"      (IGEV) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/7/38009/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Response rates associated with these regimens are 63, 62, 70, and 81 percent for GEM-P, GDP, GVD, and IGEV, respectively. The major toxicity when",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    is incorporated with other agents is myelosuppression. However, there is a rare but noted complication of diffuse interstitial pneumonitis, especially when gemcitabine is combined with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38009/abstract/19,20\">",
"     19,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There have been no randomized comparisons between these regimens. The following sections describe the phase II trials that have demonstrated their efficacy in this setting:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     GEM-P regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;A prospective, nonrandomized trial from the United Kingdom combined",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    (GEM-P) with responses in 14 of 17 patients with HL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38009/abstract/16\">",
"     16",
"    </a>",
"    ]. Myelosuppression was the main toxicity, with Grade 3 or 4 anemia, neutropenia and thrombocytopenia in 17, 61 and 54 percent of patients, respectively. Only one patient had neutropenic sepsis.",
"   </p>",
"   <p>",
"    Typical administration of GEM-P is every 28 days:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"       Gemcitabine",
"      </a>",
"      1000",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      days 1, 8, and 15 given intravenously.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       Cisplatin",
"      </a>",
"      100",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      day 15.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"       Methylprednisolone",
"      </a>",
"      1000 mg days 1 to 5 given either by mouth or intravenously.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     GDP regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;A combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    (GDP) achieved a response rate of 70 percent in 23 patients with relapsed or resistant HL; no patient progressed on treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38009/abstract/21\">",
"     21",
"    </a>",
"    ]. All patients had successful stem cell mobilization and underwent HCT with a median of 10.6 x 10(6) CD34+",
"    <span class=\"nowrap\">",
"     cells/kg.",
"    </span>",
"    Hematological toxicity was mild.",
"   </p>",
"   <p>",
"    Typical administration is in 21 day cycles:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"       Gemcitabine",
"      </a>",
"      1000",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      days 1 and 8 given intravenously.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       Dexamethasone",
"      </a>",
"      40 mg orally days 1 to 4.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       Cisplatin",
"      </a>",
"      75",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      day 1.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     GVD regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;A CALGB study employed 21-day cycles of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/59/953?source=see_link\">",
"     vinorelbine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/13/10458?source=see_link\">",
"     pegylated liposomal doxorubicin",
"    </a>",
"    (GVD) in 76 patients with recurrent or refractory HL, utilizing different doses for those with or without a prior hematopoietic cell transplant (HCT) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38009/abstract/17\">",
"     17",
"    </a>",
"    ]. The overall response rate for all patients was 70 percent with 19 percent complete remissions. Four-year event-free survival was 52 percent in HCT-naive patients treated with GVD followed by HCT, and was 10 percent in those in whom prior HCT had failed.",
"   </p>",
"   <p>",
"    The prospective trial required dose reductions that have resulted in the more typical administration of the following in 21 days cycles:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"       Gemcitabine",
"      </a>",
"      800",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      days 1 and 8 intravenously.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/59/953?source=see_link\">",
"       Vinorelbine",
"      </a>",
"      15",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      days 1 and 8.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/13/10458?source=see_link\">",
"       Pegylated Liposomal Doxorubicin",
"      </a>",
"      10",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      days 1 and 8.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     IGEV regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;An Italian trial combining",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/59/953?source=see_link\">",
"     vinorelbine",
"    </a>",
"    (IGEV) in 91 patients with",
"    <span class=\"nowrap\">",
"     relapsed/refractory",
"    </span>",
"    disease achieved an overall response rate of 81 percent, including complete remission in 54 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38009/abstract/18\">",
"     18",
"    </a>",
"    ]. There were no treatment deaths and only 8 percent required dose reduction. CD34 positive cell collections were achieved in 99 percent of patients.",
"   </p>",
"   <p>",
"    IGEV is typically administered in 21 day cycles as:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/25/38297?source=see_link\">",
"       Ifosfamide",
"      </a>",
"      2000",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      days 1 to 4 administered every 21 days",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/0/41989?source=see_link\">",
"       MESNA",
"      </a>",
"      2600",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      days 1 to 4",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"       Gemcitabine",
"      </a>",
"      800",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      days 1 and 4",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/59/953?source=see_link\">",
"       Vinorelbine",
"      </a>",
"      20",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      day 1",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/48/33536?source=see_link\">",
"       Prednisolone",
"      </a>",
"      100 mg days 1 to 4",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     OTHER COMMONLY USED REGIMENS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The other commonly used salvage regimens are",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    -based such as:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      BCNU,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/54/22376?source=see_link\">",
"       melphalan",
"      </a>",
"      (mini-BEAM) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/7/38009/abstract/22,23\">",
"       22,23",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"       Etoposide",
"      </a>",
"      , steroid,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      (ESHAP) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/7/38009/abstract/24,25\">",
"       24,25",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/25/38297?source=see_link\">",
"       Ifosfamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      (ICE) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/7/38009/abstract/26\">",
"       26",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       Dexamethasone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      (DHAP) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/7/38009/abstract/27\">",
"       27",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Mini-BEAM",
"    </span>",
"    &nbsp;&mdash;&nbsp;The component drugs of BEAM used in high-dose for HCT are used in lower dose as a transplant-conditioning regimen in a number of centers. Mini-BEAM is a reduced regimen of BCNU,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    . The initial series demonstrated an 84 percent response rate with 32 percent complete responses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38009/abstract/22\">",
"     22",
"    </a>",
"    ]. The marked myelotoxicity required transfusion of platelets and red cells in all platelets and antibiotics in approximately half. Similar response rates were noted in subsequent series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38009/abstract/23,28\">",
"     23,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Typical administration of mini-BEAM is every four weeks:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      BCNU 60",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      day 1 given intravenously",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"       Etoposide",
"      </a>",
"      75",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      days 2 to 5 given intravenously",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"       Cytarabine",
"      </a>",
"      100",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      twice daily days 2 to 5 intravenously",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/54/22376?source=see_link\">",
"       Melphalan",
"      </a>",
"      30",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      day 6 intravenously",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Dexa-BEAM is a German Hodgkin study group modification with the addition of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    (8mg orally every 8 hours on days 1 through 10) to the BEAM regimen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38009/abstract/29\">",
"     29",
"    </a>",
"    ]. In a prospective trial comparing salvage chemotherapy alone with autologous HCT , there was an 81 percent overall response rate after two cycles of Dexa-BEAM with a three-year failure-free survival rate of only 34 percent in patients who did not go on to HCT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38009/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     ESHAP regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;ESHAP (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    , steroid,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    ) has been an effective salvage program for both HL and non-Hodgkin lymphoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38009/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. It is associated with an overall response rate of approximately 70 to 80 percent. It is a modification of a previously employed regimen, DHAP (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    , cytarabine, cisplatin) which had an early response rate of 43 percent in HL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38009/abstract/29\">",
"     29",
"    </a>",
"    ]. The interval between cycles had been three to four weeks, but the German Hodgkin Study Group reduced the interval to 16 days and increased the response rate to 89 percent (21 percent complete) after two cycles in 102 patients requiring salvage therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38009/abstract/27\">",
"     27",
"    </a>",
"    ]. Although myelosuppressive, there were no serious complications and 96 percent of patients could have peripheral cells collected for HCT.",
"   </p>",
"   <p>",
"    The typical administration is every three to four weeks:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"       Etoposide",
"      </a>",
"      40",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      days 1 to 4 given intravenously",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"       Methylprednisolone",
"      </a>",
"      500 mg days 1 to 4 given intravenously",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"       Cytarabine",
"      </a>",
"      2000",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      day 5 given intravenously",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       Cisplatin",
"      </a>",
"      25",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      days 1 to 4 given intravenously",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     DHAP regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     Dexamethasone",
"    </a>",
"    , high dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    (DHAP) has been used as a salvage regimen in non-Hodgkin lymphoma and Hodgkin lymphoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38009/abstract/27\">",
"     27",
"    </a>",
"    ]. The overall response rate of patients with Hodgkin lymphoma who received prior MOPP and ABVD was 43 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38009/abstract/29\">",
"     29",
"    </a>",
"    ]. Patients with bulky disease and those who had failed more than two regimens were unlikely to benefit. However, alternative regimens containing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    could elicit responses in DHAP failures.",
"   </p>",
"   <p>",
"    The typical administration is every three to four weeks:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       Dexamethasone",
"      </a>",
"      40 mg days 1 to 4 given intravenously",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"       Cytarabine",
"      </a>",
"      2000",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      every 12 hours for two doses on day 2 given intravenously",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       Cisplatin",
"      </a>",
"      100",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      as a 24-hour infusion on day 1",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     ICE regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ICE (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    ) regimen derives primarily from investigators from Memorial Sloan-Kettering Institute as a preparatory conditioning regimen for HCT:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/25/38297?source=see_link\">",
"       Ifosfamide",
"      </a>",
"      5",
"      <span class=\"nowrap\">",
"       g/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      with equivalent dose of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/0/41989?source=see_link\">",
"       MESNA",
"      </a>",
"      given over 24 hours by continuous infusion on day 2",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"       Carboplatin",
"      </a>",
"      to an area under the curve (AUC) of 5 with a maximum of 800 mg day 2",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"       Etoposide",
"      </a>",
"      100",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       /day",
"      </span>",
"      on days 1 to 3",
"     </li>",
"     <li>",
"      G-CSF 5",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"      given on days 5 to 12",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    is based upon the area under the curve as calculated using the Calvert equation. If the glomerular filtration rate (GFR) used in the Calvert equation is estimated based upon measured serum creatinine, clinicians should consider capping the GFR at 125",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    for patients with normal renal function, at least for the first dose, with subsequent doses titrated based upon toxicity. This recommendation does not apply if the GFR is directly measured. Issues specific to dosing of carboplatin are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/48/41738?source=see_link&amp;anchor=H7#H7\">",
"     \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\", section on 'AUC dose calculation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most often two cycles are given with a two-week interval. The overall response rate is 88 percent (26 percent complete) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38009/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. The event-free survival rate for those who went on to HCT was 68 percent at 43 months. This regimen has equivalent application in non-Hodgkin's lymphoma. A modification with substitution of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/43/40630?source=see_link\">",
"     idarubicin",
"    </a>",
"    for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    has also demonstrated a high order of activity with an overall response rate in excess of 80 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38009/abstract/32\">",
"     32",
"    </a>",
"    ]. However, this modified regimen is severely myelotoxic with a high rate of hospitalization for neutropenic fever.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15846168\">",
"    <span class=\"h1\">",
"     BIOLOGIC THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three forms of biologic therapy have been evaluated in patients with Hodgkin lymphoma: immunotherapy, immunotoxins, and adoptive immunotherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15846182\">",
"    <span class=\"h2\">",
"     Brentuximab vedotin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/6/16486?source=see_link\">",
"     Brentuximab vedotin",
"    </a>",
"    (SGN-35) is an immunotoxin comprised of a CD-30 directed antibody linked to the antitubulin agent monomethyl auristatin E (MMAE) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38009/abstract/33\">",
"     33",
"    </a>",
"    ]. Brentuximab vedotin was granted accelerated approval by the US Food and Drug Administration for the treatment of patients with Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation (HCT) or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not candidates for HCT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38009/abstract/34\">",
"     34",
"    </a>",
"    ]. A subset of patients treated with brentuximab vedotin in this setting has been able to proceed with successful reduced intensity conditioning followed by allogeneic HCT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38009/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/49/21274?source=see_link\">",
"     \"Hematopoietic cell transplantation in classical Hodgkin lymphoma\"",
"    </a>",
"    .)",
"    <br/>",
"    <br/>",
"    Several small studies have demonstrated the activity of brentuximab vedotin in patients with relapsed or refractory HL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38009/abstract/36-40\">",
"     36-40",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a phase I trial of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/6/16486?source=see_link\">",
"       brentuximab vedotin",
"      </a>",
"      in 45 patients with CD30 positive hematopoietic cancers (42 of whom had Hodgkin lymphoma) relapsed or refractory after a median of three prior therapies, there were 11 complete remissions (CR), six partial remissions, and 19 cases with stable disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/7/38009/abstract/36\">",
"       36",
"      </a>",
"      ]. Side effects were generally mild with the most common being fatigue, pyrexia, diarrhea, nausea, neutropenia, and peripheral neuropathy.",
"     </li>",
"     <li>",
"      In a phase II multicenter trial, 102 patients with relapsed or refractory Hodgkin lymphoma after prior autologous HCT were treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/6/16486?source=see_link\">",
"       brentuximab vedotin",
"      </a>",
"      (1.8",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      every three weeks for up to 16 cycles) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/7/38009/abstract/37\">",
"       37",
"      </a>",
"      ]. The overall response rate was 75 percent (34 percent CR) with median times to objective response and CR of 6 and 12 weeks, respectively. Median durations of response were 20 and 3.5 months for those with CR and all patients, respectively. At a median follow-up of 18.5 months, the median progression-free survivals were 21.7 and 5.6 months for patients with CR and all patients, respectively. The most common nonhematologic toxicities were peripheral sensory neuropathy (42 percent), nausea (35 percent), and fatigue (34 percent). The most common severe (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      side effects were neutropenia (20 percent), thrombocytopenia (8 percent), anemia (6 percent), and peripheral sensory neuropathy (8 percent).",
"     </li>",
"     <li>",
"      In another phase II multicenter trial, 25 patients with relapsed Hodgkin lymphoma after prior allogeneic HCT were treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/6/16486?source=see_link\">",
"       brentuximab vedotin",
"      </a>",
"      (1.2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      or 1.8",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      every three weeks for up to 16 cycles) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/7/38009/abstract/38\">",
"       38",
"      </a>",
"      ]. The overall response rate was 50 percent (38 percent complete) with a median time to response of 8.1 weeks. At a median follow-up of 34 weeks, the median progression-free survival was 7.8 months and the median overall survival had not been reached. The most common toxicities were cough, fatigue, and pyrexia (52 percent each); nausea and peripheral sensory neuropathy (48 percent each), and dyspnea (40 percent). The most common severe (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      toxicities were neutropenia (24 percent) and anemia (20 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Progressive multifocal leukoencephalopathy is a rare complication of brentuximab treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38009/abstract/41-43\">",
"     41-43",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/3/43064?source=see_link&amp;anchor=H582252#H582252\">",
"     \"Neurologic complications of cancer treatment with biologic agents\", section on 'Brentuximab'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/3/26681?source=see_link\">",
"     \"Progressive multifocal leukoencephalopathy: Epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"    <br/>",
"    <br/>",
"    Infusion reactions are uncommon but anaphylaxis has been reported. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/19/38202?source=see_link&amp;anchor=H582577#H582577\">",
"     \"Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy\", section on 'Brentuximab'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13484010\">",
"    <span class=\"h2\">",
"     Immunotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The recombinant anti-CD20 antibody",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    is used in the treatment of many hematologic malignancies that express CD20. The value of rituximab in classic Hodgkin lymphoma is uncertain, although responses have been documented in uncontrolled trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38009/abstract/44\">",
"     44",
"    </a>",
"    ]. Researchers have speculated that circulating monotypic B-lymphocytes may be precursors (stem) cells for Hodgkin lymphoma. Prospective trials are needed to determine whether rituximab improves outcomes in patients with classic Hodgkin lymphoma.",
"   </p>",
"   <p>",
"    In contrast,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    may be more useful in the treatment of nodular lymphocyte predominant Hodgkin lymphoma. This is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/45/34520?source=see_link&amp;anchor=H18#H18\">",
"     \"Treatment of nodular lymphocyte-predominant Hodgkin lymphoma\", section on 'Rituximab'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15846214\">",
"    <span class=\"h2\">",
"     Adoptive immunotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The exquisite specificity of cytotoxic T lymphocytes (CTLs) has led investigators to attempt to isolate cells with significant antitumor activity; infusion of these cells is referred to as adoptive immunotherapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/58/16298?source=see_link&amp;anchor=H1037110587#H1037110587\">",
"     \"Immunotherapy for the prevention and treatment of relapse following hematopoietic cell transplantation\", section on 'Cytotoxic T lymphocytes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A possible role for adoptive immunotherapy in refractory Hodgkin lymphoma is based upon the ability to generate clones of cytotoxic T-lymphocytes that are specific for Epstein-Barr virus latent antigens LMP1 and LMP2 or Reed-Sternberg cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38009/abstract/45\">",
"     45",
"    </a>",
"    ]. Expanded clones of these cells may have a therapeutic role in those patients with Hodgkin lymphoma whose Reed-Sternberg cells express Epstein-Barr viral antigens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38009/abstract/46,47\">",
"     46,47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27471889\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Approximately 10 to 15 percent of patients with early stage Hodgkin lymphoma (HL) and 20 to 40 percent of patients with advanced stage HL will relapse after initial therapy. In addition, approximately 10 to 15 percent will have disease resistant to initial therapy. The vast majority of patients in community practice with relapsed disease will have had ABVD (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"       bleomycin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/3/4152?source=see_link\">",
"       vinblastine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/49/4887?source=see_link\">",
"       dacarbazine",
"      </a>",
"      ) as their primary chemotherapy. In general, patients with relapsed or refractory disease are treated with a chemotherapy regimen that is different from the one used for initial treatment. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Several regimens are commonly used, but have not been compared directly in prospective randomized trials:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"       Gemcitabine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       Cisplatin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"       Methylprednisolone",
"      </a>",
"      (GEM-P) (see",
"      <a class=\"local\" href=\"#H5\">",
"       'GEM-P regimen'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"       Gemcitabine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       Dexamethasone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       Cisplatin",
"      </a>",
"      (GDP) (see",
"      <a class=\"local\" href=\"#H6\">",
"       'GDP regimen'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"       Gemcitabine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/59/953?source=see_link\">",
"       Vinorelbine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/13/10458?source=see_link\">",
"       Pegylated Liposomal Doxorubicin",
"      </a>",
"      (GVD) (see",
"      <a class=\"local\" href=\"#H7\">",
"       'GVD regimen'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/25/38297?source=see_link\">",
"       Ifosfamide",
"      </a>",
"      with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/0/41989?source=see_link\">",
"       MESNA",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"       Gemcitabine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/59/953?source=see_link\">",
"       Vinorelbine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/48/33536?source=see_link\">",
"       Prednisolone",
"      </a>",
"      (IGEV) (see",
"      <a class=\"local\" href=\"#H8\">",
"       'IGEV regimen'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      BCNU,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/54/22376?source=see_link\">",
"       melphalan",
"      </a>",
"      (mini-BEAM) (see",
"      <a class=\"local\" href=\"#H10\">",
"       'Mini-BEAM'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"       Etoposide",
"      </a>",
"      , steroid,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      (ESHAP) (see",
"      <a class=\"local\" href=\"#H11\">",
"       'ESHAP regimen'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/25/38297?source=see_link\">",
"       Ifosfamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      (ICE) (see",
"      <a class=\"local\" href=\"#H13\">",
"       'ICE regimen'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       Dexamethasone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      (DHAP) (see",
"      <a class=\"local\" href=\"#H12\">",
"       'DHAP regimen'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Any of the regimens listed above would be acceptable second-line chemotherapy. For most patients with relapsed or refractory HL who are candidates for HCT, we suggest the use of ICE chemotherapy rather than another regimen (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). This preference is largely based upon presumed equal efficacy to other regimens, decreased toxicity when compared with DHAP and mini-BEAM, and our familiarity with the regimen. (See",
"      <a class=\"local\" href=\"#H111154724\">",
"       'Choice of regimen'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Salvage chemotherapy is usually given for a minimum of two cycles, although some patients may require more. Salvage chemotherapy can achieve durable responses and remissions in approximately one-half of these patients. Radiation therapy is indicated for patients with localized residual disease after salvage chemotherapy. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients in first relapse, in second relapse, or those with progressive, resistant disease are candidates for high dose chemotherapy and autologous hematopoietic cell transplantation (HCT). A potential limitation of excessive chemotherapy is the impairment of the peripheral stem cell collection process which could be compromised by excess bone marrow suppression. However, it appears that more than 60 to 70 percent of patients are able to proceed to autologous HCT after salvage therapy; in general, approximately 40 to 60 percent of those remain in a second remission, especially if they demonstrate sensitivity to salvage chemotherapy. Response to HCT may be predicted by a negative positron emission tomography (PET) scan. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/17/37145?source=see_link\">",
"       \"Treatment of relapse of classical Hodgkin lymphoma after initial chemotherapy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Patients who relapse following autologous HCT can only achieve palliation with conventional dose chemotherapy. Options for such patients include treatment with an immunotoxin (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/6/16486?source=see_link\">",
"       brentuximab vedotin",
"      </a>",
"      ) or referral for allogeneic transplantation. (See",
"      <a class=\"local\" href=\"#H15846182\">",
"       'Brentuximab vedotin'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/49/21274?source=see_link&amp;anchor=H14#H14\">",
"       \"Hematopoietic cell transplantation in classical Hodgkin lymphoma\", section on 'Treatment of relapse following transplantation'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38009/abstract/1\">",
"      Josting A, Franklin J, May M, et al. New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's lymphoma study group. J Clin Oncol 2002; 20:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38009/abstract/2\">",
"      Bonfante V, Santoro A, Viviani S, et al. Outcome of patients with Hodgkin's disease failing after primary MOPP-ABVD. J Clin Oncol 1997; 15:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38009/abstract/3\">",
"      Radman I, Basi N, Labar B, et al. Long-term results of conventional-dose salvage chemotherapy in patients with refractory and relapsed Hodgkin's disease (Croatian experience). Ann Oncol 2002; 13:1650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38009/abstract/4\">",
"      Santoro A, Bonadonna G, Valagussa P, et al. Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy. J Clin Oncol 1987; 5:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38009/abstract/5\">",
"      Canellos GP, Anderson JR, Propert KJ, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992; 327:1478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38009/abstract/6\">",
"      Byrne BJ, Gockerman JP. Salvage therapy in Hodgkin's lymphoma. Oncologist 2007; 12:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38009/abstract/7\">",
"      Cashen AF, Bartlett NL. Salvage regimens for Hodgkin lymphoma. Clin Adv Hematol Oncol 2008; 6:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38009/abstract/8\">",
"      Kuruvilla J, Nagy T, Pintilie M, et al. Similar response rates and superior early progression-free survival with gemcitabine, dexamethasone, and cisplatin salvage therapy compared with carmustine, etoposide, cytarabine, and melphalan salvage therapy prior to autologous stem cell transplantation for recurrent or refractory Hodgkin lymphoma. Cancer 2006; 106:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38009/abstract/9\">",
"      Wannesson L, Bargetzi M, Cairoli A, et al. Autotransplant for Hodgkin lymphoma after failure of upfront BEACOPP escalated (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisone). Leuk Lymphoma 2013; 54:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38009/abstract/10\">",
"      Yuen AR, Rosenberg SA, Hoppe RT, et al. Comparison between conventional salvage therapy and high-dose therapy with autografting for recurrent or refractory Hodgkin's disease. Blood 1997; 89:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38009/abstract/11\">",
"      Spaepen K, Stroobants S, Dupont P, et al. Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation. Blood 2003; 102:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38009/abstract/12\">",
"      Josting A, Reiser M, Rueffer U, et al. Treatment of primary progressive Hodgkin's and aggressive non-Hodgkin's lymphoma: is there a chance for cure? J Clin Oncol 2000; 18:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38009/abstract/13\">",
"      Moskowitz CH, Kewalramani T, Nimer SD, et al. Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin's disease. Br J Haematol 2004; 124:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38009/abstract/14\">",
"      Josting A, Rueffer U, Franklin J, et al. Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study Group. Blood 2000; 96:1280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38009/abstract/15\">",
"      Santoro A, Bredenfeld H, Devizzi L, et al. Gemcitabine in the treatment of refractory Hodgkin's disease: results of a multicenter phase II study. J Clin Oncol 2000; 18:2615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38009/abstract/16\">",
"      Ng M, Waters J, Cunningham D, et al. Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma. Br J Cancer 2005; 92:1352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38009/abstract/17\">",
"      Bartlett NL, Niedzwiecki D, Johnson JL, et al. Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. Ann Oncol 2007; 18:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38009/abstract/18\">",
"      Santoro A, Magagnoli M, Spina M, et al. Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma. Haematologica 2007; 92:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38009/abstract/19\">",
"      Friedberg JW, Neuberg D, Kim H, et al. Gemcitabine added to doxorubicin, bleomycin, and vinblastine for the treatment of de novo Hodgkin disease: unacceptable acute pulmonary toxicity. Cancer 2003; 98:978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38009/abstract/20\">",
"      Bredenfeld H, Franklin J, Nogova L, et al. Severe pulmonary toxicity in patients with advanced-stage Hodgkin's disease treated with a modified bleomycin, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone, and gemcitabine (BEACOPP) regimen is probably related to the combination of gemcitabine and bleomycin: a report of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 2004; 22:2424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38009/abstract/21\">",
"      Baetz T, Belch A, Couban S, et al. Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin's disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol 2003; 14:1762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38009/abstract/22\">",
"      Colwill R, Crump M, Couture F, et al. Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease before intensive therapy and autologous bone marrow transplantation. J Clin Oncol 1995; 13:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38009/abstract/23\">",
"      Mart&iacute;n A, Fern&aacute;ndez-Jim&eacute;nez MC, Caballero MD, et al. Long-term follow-up in patients treated with Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease. Br J Haematol 2001; 113:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38009/abstract/24\">",
"      Aparicio J, Segura A, Garcer&aacute; S, et al. ESHAP is an active regimen for relapsing Hodgkin's disease. Ann Oncol 1999; 10:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38009/abstract/25\">",
"      Velasquez WS, McLaughlin P, Tucker S, et al. ESHAP--an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol 1994; 12:1169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38009/abstract/26\">",
"      Moskowitz CH, Nimer SD, Zelenetz AD, et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood 2001; 97:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38009/abstract/27\">",
"      Josting A, Rudolph C, Reiser M, et al. Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease. Ann Oncol 2002; 13:1628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38009/abstract/28\">",
"      Moore S, Kayani I, Peggs K, et al. Mini-BEAM is effective as a bridge to transplantation in patients with refractory or relapsed Hodgkin lymphoma who have failed to respond to previous lines of salvage chemotherapy but not in patients with salvage-refractory DLBCL. Br J Haematol 2012; 157:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38009/abstract/29\">",
"      Brandwein JM, Callum J, Sutcliffe SB, et al. Evaluation of cytoreductive therapy prior to high dose treatment with autologous bone marrow transplantation in relapsed and refractory Hodgkin's disease. Bone Marrow Transplant 1990; 5:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38009/abstract/30\">",
"      Moskowitz CH, Bertino JR, Glassman JR, et al. Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma. J Clin Oncol 1999; 17:3776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38009/abstract/31\">",
"      Moskowitz C. Risk-adapted therapy for relapsed and refractory lymphoma using ICE chemotherapy. Cancer Chemother Pharmacol 2002; 49 Suppl 1:S9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38009/abstract/32\">",
"      Oyan B, Koc Y, Ozdemir E, et al. Ifosfamide, idarubicin, and etoposide in relapsed/refractory Hodgkin disease or non-Hodgkin lymphoma: a salvage regimen with high response rates before autologous stem cell transplantation. Biol Blood Marrow Transplant 2005; 11:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38009/abstract/33\">",
"      Okeley NM, Miyamoto JB, Zhang X, et al. Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate. Clin Cancer Res 2010; 16:888.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.accessdata.fda.gov/drugsatfda_docs/label/2011/125388s000,125399s000lbl.pdf (Accessed on August 22, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38009/abstract/35\">",
"      Chen R, Palmer JM, Thomas SH, et al. Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma. Blood 2012; 119:6379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38009/abstract/36\">",
"      Younes A, Bartlett NL, Leonard JP, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010; 363:1812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38009/abstract/37\">",
"      Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol 2012; 30:2183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38009/abstract/38\">",
"      Gopal AK, Ramchandren R, O'Connor OA, et al. Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation. Blood 2012; 120:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38009/abstract/39\">",
"      Rothe A, Sasse S, Goergen H, et al. Brentuximab vedotin for relapsed or refractory CD30+ hematologic malignancies: the German Hodgkin Study Group experience. Blood 2012; 120:1470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38009/abstract/40\">",
"      Forero-Torres A, Fanale M, Advani R, et al. Brentuximab vedotin in transplant-naive patients with relapsed or refractory hodgkin lymphoma: analysis of two phase I studies. Oncologist 2012; 17:1073.",
"     </a>",
"    </li>",
"    <li>",
"     file://dailymed.nlm.nih.gov/dailymed/about.cfm (Accessed on January 23, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38009/abstract/42\">",
"      Wagner-Johnston ND, Bartlett NL, Cashen A, Berger JR. Progressive multifocal leukoencephalopathy in a patient with Hodgkin lymphoma treated with brentuximab vedotin. Leuk Lymphoma 2012; 53:2283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38009/abstract/43\">",
"      Jalan P, Mahajan A, Pandav V, et al. Brentuximab associated progressive multifocal leukoencephalopathy. Clin Neurol Neurosurg 2012; 114:1335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38009/abstract/44\">",
"      Younes A, Romaguera J, Hagemeister F, et al. A pilot study of rituximab in patients with recurrent, classic Hodgkin disease. Cancer 2003; 98:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38009/abstract/45\">",
"      Sing AP, Ambinder RF, Hong DJ, et al. Isolation of Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes that lyse Reed-Sternberg cells: implications for immune-mediated therapy of EBV+ Hodgkin's disease. Blood 1997; 89:1978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38009/abstract/46\">",
"      Lucas KG, Salzman D, Garcia A, Sun Q. Adoptive immunotherapy with allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T-lymphocytes for recurrent, EBV-positive Hodgkin disease. Cancer 2004; 100:1892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38009/abstract/47\">",
"      Bollard CM, Aguilar L, Straathof KC, et al. Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease. J Exp Med 2004; 200:1623.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4767 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-190.111.122.2-168C04E0CB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_7_38009=[""].join("\n");
var outline_f37_7_38009=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27471889\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H111154724\">",
"      Choice of regimen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Prognostic factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      GEMCITABINE-CONTAINING REGIMENS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      GEM-P regimen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      GDP regimen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      GVD regimen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      IGEV regimen",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      OTHER COMMONLY USED REGIMENS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Mini-BEAM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      ESHAP regimen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      DHAP regimen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      ICE regimen",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15846168\">",
"      BIOLOGIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15846182\">",
"      Brentuximab vedotin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13484010\">",
"      Immunotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15846214\">",
"      Adoptive immunotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27471889\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/48/41738?source=related_link\">",
"      Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/49/21274?source=related_link\">",
"      Hematopoietic cell transplantation in classical Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/58/16298?source=related_link\">",
"      Immunotherapy for the prevention and treatment of relapse following hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/19/38202?source=related_link\">",
"      Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/54/39786?source=related_link\">",
"      Initial treatment of advanced (stage III-IV) classical Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/3/43064?source=related_link\">",
"      Neurologic complications of cancer treatment with biologic agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/3/26681?source=related_link\">",
"      Progressive multifocal leukoencephalopathy: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/31/11770?source=related_link\">",
"      Treatment of favorable prognosis early (stage I-II) classical Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/45/34520?source=related_link\">",
"      Treatment of nodular lymphocyte-predominant Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/17/37145?source=related_link\">",
"      Treatment of relapse of classical Hodgkin lymphoma after initial chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/54/27496?source=related_link\">",
"      Treatment of unfavorable prognosis early (stage I-II) classical Hodgkin lymphoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_7_38010="Fertility preservation in patients undergoing gonadotoxic treatment or gonadal resection";
var content_f37_7_38010=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Fertility preservation in patients undergoing gonadotoxic treatment or gonadal resection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/7/38010/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/7/38010/contributors\">",
"     Murat Sonmezer, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/7/38010/contributors\">",
"     Kutluk Oktay, MD, FACOG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/7/38010/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/7/38010/contributors\">",
"     Robert L Barbieri, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/7/38010/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/7/38010/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/7/38010/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 1, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H15145555\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of malignancy, as well as some precancerous and benign conditions (",
"    <a class=\"graphic graphic_table graphicRef60344 \" href=\"mobipreview.htm?21/38/22125\">",
"     table 1",
"    </a>",
"    ), may necessitate surgical resection of reproductive organs or administration of gonadotoxic chemotherapy or radiation therapy (",
"    <a class=\"graphic graphic_table graphicRef58142 \" href=\"mobipreview.htm?5/18/5421\">",
"     table 2",
"    </a>",
"    ). This often leads to infertility, which is a major quality of life concern.",
"   </p>",
"   <p>",
"    With appropriate pretreatment planning and intervention, biologic parenthood is possible for many men and women who will lose reproductive function because of surgery or gonadotoxic treatment. This topic will discuss several measures for preserving fertility in young women (",
"    <a class=\"graphic graphic_table graphicRef65144 \" href=\"mobipreview.htm?16/56/17293\">",
"     table 3",
"    </a>",
"    ) and men receiving potentially gonadotoxic agents. The approach to fertility preservation in healthy women who wish to delay child-bearing is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/61/18392?source=see_link\">",
"     \"Fertility preserving options for women of advancing age\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1314548941\">",
"    <span class=\"h1\">",
"     PRETREATMENT COUNSELING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physicians should discuss with patients the risk of infertility and possible interventions to preserve fertility prior to initiating potentially gonadotoxic therapy. This discussion should occur soon after diagnosis since some interventions to preserve fertility take time and could delay the start of treatment. Early referral to a reproductive endocrinologist can be useful [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/1\">",
"     1",
"    </a>",
"    ]. Advances in chemotherapy have led to development of less gonadotoxic treatment regimens for many cancers, such as Hodgkin lymphoma.",
"   </p>",
"   <p>",
"    Fertility preservation requires individualization. The optimal approach depends upon the type of gonadotoxic treatment (radiation versus chemotherapy), time available, patient age, the specific disease, and whether the patient has a partner. Our approach to decision making in patients with cancer is shown in the figure (",
"    <a class=\"graphic graphic_algorithm graphicRef55848 \" href=\"mobipreview.htm?6/29/6623\">",
"     algorithm 1",
"    </a>",
"    ). The American Society of Clinical Oncology (ASCO) has published similar recommendations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to the current topic, the following topics may be useful for patient counseling:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/26/1447?source=see_link\">",
"       \"Ovarian failure due to anticancer drugs and radiation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/24/13706?source=see_link\">",
"       \"Effects of cytotoxic agents on gonadal function in adult men\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/54/11114?source=see_link&amp;anchor=H29#H29\">",
"       \"Causes of male infertility\", section on 'Radiation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/50/7977?source=see_link\">",
"       \"Overview of fertility and pregnancy in cancer survivors\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     METHODS TO PRESERVE FERTILITY IN WOMEN",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no large randomized clinical trials evaluating the majority of the interventions described below, nor are there long-term follow-up studies assessing the possible impacts of fertility treatment on cancer survivors. Many oncologists remain cautious about the use of traditional assisted reproductive technology (ART) in women with estrogen-dependent malignancies, since ART involves ovarian stimulation and results in high estrogen levels.",
"   </p>",
"   <p>",
"    The presence of cancer probably does not affect ovarian reserve or responsiveness to gonadotropins prior to gonadotoxic therapy, but data are conflicting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/2-8\">",
"     2-8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Cryopreservation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cryopreservation of embryos is a proven effective technique for preserving reproductive capacity; cryopreserved thawed embryos are used in about 20 percent of all ART cycles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/9\">",
"     9",
"    </a>",
"    ]. Cryopreservation of oocytes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/10\">",
"     10",
"    </a>",
"    ] and ovarian tissue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/11\">",
"     11",
"    </a>",
"    ] are promising approaches with reports of live births, but remain investigational [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/12\">",
"     12",
"    </a>",
"    ]. Cryopreservation of the whole ovary with an intact pedicle and vascular supply is also investigational and has not yet resulted in a live birth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cryopreserved embryos and oocytes can be frozen for many years and remain viable. Frozen embryos survive the freeze&ndash;thaw process better than unfertilized oocytes (&gt;90 percent survival versus 50 to 70 percent survival). In one experienced center, the live-birth rate in patients who used frozen oocytes for in vitro fertilization (IVF) was approximately 21 percent versus 60 percent for patients undergoing IVF with fresh oocytes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/14\">",
"     14",
"    </a>",
"    ]. Thus, cryopreservation of an embryo is preferable to oocyte cryopreservation, when possible. Donor sperm purchased from a commercial sperm bank may be required, if acceptable to the patient.",
"   </p>",
"   <p>",
"    However, cryopreservation of embryos or oocytes does not guarantee preservation of fertility because chromosomal abnormalities are present in some oocytes, even in young women.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Embryo",
"    </span>",
"    &nbsp;&mdash;&nbsp;Embryo cryopreservation is a well-established technique for storing surplus embryos of patients undergoing IVF procedures. Because more than one embryo is often transferred, the percentage of frozen-thawed embryo transfers resulting in a live birth approaches the fecundity rate in natural conception and varies from 22 to 35 percent, depending on the age of the mother [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/56/37770?source=see_link\">",
"     \"In vitro fertilization\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cryopreservation of embryos may not be technically feasible for every patient planning gonadotoxic therapy for several reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Time constraints",
"      </strong>",
"      &mdash; Since gonadotoxic treatment is usually implemented immediately after cancer diagnosis, there may not be adequate time for ovarian stimulation and oocyte retrieval, which usually requires two to three weeks.",
"      <br/>",
"      <br/>",
"      Under urgent conditions, oocyte retrieval during the luteal phase and in vitro maturation (instead of conventional maturation in vivo) followed by in vitro fertilization and cryopreservation of the embryo may be an option [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/16,17\">",
"       16,17",
"      </a>",
"      ]. In",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/26/36261?source=see_link\">",
"       letrozole",
"      </a>",
"      cycles, ovarian stimulation can be started at a random time in the cycle without compromising fertilization rates [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/18\">",
"       18",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H12480392\">",
"       'Immature oocytes'",
"      </a>",
"      below.)",
"      <br/>",
"      <br/>",
"      We do not recommend ovarian stimulation after chemotherapy has been initiated because the ovarian response to ovarian stimulation and the quality of oocytes retrieved diminish with every round of chemotherapy, including the first [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/19-21\">",
"       19-21",
"      </a>",
"      ]. Chemotherapy can induce DNA double strand breaks in human oocytes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/22\">",
"       22",
"      </a>",
"      ]. Because of this, we and others advise women who receive chemotherapy to wait six months before attempting to conceive [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/23\">",
"       23",
"      </a>",
"      ], although embryo banking between induction and consolidation chemotherapy has been reported in women with leukemia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/24\">",
"       24",
"      </a>",
"      ]. Waiting six months should allow developing follicles with DNA damage to be cleared from the ovary as new follicles are recruited from surviving primordial follicles.",
"     </li>",
"     <li>",
"      <strong>",
"       No partner",
"      </strong>",
"      &mdash; IVF can only be offered to women with an available partner, unless the woman elects to use donor sperm.",
"     </li>",
"     <li>",
"      <strong>",
"       Legal and ethical issues",
"      </strong>",
"      &mdash; Ovarian stimulation and IVF may not be ethically acceptable in children with cancer. Some couples may be philosophically opposed to cryopreservation of embryos and it is illegal in some countries (eg, Germany, Switzerland, Italy).",
"     </li>",
"     <li>",
"      <strong>",
"       Estrogen sensitive tumors",
"      </strong>",
"      &mdash; Estrogen-sensitive tumors may be stimulated by the high estrogen levels resulting from ovarian stimulation (see",
"      <a class=\"local\" href=\"#H5410837\">",
"       'Issues in women with breast cancer'",
"      </a>",
"      below).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Oocytes",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88826114\">",
"    <span class=\"h4\">",
"     Mature oocytes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cryopreservation of mature oocytes is an option for women without partners who opt not to use donor sperm for IVF. In contrast to cryopreservation of embryos and sperm, oocyte cryopreservation is technically more challenging since oocytes contain more water and thus are more sensitive to cryoinjury from formation of ice crystals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/25\">",
"     25",
"    </a>",
"    ]. The meiotic spindle, cytoskeleton, cortical granules, and zona pellucidae are the structures particularly at risk from freezing. However, by using special freezing techniques, approximately 70 percent of cryopreserved oocytes survive the freeze-thaw process [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In randomized trials, the pregnancy rate with",
"    <span class=\"nowrap\">",
"     cryopreserved/warmed",
"    </span>",
"    mature oocytes was generally similar to that with fresh oocytes, although these trials were largely limited to donor oocyte populations and infertile couples with supernumerary oocytes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/28-31\">",
"     28-31",
"    </a>",
"    ]. Two large observational studies reported acceptable success rates, but lower than with fresh oocytes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. Based on these data, in 2013, the Practice Committees of the American Society for Reproductive Medicine (ASRM) and the Society for Assisted Reproductive Technology (SART) concluded that mature oocyte cryopreservation is a reasonable option for preservation of fertility when medically indicated and embryo cryopreservation is not possible [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/34\">",
"     34",
"    </a>",
"    ]. When mature oocytes are collected and frozen, issues regarding ovarian stimulation (time constraints, high estrogen levels) discussed above also apply.",
"   </p>",
"   <p>",
"    The two methods of cryopreservation are the \"slow-freeze\" technique and vitrification (conversion of water to a solid without formation of ice crystals by using a very &ldquo;fast freeze&rdquo; and cryoprotectants). Vitrification appears to be more successful than slow-freezing, but more trials are needed to establish whether one method is clearly superior to the other. In a 2011 systematic review and meta-analysis of five trials (4282 vitrified oocytes, 3524 fresh oocytes, 361 slow-frozen oocytes), compared to slow freezing, vitrification resulted in a higher oocyte survival rate (OR 2.46, 95% CI 1.82-3.32), a higher fertilization rate (OR 1.50, 95% CI 1.07-2.11), a higher rate of top-quality embryos (22.4 versus 8.0 percent, OR 3.32, 95% CI 1.37-8.02), and a higher embryo cleavage rate (day 2: 64.6 versus 47.7 percent, OR 2.00, 95% CI 1.33-3.00; day 3: 53.0 versus 33.3 percent, OR 2.25, 95% CI 1.32-3.85) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/35\">",
"     35",
"    </a>",
"    ]. The rates of ongoing pregnancy, top-quality embryo, embryo cleavage, and fertilization did not differ between the vitrification and the fresh oocyte groups.",
"   </p>",
"   <p>",
"    There is a theoretical concern that damage to the metaphase spindle of the oocyte during oocyte cryopreservation could increase the risk of karyotypic abnormalities in offspring. Such defects have not been observed to date, but experience is limited. The ASRM has published guidelines for informed consent prior to elective oocyte cryopreservation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12480392\">",
"    <span class=\"h4\">",
"     Immature oocytes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immature oocytes have been harvested from both in situ and excised ovarian tissue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/37\">",
"     37",
"    </a>",
"    ]. Development of the technique and assessment of its role in fertility treatment are ongoing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/38\">",
"     38",
"    </a>",
"    ]. The immature oocytes are matured in vitro (ie, in vitro maturation [IVM]) either before freezing or after thawing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/39\">",
"     39",
"    </a>",
"    ]; however, fresh oocytes have higher IVM rates than frozen oocytes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/40-42\">",
"     40-42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In vitro maturation of immature oocytes from unstimulated cycles is an investigational technology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/43\">",
"     43",
"    </a>",
"    ]. Compared to conventional ovarian stimulation and retrieval of mature oocytes, advantages include the avoidance of large doses of gonadotropins and their associated risks and high costs, as well as avoidance of time constraints and exposure of estrogen-sensitive tumors to high estrogen levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/44\">",
"     44",
"    </a>",
"    ]. In addition, immature oocytes are expected to be more resistant to cryoinjury than mature oocytes since they do not contain a metaphase spindle.",
"   </p>",
"   <p>",
"    However, the implantation rate per embryo transferred (5.5 to 21.6 percent) is significantly lower and early pregnancy loss per embryo transferred is higher than in conventional IVF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/43\">",
"     43",
"    </a>",
"    ]. Few pregnancies from frozen-thawed immature human oocytes have been reported, and although follow-up studies of these children are limited, their results have been reassuring [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/45-47\">",
"     45-47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H109317940\">",
"    <span class=\"h3\">",
"     Whole ovary and pedicle",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cryopreserving the entire ovary with its vascular supply might help decrease the degree of follicle loss during the initial ischemia period after transplantation, but it has been difficult to preserve both the ovarian follicles and ovarian vascular pedicle [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/48-52\">",
"     48-52",
"    </a>",
"    ]. Currently, there is no good technique that efficiently cryopreserves both the ovary and its vascular pedicle.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Ovarian tissue",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cryopreservation of ovarian tissue followed by heterotopic implantation (eg, in the abdominal wall, forearm, chest wall) or orthotopic implantation (eg, to remaining ovarian tissue or pelvic peritoneum) is an investigational approach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/53-59\">",
"     53-59",
"    </a>",
"    ]. Immature oocytes can be retrieved from the harvested ovarian tissue and frozen separately as an adjunct to ovarian tissue cryopreservation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/37\">",
"     37",
"    </a>",
"    ]. All egg-containing follicles are in the outer one millimeter of the ovary, so cryopreservation can be limited to only this strip of tissue. The combination of partial removal of&nbsp;ovarian&nbsp;tissue&nbsp;for ovarian cryopreservation followed by&nbsp;ovarian stimulation&nbsp;and&nbsp;cryopreservation of oocytes can improve the efficacy of fertility preservation without compromising the average number and quality of retrieved oocytes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ovarian tissue cryopreservation and cryopreservation of immature oocytes have similar advantages over embryo cryopreservation (no need for ovarian stimulation or a partner), and the additional advantage that the ovarian tissue can continue to produce hormones when reimplanted. However, return of ovarian function after ovarian tissue transplantation appears to be more likely when fresh rather than frozen-thawed grafts are used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/61-63\">",
"     61-63",
"    </a>",
"    ]. In animals, transplantation of frozen-thawed ovarian tissue causes significant loss of follicles due to ischemic damage to the graft [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ovarian tissue should be obtained before chemotherapy is given since ovarian reserve is diminished with each round of chemotherapy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of patients undergoing ovarian tissue cryopreservation for fertility preservation, the primordial follicle counts were significantly lower in patients who received chemotherapy compared to unexposed controls (5.4&plusmn;1.3 versus 9.6&plusmn;2.2) and patients who received alkylating agents had significantly lower primordial follicle counts compared to women treated with nonalkylating agents (2.9&plusmn;1 versus 7.9&plusmn;1.6) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/65\">",
"       65",
"      </a>",
"      ]. In vitro, ovarian cortical pieces from individuals who were previously exposed to chemotherapy (chemotherapy group) produced significantly less estradiol compared with those who were not exposed.",
"     </li>",
"     <li>",
"      In a human xenograft study, we found that, after a single dose of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      administration at a dose comparable to the regimens used to treat breast cancer, apoptotic follicle death began as early as 12 hours after the administration of the drug [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/66\">",
"       66",
"      </a>",
"      ]. By 48 hours, 93 percent of all ovarian reserve was lost through an apoptotic mechanism.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A case series of 13 live births after orthotopic autotransplantation of cryopreserved ovarian tissue reported that all of the infants were healthy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/67\">",
"     67",
"    </a>",
"    ]. Eight mothers were cancer patients and two were patients treated with high doses of chemotherapy for benign diseases (microscopic polyangiitis, sickle cell anemia).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12480896\">",
"    <span class=\"h4\">",
"     Contraindications and risks",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ovarian tissue preservation is not an option for women with ovarian cancer or at high risk of developing ovarian cancer. Women carrying BRCA 1 and BRCA 2 germline mutations have a 60 percent and 10 to 20 percent lifetime risk of developing ovarian cancer, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/68-70\">",
"     68-70",
"    </a>",
"    ]. These women are offered prophylactic oophorectomy (usually at the completion of childbearing) to decrease the risk of developing ovarian cancer or as a part of a treatment plan for breast cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/71\">",
"     71",
"    </a>",
"    ]. They are not good candidates for cryopreservation of ovarian tissue, given their increased risk of developing ovarian cancer and the relatively high incidence of occult ovarian cancer (2 to 18.5 percent) in BRCA carriers. However, it has been hypothesized that if ovarian tissue is frozen when the woman is very young and at very low risk of ovarian cancer, cryopreservation of ovarian tissue may still be considered. This approach has not been tested. If ovarian tissue is cryopreserved for reimplantation, a detailed histological analysis of the ovarian cortical pieces is mandatory, but may not completely rule out the presence of ovarian cancer. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/25/34202?source=see_link\">",
"     \"Risk-reducing bilateral salpingo-oophorectomy in women at high risk of epithelial ovarian and fallopian tubal cancer\"",
"    </a>",
"    .)",
"    <br/>",
"    <br/>",
"    In women with cancer not involving the ovary, there is a theoretical concern of reimplantation of metastatic cells from the primary tumor during autotransplantation. However, the majority of the tumors encountered during reproductive ages have relatively low potential to metastasize to ovaries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/72\">",
"     72",
"    </a>",
"    ]. Exceptions include blood borne malignancies such as leukemias [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/73-75\">",
"     73-75",
"    </a>",
"    ], as well as Burkitt's lymphoma and neuroblastoma. Early stage infiltrative ductal breast cancer, the most common histologic subtype, rarely metastasizes to the ovaries, in contrast to lobular breast cancer, which usually occurs during later years of life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/76\">",
"     76",
"    </a>",
"    ]. Animal studies indicate that the likelihood of ovarian involvement is not high in Hodgkin lymphoma, but the possibility of transmission cannot be excluded completely [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/77,78\">",
"     77,78",
"    </a>",
"    ]. The only series in humans with lymphoma reported that none of the 26 patients had evidence of ovarian involvement by histology and immunohistochemistry [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/79\">",
"     79",
"    </a>",
"    ]. In our series of 55 women with various malignancies undergoing ovarian tissue cryopreservation, no ovarian metastases were found on histological analysis of tissue samples [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/80\">",
"     80",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    When there is a significant concern about ovarian involvement, cryopreservation procedure should not be performed for the purpose of future autotransplantation. A thorough histological evaluation should be done on portions of harvested ovarian tissue to rule out micrometastases. Molecular markers can also be utilized to detect an extremely small number of metastatic cells in the tissue when such markers exist [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/53,74\">",
"     53,74",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16144729\">",
"    <span class=\"h2\">",
"     Options for protecting ovarian function",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16144814\">",
"    <span class=\"h3\">",
"     From radiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ovarian follicles are sensitive to DNA damage from ionizing radiation. Ovarian radiation can result in atrophy and decreased follicle number. The degree of ovarian damage and decreased ovarian function depend upon the patient's age and the dose of radiation delivered to the ovaries, and can be compounded by the addition of chemotherapy. Medical treatments to reduce radiation induced ovarian damage have not been successful in humans. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/26/1447?source=see_link&amp;anchor=H3#H3\">",
"     \"Ovarian failure due to anticancer drugs and radiation\", section on 'Radiation therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h4\">",
"     Transposition (oophoropexy)",
"    </span>",
"    &nbsp;&mdash;&nbsp;When a radiation field has been planned for the treatment of a cancer, the radiation oncologist and reproductive surgeon can work together to plan a surgical procedure that will move the ovary to a position that will best protect it from exposure to radiation. In selected patients with non-pelvic tumors and a narrow midline radiation field, simple oophoropexy may be useful for preventing radiation-induced ovarian injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/81\">",
"     81",
"    </a>",
"    ]. In patients receiving broad pelvic radiation, transposing the ovaries out of the radiation field is an option for preserving gonadal function in the absence of chemotherapy.",
"   </p>",
"   <p>",
"    Transposition can be performed laparoscopically just before the start of radiation therapy. Performing the procedure close to the time of irradiation decreases the chance of failure from ovarian migration back into the field of treatment. A combined approach can also be implemented: one ovary is cryopreserved and the other can be transposed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/82,83\">",
"     82,83",
"    </a>",
"    ]. The procedure and its outcome are described separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/47/6902?source=see_link&amp;anchor=H30824468#H30824468\">",
"     \"Ovarian transposition before pelvic radiation\", section on 'Procedure'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/47/6902?source=see_link&amp;anchor=H30824496#H30824496\">",
"     \"Ovarian transposition before pelvic radiation\", section on 'Pregnancy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Reported success rates are inconsistent, varying between 16 and 90 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/72\">",
"     72",
"    </a>",
"    ]. The failures are due to various factors such as scatter radiation, vascular compromise, radiation dose, the age of the patient, and whether the ovaries are shielded during the radiation procedure. Complications, such as chronic ovarian pain, infarction of the fallopian tubes, and formation of ovarian cysts have been reported during long-term follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/84-86\">",
"     84-86",
"    </a>",
"    ]. Ovaries can also \"migrate\" back to their original position.",
"   </p>",
"   <p>",
"    When ovarian function is preserved, spontaneous pregnancies have occurred without repositioning the ovaries back to their original location; therefore, ovaries are not repositioned unless the patient fails to conceive. If she needs IVF, oocyte collection from transposed ovaries may have to be performed transabdominally, rather than transvaginally. Embryos generated from the oocytes retrieved from the transposed ovaries can be used for transfer into the patient or, if she has undergone hysterectomy, they can be transferred to a gestational carrier (see",
"    <a class=\"local\" href=\"#H109317798\">",
"     'Surrogates'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/87\">",
"     87",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16144878\">",
"    <span class=\"h4\">",
"     Shielding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Shielding the ovaries to reduce the effects of scatter radiation is an option for women with radiation fields distant from pelvis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16144973\">",
"    <span class=\"h4\">",
"     Autotransplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In women planning to undergo radiation therapy to the pelvis, autotransplantation of a fresh ovary to the upper extremity with creation of vascular anastomosis removes the ovary from the radiation field and thus protects it from radiation damage (see",
"    <a class=\"local\" href=\"#H16145237\">",
"     'Autologous heterotopic transplantation'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16144915\">",
"    <span class=\"h3\">",
"     From chemotherapy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h4\">",
"     Gonadal suppression",
"    </span>",
"    &nbsp;&mdash;&nbsp;In women undergoing pelvic irradiation, gonadotropin-releasing hormone (GnRH) agonist treatment is clearly not beneficial for fertility preservation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/88,89\">",
"     88,89",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In women undergoing chemotherapy, both the efficacy and safety of GnRH agonists for prevention of ovarian toxicity are controversial and active areas of investigation (data discussed below). If used, the GnRH agonist is begun one week to six months before beginning chemotherapy and continued until the end of chemotherapeutic treatment. Side effects include hot flushes and vaginal dryness. We do not use these drugs in an attempt to preserve ovarian function in women receiving chemotherapy, but may use them to prevent menorrhagia in women at risk for severe chemotherapy-induced thrombocytopenia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/26/37285?source=see_link&amp;anchor=H6#H6\">",
"     \"Heavy or irregular uterine bleeding during chemotherapy\", section on 'GnRH agonists'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Reproductive biologists have questioned the biologic plausibility of ovarian suppression for prevention of premature menopause following chemotherapy and randomized trials have reported discordant findings of its efficacy. A 2011 systematic review and meta-analysis including six randomized trials that evaluated ovarian function after co-treatment with a GnRH agonist and chemotherapy concluded that co-treatment may be beneficial for protection of menstrual function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/90\">",
"     90",
"    </a>",
"    ]. GnRH agonist co-treatment increased the incidence of women with spontaneous menstruation (OR 3.46, 95% CI 1.13-10.57) and spontaneous ovulation (OR 5.70, 95% CI 2.29-14.20) after chemotherapy compared to controls who did not receive a GnRH agonist. However, GnRH agonist co-treatment was",
"    <strong>",
"     not",
"    </strong>",
"    associated with a statistically significant difference in the rate of spontaneous pregnancy after chemotherapy. Limitations of these findings included the small size of most of these trials, as well as the lack of adequate analyzable data, the generally short period of follow-up, methodologic weakness of one of the trials, and the use of different treatment protocols.",
"   </p>",
"   <p>",
"    After publication of the meta-analysis, results from additional randomized trials were published, with discordant results. The largest randomized trial (281 patients) of a GnRH agonist (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/11/9398?source=see_link\">",
"     triptorelin",
"    </a>",
"    ) for temporary ovarian suppression during chemotherapy of breast cancer supported the findings of the meta-analysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/91\">",
"     91",
"    </a>",
"    ]. One year after the last chemotherapy cycle, the group randomly assigned to triptorelin had a lower prevalence of early menopause (defined as no resumption of menses, postmenopausal levels of FSH and estradiol) compared to controls who did not receive triptorelin (early menopause 8.9 versus 25.9 percent; OR 0.28, 95% CI 0.14-0.59). Four pregnancies occurred after completion of treatment, three in the triptorelin plus chemotherapy group and one in the chemotherapy alone group. Limitations of this study included the short period of follow-up, small number of pregnancies, and lack of adjustment for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    use.",
"   </p>",
"   <p>",
"    In contrast, other randomized trials not included in the meta-analysis did not show a benefit from gonadal suppression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/92-94\">",
"     92-94",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one of these trials, use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/11/9398?source=see_link\">",
"       triptorelin",
"      </a>",
"      during adjuvant or neoadjuvant chemotherapy of breast cancer patients resulted in comparable amenorrhea rates; time to return to menses; and levels of FSH, inhibin A, and inhibin B in the triptorelin group and the control group [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/92\">",
"       92",
"      </a>",
"      ]. Although this trial was stopped for futility after 49 of the planned 124 patients were enrolled, it had several strengths, including stratification of patients for age, estrogen receptor status, use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      , and chemotherapy regimen; median follow-up of 18 months; and use of rigorous definitions for resumption of menses and amenorrhea.",
"     </li>",
"     <li>",
"      In another trial, the Ovarian Protection Trial in Estrogen Negative (OPTION) early breast cancer, preliminary data did not demonstrate a clear benefit of treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/22/9574?source=see_link\">",
"       goserelin",
"      </a>",
"      throughout adjuvant chemotherapy; the rate of resumption of menses was similar for women who did and did not receive ovarian suppression [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/93\">",
"       93",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A third randomized trial using GnRH analogs in breast cancer patients receiving",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      -based chemotherapy also found no benefit [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/94\">",
"       94",
"      </a>",
"      ]. Twelve months after termination of chemotherapy, no differences were observed in menstruation resumption rates between GnRH-treated patients and control group. Moreover, there were no differences in hormonal and ultrasound markers between patients receiving GnRH analogues and control group. The use of GnRH analogue co-treatment did not predict independently the odds of menstruating at 12 months.&nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When these and other data published since the 2011 meta-analysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/90,95\">",
"     90,95",
"    </a>",
"    ]&nbsp;are considered, GnRH agonist use does not have a significant beneficial effect on either maintenance of menstruation or fertility [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/96\">",
"     96",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The safety of the use of GnRH agonists in cancer patients has also not been established. Since GnRH receptors are expressed by a variety of cancers and mediate several effects (eg, inhibition of proliferation, induction of cell-cycle arrest, and inhibition of apoptosis), it is possible that GnRH agonist therapy concomitant with chemotherapy might reduce the efficacy of the implemented chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/97,98\">",
"     97,98",
"    </a>",
"    ]. GnRH agonist suppression may be safer in women with hormone-receptor negative disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/99\">",
"     99",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    More data establishing the safety of ovarian suppression in cancer patients and its long-term efficacy in preserving fertility (not just resumption of menses) are needed. Given the lack of strong evidence of safety and efficacy, we do not use this technique for fertility preservation during chemotherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16145230\">",
"    <span class=\"h2\">",
"     Transplantation of the ovary or ovarian tissue",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transplantation may involve autologous heterotopic transplantation of a fresh ovary or frozen-thawed ovarian tissue, or nonautologous orthotopic transplant of a fresh ovary or ovarian tissue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/11,100\">",
"     11,100",
"    </a>",
"    ]. Transplantation of a strip of ovarian tissue is technically easier than transplantation of an entire ovary since the latter requires more microvascular techniques.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16145237\">",
"    <span class=\"h3\">",
"     Autologous heterotopic transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ovarian tissue or an entire ovary has been transplanted subcutaneously under the forearm, lower abdominal skin, or chest wall; the optimal site has not been determined [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/101,102\">",
"     101,102",
"    </a>",
"    ]. Although heterotopic transplants have produced hormones and oocytes and embryos, no births in the absence of orthotopic ovarian tissue have been reported.",
"   </p>",
"   <p>",
"    In women planning to undergo radiation therapy to the pelvis, autotransplantation of a fresh ovary to the upper extremity with creation of vascular anastomosis removes the ovary from the radiation field and thus protects it from radiation damage (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/26/1447?source=see_link&amp;anchor=H3#H3\">",
"     \"Ovarian failure due to anticancer drugs and radiation\", section on 'Radiation therapy'",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/103,104\">",
"     103,104",
"    </a>",
"    ]. Ideally, the ovary would then continue to produce hormones and oocytes, which could be aspirated for IVF. However, studies suggest that the lifespan of auto-transplanted ovarian grafts may be limited to less than three years, mainly owing to the loss of substantial number of follicles during the ischemic period during the revascularization period immediately after transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/59,102,105,106\">",
"     59,102,105,106",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In chemotherapy patients, autologous heterotopic transplantation of a fresh ovary or ovarian tissue would not be useful since the effects of chemotherapy are systemic. However, autologous heterotopic transplantation of cryopreserved ovarian tissue after chemotherapy would be an option in these patients. Because of the limited lifespan of these grafts, an autotransplantation procedure involving cryopreserved ovarian tissue should not be performed until the woman is ready to conceive, and has received clearance from her oncologist to proceed to attempt pregnancy. It may take three to five months before the transplanted ovarian tissue begins to function. A second heterotopic autotransplant can be performed if ovarian function wanes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to the clinical situations described above, heterotopic transplantation has also been used when:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is a high risk of metastasis to, or disease recurrence in, the pelvic ovary. In such patients, ovarian tissue needs to be placed at a location where it is protected from local tumor dissemination and where it can be easily monitored, and if needed, removed.",
"     </li>",
"     <li>",
"      A pelvis that is not suitable for orthotopic transplantation due to previous radiation or severe scar formation.",
"     </li>",
"     <li>",
"      When the cost and invasiveness of orthotopic transplantation are of concern.",
"     </li>",
"     <li>",
"      When it is desirable to be able to inject agents directly into the ovarian grafts to enhance graft survival.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16145259\">",
"    <span class=\"h3\">",
"     Nonautologous orthotopic transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonautologous orthotopic transplantation takes advantage of existing ovarian vascular and neural networks to help restore function in the transplanted fresh ovary or ovarian tissue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/107\">",
"     107",
"    </a>",
"    ]. All egg-containing follicles are in the outer one millimeter of the ovary so just this strip of tissue is sutured to the recipient's ovary.",
"   </p>",
"   <p>",
"    The first case report of nonautologous orthotopic transplantation of fresh ovarian tissue was from one monozygotic twin sister to the other, who had suffered from premature ovarian failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/108\">",
"     108",
"    </a>",
"    ]. The procedure resulted in a live birth. These investigators have repeated this procedure in 10 sets of monozygotic twins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/109\">",
"     109",
"    </a>",
"    ], and successfully transplanted an intact fresh ovary [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/110\">",
"     110",
"    </a>",
"    ]. Others have reported a live birth after allografting of ovarian cortex between monozygotic twins with Turner mosaic and discordant ovarian function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/111\">",
"     111",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are two major disadvantages to nonautologous transplantation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When the ovarian tissue is removed from a donor, the donor may be put at higher risk of premature ovarian failure.",
"     </li>",
"     <li>",
"      Because an immunologically identical donor is needed, there are few potential candidates for this procedure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16145266\">",
"    <span class=\"h3\">",
"     Outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transplantation of frozen-thawed ovarian tissue was first reported in 2000 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/112\">",
"     112",
"    </a>",
"    ], followed by multiple reports of live births conceived naturally or via IVF after orthotopic implantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/58,113-117\">",
"     58,113-117",
"    </a>",
"    ]; however, the origin of some of the pregnancies following ovarian transplantation has been challenged [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/115,118\">",
"     115,118",
"    </a>",
"    ]. There have been no live births in humans after IVF from an oocyte retrieved from a heterotopic transplant, although biochemical pregnancies have been produced, as well as a non-human primate birth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/57,117,119\">",
"     57,117,119",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Large clinical studies are needed to determine the true efficiency of the ovarian tissue transplantation procedure and to determine the optimal surgical technique [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/120,121\">",
"     120,121",
"    </a>",
"    ]. It is also important to rule out spontaneous recovery of function of residual in situ ovarian tissue as a possible explanation for some reported successes.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A systematic review of case reports and small case series of women with or at high risk of premature ovarian failure summarized the reproductive outcome after autologous and heterologous transplantation of fresh and frozen-thawed ovarian tissue [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/122\">",
"       122",
"      </a>",
"      ]. The time needed to reestablish ovarian function ranged from 60 to 244 days. Four of the 23 women developed recurrent ovarian failure at six months post-procedure; all of these women had cryopreserved autologous grafts. Eight women had nine pregnancies; six occurred naturally and three were via IVF. Four of these pregnancies occurred in women with cryopreserved autologous ovarian transplants.",
"      <br/>",
"      <br/>",
"      There were trends suggesting that fresh tissue transplants were more successful than cryopreserved tissue transplants, heterologous transplants were more successful than autologous transplants, and orthotopic transplants were more successful than heterotopic transplants. The number of patients in each group was small; further research is needed to identify characteristics that predict success.",
"     </li>",
"     <li>",
"      A subsequent series described the outcome of nine women with premature ovarian failure who received a fresh strip of donor ovarian cortex from a monozygotic twin. The strip of donor ovarian cortex, which contained many small follicles, was transplanted to the surface of their ovary [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/123\">",
"       123",
"      </a>",
"      ]. All nine women resumed regular menses and ovulatory cycles 60 to 130 days after surgery, six cortical grafts functioned for &ge;3 years, one functioned for about two years, and one was still functioning at two years follow-up. Eight of the nine women had normal fallopian tubes, and six conceived naturally and delivered.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One of the limiting factors in the success of ovarian tissue transplants is the massive follicle loss during the initial revascularization phase. A study using a human xenograft model showed that S1P can accelerate ovarian graft revascularization and significantly improve follicle survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/22\">",
"     22",
"    </a>",
"    ]. Clinical studies are needed to determine the efficacy of this approach.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16144886\">",
"    <span class=\"h2\">",
"     Radical trachelectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In properly selected women with cervical cancer, radical trachelectomy is an option instead of hysterectomy and preserves the uterus for future childbearing. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/42/9898?source=see_link\">",
"     \"Fertility sparing surgery for invasive cervical cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Egg donation",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the patient has no fresh or frozen oocytes or ovarian tissue available, but her uterus is intact, fresh or frozen donor oocytes and her partner&rsquo;s sperm can be used for IVF. This is a proven approach, with success rates exceeding 60 percent per embryo transfer. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/14/24807?source=see_link\">",
"     \"Oocyte donation for assisted reproduction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several commercial egg banks are available in the United States. Through 2012, almost 9000 frozen donor oocytes from commercial egg banks were used for IVF, resulting in 602 pregnancies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/124\">",
"     124",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16144906\">",
"    <span class=\"h2\">",
"     Embryo donation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Couples in IVF programs sometimes donate their excess cryopreserved embryos, and these embryos can be implanted in a woman with a uterus even if she has no ovarian function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H109317798\">",
"    <span class=\"h2\">",
"     Surrogates",
"    </span>",
"    &nbsp;&mdash;&nbsp;A gestational surrogate is a woman who agrees to carry a pregnancy for another woman (intended mother). The intended mother provides the egg and the intended father provides the sperm; rarely, egg donors or sperm donors are involved. IVF is used to create an embryo, which is transferred into the uterus of the gestational carrier [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/125\">",
"     125",
"    </a>",
"    ]. The gestational carrier has no genetic connection to the embryo. Use of a gestational carrier is an option for women who have undergone hysterectomy but can provide their own oocytes, either fresh or frozen. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/42/15015?source=see_link\">",
"     \"Surrogate pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    By comparison, a traditional surrogate has a genetic connection to the embryo. The surrogate's own egg is fertilized by intrauterine insemination (IUI) of sperm from the intended mother&rsquo;s partner (or a sperm donor) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/126\">",
"     126",
"    </a>",
"    ]. Therefore, the surrogate carrier has a genetic, as well as a gestational, connection to the embryo.",
"   </p>",
"   <p>",
"    Use of a surrogate is also an option for women who wish to avoid pregnancy because of their high risk of recurrent breast cancer or who are receiving lifelong therapy with aromatase inhibitors or who do not want to wait until the completion of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/26/36261?source=see_link\">",
"     letrozole",
"    </a>",
"    treatment for breast cancer before having children.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21751172\">",
"    <span class=\"h2\">",
"     Adoption",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adoption is another option for parenthood, and is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/20/8520?source=see_link\">",
"     \"Adoption\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Future directions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Human ovarian tissue has been xenotransplanted to immunodeficient mice, with subsequent ovulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/127-129\">",
"     127-129",
"    </a>",
"    ]; however, aberrant microtubule organization and chromatin patterns observed during the maturation process are of significant concern [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/130,131\">",
"     130,131",
"    </a>",
"    ]. The risk of contamination with trans-species retroviral infections also needs to be addressed prior to testing this experimental approach clinically.",
"   </p>",
"   <p>",
"    Studies in rodents and nonhuman primates suggest antiapoptotic treatment with sphingosine-1-phosphate may be an effective approach in preventing cancer therapy-induced oocyte loss, but this has not been tested in humans [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/132,133\">",
"     132,133",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There may be germ stem cells in adult mice, which are capable of replenishing ovarian reserve and may originate from the bone marrow [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/134-136\">",
"     134-136",
"    </a>",
"    ]. The plausibility of this discovery in humans remains to be proven. However, menopausal changes resulting from ovarian failure caused by the chemotherapy that precedes bone marrow transplantation have been reported to spontaneously reverse, with reestablishment of normal hormonal function and viable pregnancies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/137\">",
"     137",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Uterine transplantation may be a future alternative approach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/138-140\">",
"     138-140",
"    </a>",
"    ]. However, this technique is only in the early phases of investigation. Successful revascularization of transplanted uteri has been reported in 70 percent of cases in nonhuman primates (Macaque monkey) and 80 percent of cases in dogs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/141,142\">",
"     141,142",
"    </a>",
"    ]. Normal mating and pregnancy have also been described after successful uterine transplantation in these animal models. There have been only a few reports of human uterine transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/140,143,144\">",
"     140,143,144",
"    </a>",
"    ]. Donors were deceased or from mothers to daughters. In one case, uterine necrosis developed 99 days after the transplant and required hysterectomy. In another case, a woman with Rokitansky syndrome who was the recipient of a cadaveric donor transplant had menarche 20 days after transplant surgery and 12 menstrual cycles by the time of publication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/144\">",
"     144",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5410837\">",
"    <span class=\"h1\">",
"     ISSUES IN WOMEN WITH BREAST CANCER",
"    </span>",
"    &nbsp;&mdash;&nbsp;For women desiring future pregnancy, referral to a reproductive endocrinologist as soon as the breast cancer is diagnosed facilitates performance of fertility preserving interventions while minimizing any delay between initial diagnosis and initiation of chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/145\">",
"     145",
"    </a>",
"    ]. Some strategies require two to three weeks to complete; ideally, these fertility-preserving procedures can be performed between surgery and the start of chemotherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15176856\">",
"    <span class=\"h2\">",
"     Ovarian stimulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is typically a four- to six-week hiatus between breast cancer surgery and initiation of chemotherapy for breast cancer. Although oocytes can be retrieved during a natural cycle, the yield is extremely low so controlled ovarian stimulation is routinely performed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/146\">",
"     146",
"    </a>",
"    ]. The four- to six-week interval is adequate to complete a cycle of ovarian stimulation and egg retrieval [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/147\">",
"     147",
"    </a>",
"    ]. Prompt referral to a reproductive endocrinologist may also allow time for two cycles, resulting in an increased number of oocyte retrievals for oocyte or embryo cryopreservation.",
"   </p>",
"   <p>",
"    Classical ovarian stimulation protocols usually result in estradiol levels as high as 10-fold greater than that of a natural cycle [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/148-150\">",
"     148-150",
"    </a>",
"    ]. This is a concern in women with breast cancer since many breast tumors contain estrogen receptor positive cells, which might be adversely affected by supraphysiological estradiol levels associated with ovarian stimulation. Even breast cancers labeled as estrogen receptor negative can be estrogen responsive, especially when exposed to high levels of estrogen.",
"   </p>",
"   <p>",
"    For this reason, we approach all women with breast cancer with the idea of minimizing estrogen exposure during fertility preservation procedures. Breast cancer patients who undergo ovarian stimulation with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/26/36261?source=see_link\">",
"     letrozole",
"    </a>",
"    and gonadotropins and embryo cryopreservation do not appear to have an increased risk of disease recurrence or death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/151\">",
"     151",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5410871\">",
"    <span class=\"h3\">",
"     Aromatase inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aromatase inhibitors (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/26/36261?source=see_link\">",
"     letrozole",
"    </a>",
"    ) in combination with gonadotropins have emerged as novel ovarian stimulants for performing IVF in women with breast cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/152,153\">",
"     152,153",
"    </a>",
"    ]. A presumed advantage of ovarian stimulation with aromatase inhibitors is that peak estradiol levels are close to those observed in natural cycles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/152,154\">",
"     152,154",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/6/4201?source=see_link\">",
"     \"Ovulation induction with aromatase inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We prefer a",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/26/36261?source=see_link\">",
"     letrozole",
"    </a>",
"    -FSH protocol for ovarian stimulation in most breast cancer patients undergoing IVF for embryo or oocyte cryopreservation because the combination results in low estradiol exposure and high oocyte recovery; therefore, theoretically, these drugs should have a good safety profile.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/49/22294?source=see_link\">",
"     Anastrozole",
"    </a>",
"    appears to result in significantly higher estradiol exposure than letrozole [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/155\">",
"     155",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Efficacy",
"      </strong>",
"      - The efficacy and value of a",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/26/36261?source=see_link\">",
"       letrozole",
"      </a>",
"      -FSH protocol for ovarian stimulation were illustrated in a prospective study that compared",
"      <span class=\"nowrap\">",
"       letrozole/low-dose",
"      </span>",
"      FSH (LetFSH-IVF),",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"        tamoxifen",
"       </a>",
"       /low-dose",
"      </span>",
"      FSH (TamFSH-IVF), and tamoxifen alone [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/154\">",
"       154",
"      </a>",
"      ]. LetFSH-IVF resulted in the highest embryo yield (5.3&plusmn;0.8 versus 3.8 &plusmn;0.8 with TamFSH-IVF and 1.3&plusmn;0.2 with Tam-IVF) and lowest peak estradiol levels (380&plusmn; 57 versus 419&plusmn;39 with Tam-IVF and 1182 &plusmn; 271",
"      <span class=\"nowrap\">",
"       pg/mL",
"      </span>",
"      with TamFSH-IVF).",
"      <br/>",
"      <br/>",
"      Subsequent studies demonstrated that",
"      <span class=\"nowrap\">",
"       letrozole/FSH",
"      </span>",
"      stimulation reduced the gonadotropin requirement by 44 percent compared with age-matched retrospective controls (women who underwent IVF for tubal disease) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/156\">",
"       156",
"      </a>",
"      ]. The length of stimulation, number of embryos obtained, and fertilization rates were similar for both groups.",
"      <br/>",
"      <br/>",
"      Use of a GnRH agonist trigger improves outcomes by increasing the yield of mature oocytes and embryos in aromatase inhibitor cycles and also decreases the post-trigger estradiol exposure, as well as the risk of ovarian hyperstimulation syndrome in women with breast cancer [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/157\">",
"       157",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Safety",
"      </strong>",
"      - The safety of a",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/26/36261?source=see_link\">",
"       letrozole",
"      </a>",
"      -FSH protocol was illustrated in a prospective study of 215 women with breast cancer in which 79 women elected to undergo controlled ovarian stimulation with letrozole and gonadotropins and 136 women did not undertake a fertility-preserving procedure (controls) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/151\">",
"       151",
"      </a>",
"      ]. Although the time between breast surgery and initiation of chemotherapy was longer for women who underwent IVF than for those who did not (mean 45 versus 34 days), the hazard ratio for cancer recurrence for women who underwent IVF was 0.56 (95% CI 0.17-1.9); survival was not significantly compromised compared with controls.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An additional concern in BRCA1 mutation carriers is that these patients appear to have a significantly lower ovarian response rate to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/26/36261?source=see_link\">",
"     letrozole",
"    </a>",
"    -FSH than BRCA mutation-negative patients (3 versus 33 percent), and produce fewer eggs (7 versus 12) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/158\">",
"     158",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15177194\">",
"    <span class=\"h3\">",
"     Tamoxifen",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     Tamoxifen",
"    </a>",
"    , a selective estrogen receptor modulator with antiestrogenic actions on breast tissue, is as effective as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    citrate in the treatment of anovulatory infertility, and thus appears to be useful in women with breast cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/159\">",
"     159",
"    </a>",
"    ]. This was illustrated in a prospective study that examined the effectiveness and safety of tamoxifen for ovarian stimulation in breast cancer patients and then compared these results to a retrospective control group of breast cancer patients who had natural cycle IVF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/160\">",
"     160",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients stimulated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    had fewer cancelled cycles",
"    <span class=\"nowrap\">",
"     (1/15",
"    </span>",
"    versus",
"    <span class=\"nowrap\">",
"     4/9),",
"    </span>",
"    and a higher number of mature oocytes (1.6&plusmn;0.3 versus 0.7&plusmn;0.2 in controls) and total embryos (1.6&plusmn;0.3 versus 0.6&plusmn;0.2 in controls). An embryo could be generated in 12 of 12 patients stimulated with tamoxifen; in contrast, natural cycle IVF resulted in embryos in only three of five patients. Although the peak estradiol levels were higher in the tamoxifen group than in unstimulated controls, cancer recurrence rates were not increased after a mean follow-up of approximately two years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/154\">",
"     154",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15177048\">",
"    <span class=\"h2\">",
"     Options for women who cannot undergo ovarian stimulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;For women with large or otherwise locally advanced (eg, inflammatory) breast cancers, neoadjuvant chemotherapy is begun immediately after diagnosis and before surgical treatment. When ovarian stimulation is not possible for time or safety issues, harvesting immature oocytes is an option (see",
"    <a class=\"local\" href=\"#H12480392\">",
"     'Immature oocytes'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    BRCA carriers and other women with hereditary breast-ovarian cancer syndromes are",
"    <strong>",
"     not",
"    </strong>",
"    good candidates for cryopreservation of ovarian tissue for later transplantation, given their risk of developing ovarian cancer and the relatively high incidence of occult ovarian cancer (see",
"    <a class=\"local\" href=\"#H7\">",
"     'Ovarian tissue'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H12480896\">",
"     'Contraindications and risks'",
"    </a>",
"    above). In the future, however, it may be possible to culture frozen-thawed ovarian tissue strips to achieve oocyte maturation and perform IVF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/161\">",
"     161",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Gonadal suppression is another option, but its efficacy is controversial (see",
"    <a class=\"local\" href=\"#H12\">",
"     'Gonadal suppression'",
"    </a>",
"    above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     METHODS TO PRESERVE FERTILITY IN MEN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cryopreservation of the ejaculated sperm is a well-established technique. This option should be offered to all post-pubertal boys and adults undergoing cancer treatment. Gonadal shielding may be an option in men receiving radiation therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When no sperm are found in the ejaculate or if the patient is unable to ejaculate, sperm may be recovered by epididymal sperm aspiration or testicular sperm extraction (TESA) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/162,163\">",
"     162,163",
"    </a>",
"    ]. Patients who were previously considered sterile due to having persistent postchemotherapy azoospermia may also benefit from TESA. In one study, sperm could be recovered by TESA performed by a microsurgical technique in 9 out of 20 patients who were rendered azoospermic due to prior chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/162\">",
"     162",
"    </a>",
"    ]. Following ICSI of the partner's oocytes, clinical pregnancy was achieved in three patients, resulting in term deliveries in two patients.",
"   </p>",
"   <p>",
"    Transrectal electroejaculation may be utilized to collect sperm in patients who experience ejaculation problems secondary to retroperitoneal lymph node dissection performed as a part of the surgical treatment of their cancer.",
"   </p>",
"   <p>",
"    Donor sperm insemination is an option if autologous cryopreserved sperm are not available. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/10/11433?source=see_link\">",
"     \"Donor insemination\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Suppression of testicular function during chemotherapy by administration of GnRH agonists has not been successful and is not recommended as the main protective measure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/164,165\">",
"     164,165",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15177249\">",
"    <span class=\"h2\">",
"     Future directions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cryopreservation of semen provides only a limited source of spermatozoa and is not an option for prepubertal boys. Although no births have been achieved in humans to date, promising results have come from studies with spermatogonial stem cell transplantation, cryopreservation of testicular tissue for autotransplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/166,167\">",
"     166,167",
"    </a>",
"    ], xenotransplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/168\">",
"     168",
"    </a>",
"    ], and in vitro maturation of sperm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/7/38010/abstract/169-172\">",
"     169-172",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?18/7/18546?source=see_link\">",
"       \"Patient information: Preserving fertility after cancer treatment in children (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?10/57/11154?source=see_link\">",
"       \"Patient information: Preserving fertility after cancer treatment in men (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?12/18/12579?source=see_link\">",
"       \"Patient information: Preserving fertility after cancer treatment in women (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Many patients are at risk of long-term gonadal failure as a consequence of treatment with gonadotoxic chemotherapy or radiation therapy or surgical removal. This risk should be discussed with patients who are to receive these therapies. In addition, we suggest early referral to a reproductive endocrinologist to review options for fertility preservation. &nbsp;(See",
"      <a class=\"local\" href=\"#H1314548941\">",
"       'Pretreatment counseling'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most well-established method for preservation of child-bearing potential in women at risk of gonadal failure is embryo cryopreservation. We recommend offering this technique to all eligible patients (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Embryo'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest ovarian transposition be offered to women who will receive pelvic radiation, but no chemotherapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Transposition (oophoropexy)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When embryo cryopreservation is not feasible, cryopreservation of oocytes matured in vivo is a reasonable option. In vitro maturation of oocytes is an investigational procedure; implantation and ongoing pregnancy rates are lower than with conventional in vitro fertilization (IVF) using in vivo matured oocytes. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Oocytes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cryopreservation of ovarian tissue is investigational, not widely available, and the true efficiency is unknown. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Ovarian tissue'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Cryopreservation of ovarian tissue is not an option for women with ovarian cancer or at high risk of developing ovarian cancer. (See",
"      <a class=\"local\" href=\"#H12480896\">",
"       'Contraindications and risks'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Use of GnRH agonist co-treatment for protecting gonadal function against chemotherapeutic injury is controversial owing to its uncertain benefits and theoretical risks. We do not suggest GnRH agonist co-treatment as a means of preserving fertility against chemotherapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Gonadal suppression'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Oocyte donation and use of gestational carriers or surrogates are successful methods to treat infertility due to end-organ failure in women. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Egg donation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H109317798\">",
"       'Surrogates'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend offering cryopreservation of sperm to all postpubertal male cancer patients before starting cytotoxic therapy (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). We suggest offering testicular tissue cryopreservation in prepubertal boys (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). This is an experimental technology with no known success in human studies; it should only be offered under study protocols. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Methods to preserve fertility in men'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/1\">",
"      Lee SJ, Schover LR, Partridge AH, et al. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol 2006; 24:2917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/2\">",
"      Das M, Shehata F, Moria A, et al. Ovarian reserve, response to gonadotropins, and oocyte maturity in women with malignancy. Fertil Steril 2011; 96:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/3\">",
"      Knopman JM, Noyes N, Talebian S, et al. Women with cancer undergoing ART for fertility preservation: a cohort study of their response to exogenous gonadotropins. Fertil Steril 2009; 91:1476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/4\">",
"      Robertson AD, Missmer SA, Ginsburg ES. Embryo yield after in vitro fertilization in women undergoing embryo banking for fertility preservation before chemotherapy. Fertil Steril 2011; 95:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/5\">",
"      Pal L, Leykin L, Schifren JL, et al. Malignancy may adversely influence the quality and behaviour of oocytes. Hum Reprod 1998; 13:1837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/6\">",
"      Quintero RB, Helmer A, Huang JQ, Westphal LM. Ovarian stimulation for fertility preservation in patients with cancer. Fertil Steril 2010; 93:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/7\">",
"      Domingo J, Guill&eacute;n V, Ayll&oacute;n Y, et al. Ovarian response to controlled ovarian hyperstimulation in cancer patients is diminished even before oncological treatment. Fertil Steril 2012; 97:930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/8\">",
"      Almog B, Azem F, Gordon D, et al. Effects of cancer on ovarian response in controlled ovarian stimulation for fertility preservation. Fertil Steril 2012; 98:957.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. Assisted Reproductive Technology. 2008 Assisted Reproductive Technology Report. file://www.cdc.gov/art/ART2008/section3.htm (Accessed on May 17, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/10\">",
"      Borini A, Bianchi V. Cryopreservation of mature and immature oocytes. Clin Obstet Gynecol 2010; 53:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/11\">",
"      Donnez J, Dolmans MM. Cryopreservation and transplantation of ovarian tissue. Clin Obstet Gynecol 2010; 53:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/12\">",
"      ACOG Committee Opinion No. 405: ovarian tissue and oocyte cryopreservation. Obstet Gynecol 2008; 111:1255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/13\">",
"      Bromer JG, Patrizio P. Fertility preservation: the rationale for cryopreservation of the whole ovary. Semin Reprod Med 2009; 27:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/14\">",
"      Oktay K, Cil AP, Bang H. Efficiency of oocyte cryopreservation: a meta-analysis. Fertil Steril 2006; 86:70.",
"     </a>",
"    </li>",
"    <li>",
"     Society for Assisted Reproductive Technology. IVF success rates. Clinic summary report 2009. https://www.sartcorsonline.com/rptCSR_PublicMultYear.aspx?ClinicPKID=0 (Accessed on May 17, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/16\">",
"      Oktay K, Buyuk E, Rodriguez-Wallberg KA, Sahin G. In vitro maturation improves oocyte or embryo cryopreservation outcome in breast cancer patients undergoing ovarian stimulation for fertility preservation. Reprod Biomed Online 2010; 20:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/17\">",
"      Maman E, Meirow D, Brengauz M, et al. Luteal phase oocyte retrieval and in vitro maturation is an optional procedure for urgent fertility preservation. Fertil Steril 2011; 95:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/18\">",
"      S&ouml;nmezer M, T&uuml;rk&ccedil;&uuml;olu I, Cokun U, Oktay K. Random-start controlled ovarian hyperstimulation for emergency fertility preservation in letrozole cycles. Fertil Steril 2011; 95:2125.e9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/19\">",
"      Ginsburg ES, Yanushpolsky EH, Jackson KV. In vitro fertilization for cancer patients and survivors. Fertil Steril 2001; 75:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/20\">",
"      Dolmans MM, Demylle D, Martinez-Madrid B, Donnez J. Efficacy of in vitro fertilization after chemotherapy. Fertil Steril 2005; 83:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/21\">",
"      Barton SE, Missmer SA, Berry KF, Ginsburg ES. Female cancer survivors are low responders and have reduced success compared with other patients undergoing assisted reproductive technologies. Fertil Steril 2012; 97:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/22\">",
"      Soleimani R, Heytens E, Oktay K. Enhancement of neoangiogenesis and follicle survival by sphingosine-1-phosphate in human ovarian tissue xenotransplants. PLoS One 2011; 6:e19475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/23\">",
"      Lawrenz B, Banys M, Henes M, et al. Pregnancy after breast cancer: case report and review of the literature. Arch Gynecol Obstet 2011; 283:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/24\">",
"      Rossi BV, Ashby RK, Srouji SS. Embryo banking between induction and consolidation chemotherapy in women with leukemia. Fertil Steril 2011; 96:1412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/25\">",
"      Gosden RG. Prospects for oocyte banking and in vitro maturation. J Natl Cancer Inst Monogr 2005; :60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/26\">",
"      Porcu E, Venturoli S. Progress with oocyte cryopreservation. Curr Opin Obstet Gynecol 2006; 18:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/27\">",
"      Jain JK, Paulson RJ. Oocyte cryopreservation. Fertil Steril 2006; 86:1037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/28\">",
"      Cobo A, Kuwayama M, P&eacute;rez S, et al. Comparison of concomitant outcome achieved with fresh and cryopreserved donor oocytes vitrified by the Cryotop method. Fertil Steril 2008; 89:1657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/29\">",
"      Parmegiani L, Cognigni GE, Bernardi S, et al. Efficiency of aseptic open vitrification and hermetical cryostorage of human oocytes. Reprod Biomed Online 2011; 23:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/30\">",
"      Rienzi L, Romano S, Albricci L, et al. Embryo development of fresh 'versus' vitrified metaphase II oocytes after ICSI: a prospective randomized sibling-oocyte study. Hum Reprod 2010; 25:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/31\">",
"      Cobo A, Meseguer M, Remoh&iacute; J, Pellicer A. Use of cryo-banked oocytes in an ovum donation programme: a prospective, randomized, controlled, clinical trial. Hum Reprod 2010; 25:2239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/32\">",
"      Borini A, Levi Setti PE, Anserini P, et al. Multicenter observational study on slow-cooling oocyte cryopreservation: clinical outcome. Fertil Steril 2010; 94:1662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/33\">",
"      Scaravelli G, Vigiliano V, Mayorga JM, et al. Analysis of oocyte cryopreservation in assisted reproduction: the Italian National Register data from 2005 to 2007. Reprod Biomed Online 2010; 21:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/34\">",
"      The Practice Committees of the American Society for Reproductive Medicine and the Society for Assisted Reproductive Technology. Mature oocyte cryopreservation: a guideline. Fertil Steril 2013; 99:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/35\">",
"      Cobo A, Diaz C. Clinical application of oocyte vitrification: a systematic review and meta-analysis of randomized controlled trials. Fertil Steril 2011; 96:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/36\">",
"      Practice Committee of the Society for Assisted Reproductive Technology, Practice Committee of the American Society for Reproductive Medicine. Essential elements of informed consent for elective oocyte cryopreservation: a Practice Committee opinion. Fertil Steril 2007; 88:1495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/37\">",
"      Huang JY, Tulandi T, Holzer H, et al. Combining ovarian tissue cryobanking with retrieval of immature oocytes followed by in vitro maturation and vitrification: an additional strategy of fertility preservation. Fertil Steril 2008; 89:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/38\">",
"      Ata B, Shalom-Paz E, Chian RC, Tan SL. In vitro maturation of oocytes as a strategy for fertility preservation. Clin Obstet Gynecol 2010; 53:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/39\">",
"      Telfer EE, McLaughlin M. In vitro development of ovarian follicles. Semin Reprod Med 2011; 29:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/40\">",
"      Cao Y, Xing Q, Zhang ZG, et al. Cryopreservation of immature and in-vitro matured human oocytes by vitrification. Reprod Biomed Online 2009; 19:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/41\">",
"      Wang H, Racowsky C, Combelles CM. Is it best to cryopreserve human cumulus-free immature oocytes before or after in vitro maturation? Cryobiology 2012; 65:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/42\">",
"      Lee JA, Barritt J, Moschini RM, et al. Optimizing human oocyte cryopreservation for fertility preservation patients: should we mature then freeze or freeze then mature? Fertil Steril 2013; 99:1356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/43\">",
"      The Practice Committees of the American Society for Reproductive Medicine and the Society for Assisted Reproductive Technology. In vitro maturation: a committee opinion. Fertil Steril 2013; 99:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/44\">",
"      Jurema MW, Nogueira D. In vitro maturation of human oocytes for assisted reproduction. Fertil Steril 2006; 86:1277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/45\">",
"      Chian RC, Gilbert L, Huang JY, et al. Live birth after vitrification of in vitro matured human oocytes. Fertil Steril 2009; 91:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/46\">",
"      S&ouml;derstr&ouml;m-Anttila V, Salokorpi T, Pihlaja M, et al. Obstetric and perinatal outcome and preliminary results of development of children born after in vitro maturation of oocytes. Hum Reprod 2006; 21:1508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/47\">",
"      Chian RC, Huang JY, Gilbert L, et al. Obstetric outcomes following vitrification of in vitro and in vivo matured oocytes. Fertil Steril 2009; 91:2391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/48\">",
"      Imhof M, Hofstetter G, Bergmeister lH, et al. Cryopreservation of a whole ovary as a strategy for restoring ovarian function. J Assist Reprod Genet 2004; 21:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/49\">",
"      Revel A, Elami A, Bor A, et al. Whole sheep ovary cryopreservation and transplantation. Fertil Steril 2004; 82:1714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/50\">",
"      Imhof M, Bergmeister H, Lipovac M, et al. Orthotopic microvascular reanastomosis of whole cryopreserved ovine ovaries resulting in pregnancy and live birth. Fertil Steril 2006; 85 Suppl 1:1208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/51\">",
"      Bedaiwy MA, Hussein MR, Biscotti C, Falcone T. Cryopreservation of intact human ovary with its vascular pedicle. Hum Reprod 2006; 21:3258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/52\">",
"      Martinez-Madrid B, Camboni A, Dolmans MM, et al. Apoptosis and ultrastructural assessment after cryopreservation of whole human ovaries with their vascular pedicle. Fertil Steril 2007; 87:1153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/53\">",
"      Oktay KH, Yih M. Preliminary experience with orthotopic and heterotopic transplantation of ovarian cortical strips. Semin Reprod Med 2002; 20:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/54\">",
"      Schubert B, Canis M, Darcha C, et al. Human ovarian tissue from cortex surrounding benign cysts: a model to study ovarian tissue cryopreservation. Hum Reprod 2005; 20:1786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/55\">",
"      Poirot C, Vacher-Lavenu MC, Helardot P, et al. Human ovarian tissue cryopreservation: indications and feasibility. Hum Reprod 2002; 17:1447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/56\">",
"      Schmidt KL, Andersen CY, Loft A, et al. Follow-up of ovarian function post-chemotherapy following ovarian cryopreservation and transplantation. Hum Reprod 2005; 20:3539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/57\">",
"      Rosendahl M, Loft A, Byskov AG, et al. Biochemical pregnancy after fertilization of an oocyte aspirated from a heterotopic autotransplant of cryopreserved ovarian tissue: case report. Hum Reprod 2006; 21:2006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/58\">",
"      Demeestere I, Simon P, Buxant F, et al. Ovarian function and spontaneous pregnancy after combined heterotopic and orthotopic cryopreserved ovarian tissue transplantation in a patient previously treated with bone marrow transplantation: case report. Hum Reprod 2006; 21:2010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/59\">",
"      Kim SS, Lee WS, Chung MK, et al. Long-term ovarian function and fertility after heterotopic autotransplantation of cryobanked human ovarian tissue: 8-year experience in cancer patients. Fertil Steril 2009; 91:2349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/60\">",
"      Huober-Zeeb C, Lawrenz B, Popovici RM, et al. Improving fertility preservation in cancer: ovarian tissue cryobanking followed by ovarian stimulation can be efficiently combined. Fertil Steril 2011; 95:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/61\">",
"      Greve T, Schmidt KT, Kristensen SG, et al. Evaluation of the ovarian reserve in women transplanted with frozen and thawed ovarian cortical tissue. Fertil Steril 2012; 97:1394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/62\">",
"      Oktay K, Oktem O. Ovarian cryopreservation and transplantation for fertility preservation for medical indications: report of an ongoing experience. Fertil Steril 2010; 93:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/63\">",
"      Schmidt KT, Rosendahl M, Ernst E, et al. Autotransplantation of cryopreserved ovarian tissue in 12 women with chemotherapy-induced premature ovarian failure: the Danish experience. Fertil Steril 2011; 95:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/64\">",
"      Baird DT, Webb R, Campbell BK, et al. Long-term ovarian function in sheep after ovariectomy and transplantation of autografts stored at -196 C. Endocrinology 1999; 140:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/65\">",
"      Oktem O, Oktay K. Quantitative assessment of the impact of chemotherapy on ovarian follicle reserve and stromal function. Cancer 2007; 110:2222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/66\">",
"      Oktem O, Oktay K. A novel ovarian xenografting model to characterize the impact of chemotherapy agents on human primordial follicle reserve. Cancer Res 2007; 67:10159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/67\">",
"      Donnez J, Silber S, Andersen CY, et al. Children born after autotransplantation of cryopreserved ovarian tissue. a review of 13 live births. Ann Med 2011; 43:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/68\">",
"      Struewing JP, Hartge P, Wacholder S, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997; 336:1401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/69\">",
"      Satagopan JM, Offit K, Foulkes W, et al. The lifetime risks of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Cancer Epidemiol Biomarkers Prev 2001; 10:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/70\">",
"      Liede A, Narod SA. Hereditary breast and ovarian cancer in Asia: genetic epidemiology of BRCA1 and BRCA2. Hum Mutat 2002; 20:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/71\">",
"      Kauff ND, Satagopan JM, Robson ME, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2002; 346:1609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/72\">",
"      Sonmezer M, Oktay K. Fertility preservation in female patients. Hum Reprod Update 2004; 10:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/73\">",
"      Dolmans MM, Marinescu C, Saussoy P, et al. Reimplantation of cryopreserved ovarian tissue from patients with acute lymphoblastic leukemia is potentially unsafe. Blood 2010; 116:2908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/74\">",
"      Meirow D, Hardan I, Dor J, et al. Searching for evidence of disease and malignant cell contamination in ovarian tissue stored from hematologic cancer patients. Hum Reprod 2008; 23:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/75\">",
"      Rosendahl M, Andersen MT, Ralfki&aelig;r E, et al. Evidence of residual disease in cryopreserved ovarian cortex from female patients with leukemia. Fertil Steril 2010; 94:2186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/76\">",
"      Curtin JP, Barakat RR, Hoskins WJ. Ovarian disease in women with breast cancer. Obstet Gynecol 1994; 84:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/77\">",
"      Shaw JM, Bowles J, Koopman P, et al. Fresh and cryopreserved ovarian tissue samples from donors with lymphoma transmit the cancer to graft recipients. Hum Reprod 1996; 11:1668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/78\">",
"      Kim SS, Radford J, Harris M, et al. Ovarian tissue harvested from lymphoma patients to preserve fertility may be safe for autotransplantation. Hum Reprod 2001; 16:2056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/79\">",
"      Seshadri, T, Gook, D, Lade, S, Spencer, A, et al. Lack of evidence of disease contamination in ovarian tissue harvested for cryopreservation from patients with Hodgkin lymphoma and analysis of factors predictive of oocyte yield. Br J Cancer 2006; 10:94.",
"     </a>",
"    </li>",
"    <li>",
"     Elassar, A, Oktem, O, et al. Fertility preservation with ovarian cryopreservation: a decade of experience. Fertil Steril 1:S12.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/81\">",
"      Kuohung W, Ram K, Cheng DM, et al. Laparoscopic oophoropexy prior to radiation for pediatric brain tumor and subsequent ovarian function. Hum Reprod 2008; 23:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/82\">",
"      Martin JR, Kodaman P, Oktay K, Taylor HS. Ovarian cryopreservation with transposition of a contralateral ovary: a combined approach for fertility preservation in women receiving pelvic radiation. Fertil Steril 2007; 87:189.e5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/83\">",
"      Elizur SE, Tulandi T, Meterissian S, et al. Fertility preservation for young women with rectal cancer--a combined approach from one referral center. J Gastrointest Surg 2009; 13:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/84\">",
"      Gabriel DA, Bernard SA, Lambert J, Croom RD 3rd. Oophoropexy and the management of Hodgkin's disease. A reevaluation of the risks and benefits. Arch Surg 1986; 121:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/85\">",
"      Williams RS, Littell RD, Mendenhall NP. Laparoscopic oophoropexy and ovarian function in the treatment of Hodgkin disease. Cancer 1999; 86:2138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/86\">",
"      Anderson B, LaPolla J, Turner D, et al. Ovarian transposition in cervical cancer. Gynecol Oncol 1993; 49:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/87\">",
"      Agorastos T, Zafrakas M, Mastrominas M. Long-term follow-up after cervical cancer treatment and subsequent successful surrogate pregnancy. Reprod Biomed Online 2009; 19:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/88\">",
"      Ataya K, Pydyn E, Ramahi-Ataya A, Orton CG. Is radiation-induced ovarian failure in rhesus monkeys preventable by luteinizing hormone-releasing hormone agonists?: Preliminary observations. J Clin Endocrinol Metab 1995; 80:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/89\">",
"      Gosden RG, Wade JC, Fraser HM, et al. Impact of congenital or experimental hypogonadotrophism on the radiation sensitivity of the mouse ovary. Hum Reprod 1997; 12:2483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/90\">",
"      Bedaiwy MA, Abou-Setta AM, Desai N, et al. Gonadotropin-releasing hormone analog cotreatment for preservation of ovarian function during gonadotoxic chemotherapy: a systematic review and meta-analysis. Fertil Steril 2011; 95:906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/91\">",
"      Del Mastro L, Boni L, Michelotti A, et al. Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial. JAMA 2011; 306:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/92\">",
"      Munster PN, Moore AP, Ismail-Khan R, et al. Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer. J Clin Oncol 2012; 30:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/93\">",
"      Leonard RC, Adamson D, Anderson R, et al. The OPTION trial of adjuvant ovarian protection by goserelin in adjuvant chemotherapy for early breast cancer. J Clin Oncol 2010; 28:89S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/94\">",
"      Elgindy EA, El-Haieg DO, Khorshid OM, et al. Gonadatrophin suppression to prevent chemotherapy-induced ovarian damage: a randomized controlled trial. Obstet Gynecol 2013; 121:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/95\">",
"      Demeestere I, Brice P, Peccatori FA, et al. Gonadotropin-releasing hormone agonist for the prevention of chemotherapy-induced ovarian failure in patients with lymphoma: 1-year follow-up of a prospective randomized trial. J Clin Oncol 2013; 31:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/96\">",
"      Balkenende E, Dahhan T, van der Veen F, Goddijn M. Comment on GnRH analogue cotreatment with chemotherapy for preservation of ovarian function. Fertil Steril 2011; 96:e155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/97\">",
"      Vitale AM, Abramovich D, Peluffo MC, et al. Effect of gonadotropin-releasing hormone agonist and antagonist on proliferation and apoptosis of human luteinized granulosa cells. Fertil Steril 2006; 85:1064.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/98\">",
"      Emons G, Gr&uuml;ndker C, G&uuml;nthert AR, et al. GnRH antagonists in the treatment of gynecological and breast cancers. Endocr Relat Cancer 2003; 10:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/99\">",
"      Rugo HS, Rosen MP. Reducing the long-term effects of chemotherapy in young women with early-stage breast cancer. JAMA 2011; 306:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/100\">",
"      Bedaiwy MA, Falcone T. Whole ovary transplantation. Clin Obstet Gynecol 2010; 53:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/101\">",
"      Oktay K, Buyuk E, Veeck L, et al. Embryo development after heterotopic transplantation of cryopreserved ovarian tissue. Lancet 2004; 363:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/102\">",
"      Oktay K, Economos K, Kan M, et al. Endocrine function and oocyte retrieval after autologous transplantation of ovarian cortical strips to the forearm. JAMA 2001; 286:1490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/103\">",
"      Leporrier M, von Theobald P, Roffe JL, Muller G. A new technique to protect ovarian function before pelvic irradiation. Heterotopic ovarian autotransplantation. Cancer 1987; 60:2201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/104\">",
"      Hilders CG, Baranski AG, Peters L, et al. Successful human ovarian autotransplantation to the upper arm. Cancer 2004; 101:2771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/105\">",
"      Radford JA, Lieberman BA, Brison DR, et al. Orthotopic reimplantation of cryopreserved ovarian cortical strips after high-dose chemotherapy for Hodgkin's lymphoma. Lancet 2001; 357:1172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/106\">",
"      W&oslash;lner-Hanssen P, H&auml;gglund L, Ploman F, et al. Autotransplantation of cryopreserved ovarian tissue to the right forearm 4(1/2) years after autologous stem cell transplantation. Acta Obstet Gynecol Scand 2005; 84:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/107\">",
"      S&aacute;nchez M, Alam&aacute; P, Gadea B, et al. Fresh human orthotopic ovarian cortex transplantation: long-term results. Hum Reprod 2007; 22:786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/108\">",
"      Silber SJ, Lenahan KM, Levine DJ, et al. Ovarian transplantation between monozygotic twins discordant for premature ovarian failure. N Engl J Med 2005; 353:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/109\">",
"      Silber SJ, Gosden RG. Ovarian transplantation in a series of monozygotic twins discordant for ovarian failure. N Engl J Med 2007; 356:1382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/110\">",
"      Silber SJ, Grudzinskas G, Gosden RG. Successful pregnancy after microsurgical transplantation of an intact ovary. N Engl J Med 2008; 359:2617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/111\">",
"      Donnez J, Dolmans MM, Squifflet J, et al. Live birth after allografting of ovarian cortex between monozygotic twins with Turner syndrome (45,XO/46,XX mosaicism) and discordant ovarian function. Fertil Steril 2011; 96:1407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/112\">",
"      Oktay K, Karlikaya G. Ovarian function after transplantation of frozen, banked autologous ovarian tissue. N Engl J Med 2000; 342:1919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/113\">",
"      Donnez J, Dolmans MM, Demylle D, et al. Livebirth after orthotopic transplantation of cryopreserved ovarian tissue. Lancet 2004; 364:1405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/114\">",
"      Meirow D, Levron J, Eldar-Geva T, et al. Pregnancy after transplantation of cryopreserved ovarian tissue in a patient with ovarian failure after chemotherapy. N Engl J Med 2005; 353:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/115\">",
"      Oktay K, T&uuml;rk&ccedil;&uuml;olu I, Rodriguez-Wallberg KA. Four spontaneous pregnancies and three live births following subcutaneous transplantation of frozen banked ovarian tissue: what is the explanation? Fertil Steril 2011; 95:804.e7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/116\">",
"      Silber SJ, DeRosa M, Pineda J, et al. A series of monozygotic twins discordant for ovarian failure: ovary transplantation (cortical versus microvascular) and cryopreservation. Hum Reprod 2008; 23:1531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/117\">",
"      Andersen CY, Rosendahl M, Byskov AG, et al. Two successful pregnancies following autotransplantation of frozen/thawed ovarian tissue. Hum Reprod 2008; 23:2266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/118\">",
"      Oktay K, Tilly J. Livebirth after cryopreserved ovarian tissue autotransplantation. Lancet 2004; 364:2091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/119\">",
"      Lee DM, Yeoman RR, Battaglia DE, et al. Live birth after ovarian tissue transplant. Nature 2004; 428:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/120\">",
"      Oktay K. Spontaneous conceptions and live birth after heterotopic ovarian transplantation: is there a germline stem cell connection? Hum Reprod 2006; 21:1345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/121\">",
"      Bedaiwy MA, Shahin AY, Falcone T. Reproductive organ transplantation: advances and controversies. Fertil Steril 2008; 90:2031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/122\">",
"      Bedaiwy MA, El-Nashar SA, El Saman AM, et al. Reproductive outcome after transplantation of ovarian tissue: a systematic review. Hum Reprod 2008; 23:2709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/123\">",
"      Silber S, Kagawa N, Kuwayama M, Gosden R. Duration of fertility after fresh and frozen ovary transplantation. Fertil Steril 2010; 94:2191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/124\">",
"      Quaas AM, Melamed A, Chung K, et al. Egg banking in the United States: current status of commercially available cryopreserved oocytes. Fertil Steril 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/125\">",
"      Utian WH, Sheean L, Goldfarb JM, Kiwi R. Successful pregnancy after in vitro fertilization and embryo transfer from an infertile woman to a surrogate. N Engl J Med 1985; 313:1351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/126\">",
"      Utian WH, Goldfarb JM, Kiwi R, et al. Preliminary experience with in vitro fertilization-surrogate gestational pregnancy. Fertil Steril 1989; 52:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/127\">",
"      Oktay K, Newton H, Mullan J, Gosden RG. Development of human primordial follicles to antral stages in SCID/hpg mice stimulated with follicle stimulating hormone. Hum Reprod 1998; 13:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/128\">",
"      Oktay K, Newton H, Gosden RG. Transplantation of cryopreserved human ovarian tissue results in follicle growth initiation in SCID mice. Fertil Steril 2000; 73:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/129\">",
"      Gook DA, McCully BA, Edgar DH, McBain JC. Development of antral follicles in human cryopreserved ovarian tissue following xenografting. Hum Reprod 2001; 16:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/130\">",
"      Lucifero D, Mertineit C, Clarke HJ, et al. Methylation dynamics of imprinted genes in mouse germ cells. Genomics 2002; 79:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/131\">",
"      Kim SS, Kang HG, Kim NH, et al. Assessment of the integrity of human oocytes retrieved from cryopreserved ovarian tissue after xenotransplantation. Hum Reprod 2005; 20:2502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/132\">",
"      Morita Y, Perez GI, Paris F, et al. Oocyte apoptosis is suppressed by disruption of the acid sphingomyelinase gene or by sphingosine-1-phosphate therapy. Nat Med 2000; 6:1109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/133\">",
"      Zelinski MB, Murphy MK, Lawson MS, et al. In vivo delivery of FTY720 prevents radiation-induced ovarian failure and infertility in adult female nonhuman primates. Fertil Steril 2011; 95:1440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/134\">",
"      Johnson J, Canning J, Kaneko T, et al. Germline stem cells and follicular renewal in the postnatal mammalian ovary. Nature 2004; 428:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/135\">",
"      Johnson J, Bagley J, Skaznik-Wikiel M, et al. Oocyte generation in adult mammalian ovaries by putative germ cells in bone marrow and peripheral blood. Cell 2005; 122:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/136\">",
"      Lee HJ, Selesniemi K, Niikura Y, et al. Bone marrow transplantation generates immature oocytes and rescues long-term fertility in a preclinical mouse model of chemotherapy-induced premature ovarian failure. J Clin Oncol 2007; 25:3198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/137\">",
"      Hershlag A, Schuster MW. Return of fertility after autologous stem cell transplantation. Fertil Steril 2002; 77:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/138\">",
"      Br&auml;nnstr&ouml;m M, Diaz-Garcia C, Hanafy A, et al. Uterus transplantation: animal research and human possibilities. Fertil Steril 2012; 97:1269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/139\">",
"      Del Priore G, Stega J, Sieunarine K, et al. Human uterus retrieval from a multi-organ donor. Obstet Gynecol 2007; 109:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/140\">",
"      Grynberg M, Ayoubi JM, Bulletti C, et al. Uterine transplantation: a promising surrogate to surrogacy? Ann N Y Acad Sci 2011; 1221:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/141\">",
"      Barzilai A, Paldi E, Gal D, Hampel N. Autotransplantation of the uterus and ovaries in dogs. Isr J Med Sci 1973; 9:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/142\">",
"      Eraslan S, Hamernik RJ, Hardy JD. Replantation of uterus and ovaries in dogs, with successful pregnancy. Arch Surg 1966; 92:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/143\">",
"      Hansen A. Swedish surgeons report world's first uterus transplantations from mother to daughter. BMJ 2012; 345:e6537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/144\">",
"      Ozkan O, Akar ME, Ozkan O, et al. Preliminary results of the first human uterus transplantation from a multiorgan donor. Fertil Steril 2013; 99:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/145\">",
"      Lee S, Ozkavukcu S, Heytens E, et al. Value of early referral to fertility preservation in young women with breast cancer. J Clin Oncol 2010; 28:4683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/146\">",
"      Ubaldi F, Rienzi L, Ferrero S, et al. Natural in vitro fertilization cycles. Ann N Y Acad Sci 2004; 1034:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/147\">",
"      Baynosa J, Westphal LM, Madrigrano A, Wapnir I. Timing of breast cancer treatments with oocyte retrieval and embryo cryopreservation. J Am Coll Surg 2009; 209:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/148\">",
"      Pittaway DE, Wentz AC. Evaluation of the exponential rise of serum estradiol concentrations in human menopausal gonadotropin-induced cycles. Fertil Steril 1983; 40:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/149\">",
"      Pe&ntilde;a JE, Chang PL, Chan LK, et al. Supraphysiological estradiol levels do not affect oocyte and embryo quality in oocyte donation cycles. Hum Reprod 2002; 17:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/150\">",
"      Chen CH, Zhang X, Barnes R, et al. Relationship between peak serum estradiol levels and treatment outcome in in vitro fertilization cycles after embryo transfer on day 3 or day 5. Fertil Steril 2003; 80:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/151\">",
"      Azim AA, Costantini-Ferrando M, Oktay K. Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a prospective controlled study. J Clin Oncol 2008; 26:2630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/152\">",
"      Fatemi HM, Kolibianakis E, Tournaye H, et al. Clomiphene citrate versus letrozole for ovarian stimulation: a pilot study. Reprod Biomed Online 2003; 7:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/153\">",
"      Oktay K. Further evidence on the safety and success of ovarian stimulation with letrozole and tamoxifen in breast cancer patients undergoing in vitro fertilization to cryopreserve their embryos for fertility preservation. J Clin Oncol 2005; 23:3858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/154\">",
"      Oktay K, Buyuk E, Libertella N, et al. Fertility preservation in breast cancer patients: a prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation. J Clin Oncol 2005; 23:4347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/155\">",
"      Azim AA, Costantini-Ferrando M, Lostritto K, Oktay K. Relative potencies of anastrozole and letrozole to suppress estradiol in breast cancer patients undergoing ovarian stimulation before in vitro fertilization. J Clin Endocrinol Metab 2007; 92:2197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/156\">",
"      Oktay K, Hourvitz A, Sahin G, et al. Letrozole reduces estrogen and gonadotropin exposure in women with breast cancer undergoing ovarian stimulation before chemotherapy. J Clin Endocrinol Metab 2006; 91:3885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/157\">",
"      Oktay K, T&uuml;rk&ccedil;&uuml;olu I, Rodriguez-Wallberg KA. GnRH agonist trigger for women with breast cancer undergoing fertility preservation by aromatase inhibitor/FSH stimulation. Reprod Biomed Online 2010; 20:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/158\">",
"      Oktay K, Kim JY, Barad D, Babayev SN. Association of BRCA1 mutations with occult primary ovarian insufficiency: a possible explanation for the link between infertility and breast/ovarian cancer risks. J Clin Oncol 2010; 28:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/159\">",
"      Boostanfar R, Jain JK, Mishell DR Jr, Paulson RJ. A prospective randomized trial comparing clomiphene citrate with tamoxifen citrate for ovulation induction. Fertil Steril 2001; 75:1024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/160\">",
"      Oktay K, Buyuk E, Davis O, et al. Fertility preservation in breast cancer patients: IVF and embryo cryopreservation after ovarian stimulation with tamoxifen. Hum Reprod 2003; 18:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/161\">",
"      Johnson J, Patrizio P. Ovarian cryopreservation strategies and the fine control of ovarian follicle development in vitro. Ann N Y Acad Sci 2011; 1221:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/162\">",
"      Chan PT, Palermo GD, Veeck LL, et al. Testicular sperm extraction combined with intracytoplasmic sperm injection in the treatment of men with persistent azoospermia postchemotherapy. Cancer 2001; 92:1632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/163\">",
"      K&ouml;hn FM, Schroeder-Printzen I, Weidner W, et al. Testicular sperm extraction in a patient with metachronous bilateral testicular cancer. Hum Reprod 2001; 16:2343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/164\">",
"      Johnson DH, Linde R, Hainsworth JD, et al. Effect of a luteinizing hormone releasing hormone agonist given during combination chemotherapy on posttherapy fertility in male patients with lymphoma: preliminary observations. Blood 1985; 65:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/165\">",
"      Shetty G, Meistrich ML. Hormonal approaches to preservation and restoration of male fertility after cancer treatment. J Natl Cancer Inst Monogr 2005; :36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/166\">",
"      Wyns C, Van Langendonckt A, Wese FX, et al. Long-term spermatogonial survival in cryopreserved and xenografted immature human testicular tissue. Hum Reprod 2008; 23:2402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/167\">",
"      Keros V, Hultenby K, Borgstr&ouml;m B, et al. Methods of cryopreservation of testicular tissue with viable spermatogonia in pre-pubertal boys undergoing gonadotoxic cancer treatment. Hum Reprod 2007; 22:1384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/168\">",
"      Wyns C, Curaba M, Martinez-Madrid B, et al. Spermatogonial survival after cryopreservation and short-term orthotopic immature human cryptorchid testicular tissue grafting to immunodeficient mice. Hum Reprod 2007; 22:1603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/169\">",
"      Schlatt S, Kim SS, Gosden R. Spermatogenesis and steroidogenesis in mouse, hamster and monkey testicular tissue after cryopreservation and heterotopic grafting to castrated hosts. Reproduction 2002; 124:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/170\">",
"      Orwig KE, Schlatt S. Cryopreservation and transplantation of spermatogonia and testicular tissue for preservation of male fertility. J Natl Cancer Inst Monogr 2005; :51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/171\">",
"      Schlatt S, Honaramooz A, Ehmcke J, et al. Limited survival of adult human testicular tissue as ectopic xenograft. Hum Reprod 2006; 21:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/7/38010/abstract/172\">",
"      Nieman CL, Kazer R, Brannigan RE, et al. Cancer survivors and infertility: a review of a new problem and novel answers. J Support Oncol 2006; 4:171.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7440 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-83.177.194.223-8B216F4EAC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_7_38010=[""].join("\n");
var outline_f37_7_38010=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15145555\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1314548941\">",
"      PRETREATMENT COUNSELING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      METHODS TO PRESERVE FERTILITY IN WOMEN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Cryopreservation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Embryo",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Oocytes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H88826114\">",
"      Mature oocytes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H12480392\">",
"      Immature oocytes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H109317940\">",
"      - Whole ovary and pedicle",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Ovarian tissue",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H12480896\">",
"      Contraindications and risks",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16144729\">",
"      Options for protecting ovarian function",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16144814\">",
"      - From radiation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Transposition (oophoropexy)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H16144878\">",
"      Shielding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H16144973\">",
"      Autotransplantation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16144915\">",
"      - From chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Gonadal suppression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16145230\">",
"      Transplantation of the ovary or ovarian tissue",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16145237\">",
"      - Autologous heterotopic transplantation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16145259\">",
"      - Nonautologous orthotopic transplantation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16145266\">",
"      - Outcome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16144886\">",
"      Radical trachelectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Egg donation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16144906\">",
"      Embryo donation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H109317798\">",
"      Surrogates",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21751172\">",
"      Adoption",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Future directions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5410837\">",
"      ISSUES IN WOMEN WITH BREAST CANCER",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15176856\">",
"      Ovarian stimulation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5410871\">",
"      - Aromatase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15177194\">",
"      - Tamoxifen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15177048\">",
"      Options for women who cannot undergo ovarian stimulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      METHODS TO PRESERVE FERTILITY IN MEN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15177249\">",
"      Future directions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/7440\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/7440|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?6/29/6623\" title=\"algorithm 1\">",
"      Approach to fertility preservation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/7440|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?21/38/22125\" title=\"table 1\">",
"      Potential candidates for fertility preservation interventions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?5/18/5421\" title=\"table 2\">",
"      Ovarian failure anticancer Rx",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/56/17293\" title=\"table 3\">",
"      Fertility preservation for women treated w gonadotoxic therapies",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/20/8520?source=related_link\">",
"      Adoption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/54/11114?source=related_link\">",
"      Causes of male infertility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/10/11433?source=related_link\">",
"      Donor insemination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/24/13706?source=related_link\">",
"      Effects of cytotoxic agents on gonadal function in adult men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/61/18392?source=related_link\">",
"      Fertility preserving options for women of advancing age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/42/9898?source=related_link\">",
"      Fertility sparing surgery for invasive cervical cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/26/37285?source=related_link\">",
"      Heavy or irregular uterine bleeding during chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/56/37770?source=related_link\">",
"      In vitro fertilization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/14/24807?source=related_link\">",
"      Oocyte donation for assisted reproduction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/26/1447?source=related_link\">",
"      Ovarian failure due to anticancer drugs and radiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/47/6902?source=related_link\">",
"      Ovarian transposition before pelvic radiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/50/7977?source=related_link\">",
"      Overview of fertility and pregnancy in cancer survivors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/6/4201?source=related_link\">",
"      Ovulation induction with aromatase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?18/7/18546?source=related_link\">",
"      Patient information: Preserving fertility after cancer treatment in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?10/57/11154?source=related_link\">",
"      Patient information: Preserving fertility after cancer treatment in men (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?12/18/12579?source=related_link\">",
"      Patient information: Preserving fertility after cancer treatment in women (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/25/34202?source=related_link\">",
"      Risk-reducing bilateral salpingo-oophorectomy in women at high risk of epithelial ovarian and fallopian tubal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/42/15015?source=related_link\">",
"      Surrogate pregnancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_7_38011="Criteria for Takayasu arteritis";
var content_f37_7_38011=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F62022&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F62022&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Criterion",
"       </td>",
"       <td class=\"subtitle1\">",
"        Definition",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Age at disease one &le;40 years",
"       </td>",
"       <td>",
"        Development of symptoms or findings related to Takayasu arteritis at age &le;40 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Claudication of extremities",
"       </td>",
"       <td>",
"        Development and worsening of fatigue and discomfort in muscles of",
"one or more extremities while in use, especially the upper extremities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Decreased brachial artery pressure",
"       </td>",
"       <td>",
"        Decreased pulsation of one or both brachial arteries",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Blood pressure difference &gt;10 mmHg",
"       </td>",
"       <td>",
"        Difference of &gt;10 mmHg in systolic blood pressure between arms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bruit over subclavian arteries or aorta",
"       </td>",
"       <td>",
"        Bruit audible on auscultation over one or both subclavian arteries or abdominal aorta",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Arteriogram abnormality",
"       </td>",
"       <td>",
"        Arteriographic narrowing or occlusion of the entire aorta, its",
"primary branches, or large arteries in the proximal upper or lower",
"extremities, not due to arteriosclerosis, fibromuscular dysplasia, or",
"similar causes; changes usually foci or segmental",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    For purposes of classification, a patient shall be said to have Takayasu arteritis if at least three of these six criteria are present. The presence of any three or more criteria yields a sensitivity of 90.5 percent and a specificity of 97.8 percent.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Arend, WP, Michel, BA, Block, DA, et al, Arthritis Rheum 1990; 33:1129.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_7_38011=[""].join("\n");
var outline_f37_7_38011=null;
var title_f37_7_38012="Pallor diff dx child";
var content_f37_7_38012=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F65774&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F65774&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis for pallor in children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Decreased erythrocyte or hemoglobin production",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Iron deficiency",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Folic acid",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Vitamin B12 deficiency",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Diamond-Blackfan anemia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Fanconi's anemia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Aplastic anemia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Transient erythroblastopenia of childhood (TEC)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Malignancy*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Thalassemias",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Sideroblastic anemia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Lead poisoning",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Anemia of chronic disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Increased erythrocyte destruction",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Hereditary spherocytosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Elliptocytosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stomatocytosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Pyknocytosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       G6PD deficiency",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Pyruvate kinase deficiency",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Sickle cell syndromes*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Unstable hemoglobins",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Autoimmune hemolytic anemia*&bull;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Isoimmune hemolytic anemia*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Disseminated intravascular coagulation*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Hemolytic uremic syndrome*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Thrombotic thrombocytopenic Purpura*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Cavernous hemangioma (Kasabach Merritt syndrome)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Blood loss",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Severe trauma*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Meckel's diverticulum",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Peptic ulcer",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Idiopathic pulmonary hemosiderosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Nonhematologic",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Respiratory failure*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Shock*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Hypoglycemia*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Pheochromocytoma*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Skin edema",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Fair skinned complexion",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Life threatening.",
"     <br>",
"      &bull; Potential causes of autoimmune hemolytic anemia include idiopathic, viral infection (eg, mononucleosis, influenza, coxsackie, measles, varicella, cytomegalovirus), bacterial infection (eg,",
"      <em>",
"       Escherichia coli",
"      </em>",
"      , Pneumococcus, Streptococcus, typhoid fever, mycoplasma), drugs, inflammatory and collagen vascular disease (eg, systemic lupus erythematosus), and malignancy.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_7_38012=[""].join("\n");
var outline_f37_7_38012=null;
var title_f37_7_38013="Contents: Allergen immunotherapy";
var content_f37_7_38013=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"mobipreview.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"mobipreview.htm?43/1/44061\">",
"       Allergy and Immunology",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Allergen immunotherapy",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"mobipreview.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Allergen immunotherapy",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/25/33175\">",
"           Allergen sampling in the environment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/49/15127\">",
"           An overview of allergen extracts",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/46/9960\">",
"           Rush and ultra-rush venom immunotherapy for Hymenoptera allergy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/24/40327\">",
"           SCIT: Preparation of allergen extracts for therapeutic use",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/14/1256\">",
"           SCIT: Standard schedules, administration techniques, and monitoring",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?43/13/44248\">",
"           Subcutaneous aeroallergen immunotherapy: Accelerated schedules (cluster and rush)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/8/39049\">",
"           Subcutaneous immunotherapy for allergic disease: Indications and efficacy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/27/27062\">",
"           Subcutaneous immunotherapy for allergic disease: Therapeutic mechanisms",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/34/1578\">",
"           Sublingual and oral immunotherapy for allergic rhinitis",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-77660107D9-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f37_7_38013=[""].join("\n");
var outline_f37_7_38013=null;
var title_f37_7_38014="Bone mass lifeline";
var content_f37_7_38014=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F77920&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F77920&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 507px\">",
"   <div class=\"ttl\">",
"    Schematic representation of bone mass changes with age",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 487px; height: 397px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic&nbsp;representation of the bone mass life-line in individuals who achieve their full genetic potential for skeletal mass (red) and in those who do not (blue). The magnitude of the difference between curves is not intended to be to scale. Along the bottom of the graph are several factors known to be of particular importance.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Robert P. Heaney, 1999.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_7_38014=[""].join("\n");
var outline_f37_7_38014=null;
var title_f37_7_38015="Gastrojejunostomy";
var content_f37_7_38015=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F53190&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F53190&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Gastrojejunostomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 459px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An end-to-side gastrojejunostomy can be fashioned to bypass an obstructed segment of&nbsp;duodenum using sutures or staples.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_7_38015=[""].join("\n");
var outline_f37_7_38015=null;
